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Superovulation in assisted conception can create Ovarian Hyperstimulation Syndrome 
(OHSS). Morbidity and even mortality that can occur with OHSS should be avoided by 
using the lowest risk and safest treatment strategy. Women with Polycystic Ovary 
Syndrome (PCOS) are at high risk of over response due to the ample number of antral 
follicles capable of responding to stimulation. Diagnosis of PCOS is based on a 
collection of subjective symptoms, signs and laboratory investigations. Anti-Mullerian 
Hormone (AMH), produced by the granulosa cells of the antral follicles, is elevated in 
women with PCOS. In a consecutive series of women presenting to an infertility clinic, 
the finding of increased AMH in those with PCOS was confirmed. Furthermore, AMH 
was shown to correlate with anovulation and hyperandrogenism. A single AMH value is 
interchangeable with any of the Rotterdam diagnostic criteria. Proposed values are 
29pmol/L for polycystic ovarian morphology and 45pmol/L for either anovulation or 
hyperandrogenism using the generation II assay. Metformin has been shown to reduce 
the risk of OHSS in an agonist IVF cycle. The antagonist cycle is recommended for those 
at high risk of over-response. In a randomised double-blinded placebo controlled trial 
on 153 recruited patients; metformin was shown to have no effect on the incidence of 
OHSS in an antagonist cycle. There was no improvement in clinical pregnancy or live 
birth rate. The trial highlighted the discrepancy in clinical outcome between a White 
Caucasian and South Asian population. Avoidance of superovulation is an attractive 
option offered by in vitro maturation (IVM). A pilot study of 30 IVM cycles proved that 
immature oocytes can mature and fertilise in vitro at similar published rates. 
Unfortunately, no clinical pregnancies were created despite adequate transferred 
embryo quality. Although no incidence of OHSS, IVM appears to have been superseded 
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Increasing use of superovulation in assisted conception has amplified the risk posed by 
ovarian hyperstimulation. For those with Polycystic Ovary Syndrome (PCOS) the risk is 
heightened due to the large cohort of antral follicles capable of producing an 
exuberant response to stimulation. Ovarian hyperstimulation syndrome (OHSS) 
subjects a relatively young and healthy population of women undergoing assisted 
conception treatment to the significant risk of morbidity and even mortality. This 
iatrogenic complication of assisted reproduction technology (ART) is unacceptable and 
requires that effective measures are put in place to limit the risk of morbidity attached 
to treatment. For women with PCOS, the often subjective diagnosis and lack of 
rigorous risk stratification measures can hamper safe assisted conception. Anti-
Müllerian Hormone (AMH), a product of the ovarian granulosa cells, is elevated in 
those with PCOS. There has been suggested correlation with anovulation and 
hyperandrogenaemia. The hormone test therefore has the potential to aid diagnosis 
and furthermore, quantify risk for women undergoing ART. When superovulation 
strategies are used, effective adjuvants that limit risk would be ideal. Metformin, an 
insulin sensitiser, has been used successfully to reduce OHSS in the conventional long 
treatment protocols centred on the use of gonadotrophin releasing hormone (GnRH) 
agonists. During GnRH antagonist treatment cycles, as recommended for women with 
PCOS, limited evidence is available for the merit of the addition of metformin. Finally, 
given that exposure to supra-physiological doses of exogenous gonadotrophin are 
fundamental to the development of OHSS; treatment strategies which eliminate this 
problem are theoretically favourable. In vitro maturation (IVM), the process of 




success. Optimisation of clinical and laboratory methods could strengthen the 
argument for use of this technique, particularly if suggested high clinical pregnancy 
rates could be replicated. This literature review will cover the current evidence 
available for the diagnosis of PCOS, including the use of AMH for this purpose. The 
review will also address the use of metformin in an antagonist cycle and IVM for 
women with PCOS. 
                        
1.2 Background  
Polycystic Ovary Syndrome is the most common endocrine disturbance to affect 
women of reproductive years. Presentation occurs through adolescence into 
adulthood and can have far reaching long term health consequences. Although 
multifactorial in nature, the absolute aetiology of PCOS remains elusive. A complex 
interplay within the normal ovary allows recruitment of primordial follicles into the 
growing follicular pool. A coordinated transition allows an antral follicle and oocyte to 
progress and ultimately reach ovulation. Unfortunately in PCOS, this coordination is 
often lost. Insulin resistance, rebound hyperinsulinaemia and hyperandrogenism are 
considered central to the pathophysiology of PCOS (1). These actions contribute to the 
anovulatory subfertility, menstrual disturbance and stereotypical ultrasound features 
of a polycystic ovary (2). 
In addition to subfertility, the long term health consequences of PCOS include type two 
diabetes mellitus (T2DM) and endometrial carcinoma (3). A systematic review found 
an associated 2.5-fold increase in impaired glucose tolerance and a 4-fold increase in 
T2DM in PCOS (4). Furthermore, unopposed oestrogen secretion stimulates unchecked 
endometrial proliferation, which left unmanaged can lead to hyperplastic change (5). 
Finally the quality of life is often considered secondary to the clinical manifestations of 
PCOS. Yet women with PCOS have a lower reported health-related quality of life, in 
particular with regard to psychological health. Suicide attempt is up to 7 times higher 






Prevalence of the syndrome is dependent on the diagnostic criteria used. The most 
common and inclusive classification, the Rotterdam consensus (7), gives a broad 
estimate of 15%. Other diagnostic systems place more emphasis on hyperandrogenism, 
resulting in a reduced overall prevalence of the condition (8). Socioeconomic status 
can affect presentation, with those from a lower socioeconomic class often having 
higher body mass indices (BMI), increased insulin resistance and a tendency toward an 
anovulatory phenotype (9). In some societies, the opposite occurs with the rich having 
a higher BMI (10).   
PCOS encompasses >90% of the World Health Organisation (WHO) group 2 
anovulatory disorders (11). The normo-gonadotrophic anovulation creates an 
increased time to pregnancy but not necessarily a reduction in final family size (12). 
Interestingly, it has been shown that women with PCOS may retain fertility with 
advancing age when compared with age matched non-PCOS counterparts (13). Over 
time the impact of hyperandrogenism decreases but metabolic disturbance remains a 
concern (14).  
 
1.2.2 Insulin resistance 
Women with PCOS are more insulin resistant than their non-PCOS counterparts, with 
50-70% having demonstrable evidence of insulin resistance (15). A compensatory 
hyperinsulinaemia attempts to maintain normal glucose metabolism. Unfortunately, it 
is this response that drives many of the outward phenotypic expressions of PCOS. A 
possible explanation for insulin resistance is a post-receptor signalling pathway-specific 
impairment within PCOS (16). This impairment allows metabolic resistance but 
maintains an intact steroidogenic response to insulin within the ovary.  Insulin 
stimulates cytochrome P450c17 and aromatase activity, increasing thecal cell 
androgen production (17, 18) and granulosa cell oestradiol conversion (19).  Increased 
ovarian exposure to insulin amplifies Luteinising Hormone (LH) and insulin-like growth 




granulosa cells and excessive thecal androgen production (20, 21). Insulin, alongside 
IGF-1 and androgens, reduces the hepatic production of sex hormone binding globulin 
(SHBG). This reduction allows a higher proportion of bioactive hormone to remain in 
the circulation. In addition, there may be increased pulse amplitude and frequency of 
LH (22) plus a premature follicle sensitisation to the increased circulating LH (23). 
Obesity amplifies the effect of insulin resistance, through the metabolic products of  
visceral fat such as free fatty acids or the adipokines including interleukin-1, 
interleukin-6 and tumour necrosis factor α (24). Obesity is seen in 38-66% of those 
with PCOS, with clear correlation between symptoms and reproductive outcome (25).  
 
1.2.3 Glucose and insulin interaction 
Insulin is produced by the β cells of the islets of Langerhans in the pancreas. Insulin is 
important in glucose homeostasis and impacts on reproductive and mitotic functions. 
Circulating levels of insulin rise rapidly in response to elevated blood glucose in a dose 
dependent manner (26). Insulin is a polypeptide hormone, composed of two 
polypeptide chains (A-chain and B-chain) linked by two disulphide bonds. Initially 
insulin is synthesised as a pre-prohormone. On entry to the rough endoplasmic 
reticulum, a short hydrophobic signal sequence at the N-terminal is cleaved to produce 
proinsulin. Folding occurs and then transportation to the Golgi complex in micro 
vesicles. Within the Golgi complex, a protease removes an inactive C-peptide, resulting 
in active insulin leaving the complex via storage vesicles which associate with zinc (26). 
A process of exocytosis occurs in response to glucose stimulation of the pancreatic β 
cells, which requires Potassium (K⁺), Adenosine triphosphate (ATP) and Calcium (Ca²⁺) 
(27).  Glucose enters the β cell via a glucose transporter (GLUT-2), which is 
concentrated in the microvilli of the canaliculi which lie between the cells. The process 
of glucose phosphorylation by glucokinase is the rate limiting step of islet glucose use. 
The main pathways for glucose metabolism include glycolysis (oxidation leading to ATP 
production), the pentose phosphate pathway (oxidation generates nicotinamide 
adenine dinucleotide phosphate (NADPH)) and glycogen synthesis via uridine 




concentrations of ATP rise, closing K⁺ channels. Suppression of the K⁺ efflux leads to 
cell depolarisation. In turn, depolarisation opens a Ca²⁺ channel allowing a rapid Ca²⁺ 
influx. This activates mechanisms for the vesicle movement and insulin exocytosis (see 
Figure ‎1-1) (28, 29). Using a tyrosine kinase receptor for signal transduction, insulin 
creates a cascade of events including activation of enzymes, translocation of glucose 
transporters to the plasma membrane and altered transcription processes within the 
target cell. Rapid glucose uptake into muscle and adipose tissue is initiated by the 
glucose transporter, GLUT 4. Translocation of this transporter is mediated by 
phosphatidylinositol 3-kinase (PI3-K). Directed conversion of glucose into glycogen, 
pyruvate, lactate and fatty acids then occurs. This anabolic property of insulin allows 
efficient storage of excess nutrients while endogenous substrate mobilisation is 
supressed. Hepatic production of glucose is suppressed. 
 
Figure ‎1-1 - Glucose and insulin action 
 
Glucose enters the pancreatic β cell of the Islet of Langerhans via a glucose transporter (GLUT-2). During 
glucose oxidation, the levels of ATP increase, preventing an efflux of potassium (K⁺), which in turn leads 





1.2.4 Ovarian steroidogenesis 
Ovarian steroidogenesis in the normal ovary requires the coordinated communication 
between the hypothalamic-pituitary axis and the ovarian thecal and granulosa cells. 
Figure ‎1-2 provides a simplified schematic presentation of some of the major pathways, 
hormones and proteins involved in the steroidogenic process (30). It is recognised that 
Follicle Stimulating Hormone (FSH) uses a number of signalling pathways to 
orchestrate its action, including the cyclic adenosine monophosphate (cAMP) 
dependant protein kinase A (PKA) and PI3K pathways (31, 32). The conversion of ATP 
to cAMP is driven by stimulation of adenylate cyclase via G protein coupled receptors. 
The main actions of FSH include stimulation of granulosa cell proliferation, induction of 
aromatase and aiding LH receptor induction in Graffian follicles prior to ovulation (30). 
Luteinising hormone on the other hand primarily targets the thecal cells, hence the 
term ‘2-cell 2-gonadtrophin theory’. The main action of LH is to stimulate the 
production of thecal androgens required by the granulosa cell for oestrogen 
production. Other factors including insulin help to modulate androgen production in 
the thecal cell and sensitise the granulosa cells to the effects of FSH.  
Activin and Inhibin are produced from the granulosa cells and regulate the 
hypothalamic-pituitary axis. Activin aids granulosa cell proliferation, increases FSH-
receptor expression and improves oocyte maturation whilst delaying luteinisation. In 
contrast, inhibin aids LH-induced production of androgens and increases progesterone 
production from the granulosa cells (33). Locally produced factors such as AMH limit 






Figure ‎1-2 Pituitary and the two cell two gonadotrophin theory 
 
Gonadotrophins released from the anterior pituitary target the thecal and granulosa cells situated in the 
ovary. Luteinising hormone (LH; alongside numerous factors including insulin) stimulate the conversion 
of cholesterol to androstendione, which passes into the granulosa cell. Follicle stimulating hormone 
(FSH) drives the aromatisation of androgens to oestrone and oestradiol via at least the cAMP driven 
Protein Kinase A (PKA) pathway and aids the induction of LH receptors on the granulosa cells. Activin 
and Inhibin produced by the granulosa feedback to the hypothalamic-pituitary axis. Anti- Müllerian 
Hormone (AMH) exerts an inhibitory control over granulosa cell proliferation. ATP: adenosine 
triphosphate, cAMP: cyclic adenosine monophosphate, P450arom: cytochrome p450 aromatase, 17β-
HSD: 17β-Hydroxysteroid dehydrogenase, -ve: negative, +ve: positive 
 
Both the ovary and adrenal gland contribute to hyperandrogenemia (HA) in PCOS. 
Hyperandrogenemia persists despite either dexamethasone suppression of adrenal 
steroidogenesis or GnRH agonist ovarian suppression (35). A basal increase in thecal 
cell androgen production is seen from a polycystic ovary (PCO), irrespective of 
ovulatory status (36). An exaggerated response to trophic hormones (LH/insulin) also 
occurs (23, 37, 38). Granulosa cell activity, on the other hand, is determined by 




increased response to FSH leading to increased oestradiol production. Premature 
responsiveness to LH also occurs (37). Increased frequency of pulsatile GnRH can 
selectively increase the LH: FSH secretion. LH stimulates thecal androgen production.  
Due to the shift in equilibrium and relatively low level of activity of granulosa cell 
aromatase in pre-antral and early antral follicles, incomplete aromatization of 
testosterone occurs i.e. more testosterone remains unconverted and therefore 
increases androgen levels, secondary to the relative deficiency of FSH in the adjacent 
granulosa cells. This last point contributes to the follicle arrest observed in anovulatory 
PCOS. Pre-antral/ early antral follicles are responsive to FSH, but the pre-ovulatory 
follicles are dependant on FSH leading to degeneration of big follicles when there is a 
relative FSH deficiency. Zhu et al (34, 39) suggest that there is a similar activin receptor 
expression between normal women and women with PCOS, but increased betaglycan 
in the latter. Betaglycan is vital for inhibin action and enhanced expression may 
facilitate antagonism of activin. The authors suggest that compromised FSH-receptor 
expression may therefore contribute to the accumulation of small follicles. 
Furthermore, inhibin mediated antagonism of activin and co-factors may lead to 
increased thecal androgen production.    
Insulin action on the normal ovary and PCO is mediated via the insulin receptors 
located on both thecal and granulosa cells (37, 40). Despite the metabolic insulin 
resistance in PCOS, insulin driven ovarian steroidogenesis remains intact (41). Insulin 
increases (see Figure ‎1-3 for the steroid pathway) aromatase and CYP450c17 action 
(17) and stimulates oestradiol conversion in the granulosa cells (19, 35). Within the 
adrenals and gonads, a single CYP450c17 gene catalyses the activity of 17α-
hydroxylase and 17,20-lyase activity. The ratio of these enzymes determines the 
amount of c19 or c21 steroids produced. Increased 17α-hydroxylase activity generates 
more c21 steroids e.g. cortisol. If both enzymes are active then c19 steroids e.g. sex 
steroid dehydroepiandrosterone (DHEA) are produced. The c19 steroids 
androstenedione and DHEA act predominantly as sex-steroid precursors due to a 
reduced affinity with the androgen receptor. Within the target tissues they are 
converted to oestrogens or androgens, by aromatase and 17β-hydroxysteroid 




of 17,20-lyase:17αhydroxylase activity and therefore HA. It is proposed that a single 
kinase may contribute via serine phosphorylation to HA and insulin resistance seen in 
PCOS (35).  
 
Figure ‎1-3 Steroidogenic pathway
 
Conversion of cholesterol to pregnenolone initiates biosynthesis of all steroid hormones. Pregnenolone 
is converted to DHEA via ∆⁵ steroid pathway. Progesterone is converted to androstenedione via ∆⁴ 
steroid pathway. Within the adrenal gland, 17-OH progesterone is either converted to cortisol or the sex 
hormones. P450 scc: Cytochrome P450 side chain cleavage; 3β HSD: 3β-hydroxysteroid dehydrogenase; 
17β HSD: 17β-hydroxysteroid dehydrogenase. P450 c17 includes 17α hydroxylase and 17,20 lyase. 
 
Excess insulin also binds to IGF-1 receptors, enhancing theca cell androgen production 
in response to LH stimulation (17, 42). In addition, hyperinsulinemia inhibits the 
hepatic secretion of insulin-like growth factor binding protein-1 (IGFBP-1) leading to 
increased bio-availability of IGF-1 and 2 (43). These are important regulators of ovarian 
follicular maturation and further augment ovarian androgen production. A suggested 
link exists between increased CYP450c17 and reduced phosphorylation of inhibitory 
Mitogen activated protein kinase - extracellular-signal-regulated kinase 1/2 (MAPK-




suggested that inhibition of MAPK –ERK1/2 has no effect on the 17α-hydroxylase 
activity of CYP450c17. Increased insulin receptor substrates (IRS) 1 and 2 are seen in 
PCOS thecal cells and skeletal muscle but not granulosa cells (47). This cell specific 
alteration in the IRS protein concentration reflects the amplification effect insulin has 
on thecal androgen biosynthesis. Furthermore, altered Tyrosine auto-phosphorylation 
of the insulin receptor may be decreased in women with PCOS (48).  
 
1.2.5 Ethnic variation 
Throughout the world in different ethnic groups, a wide diversity exists in the 
prevalence of PCOS and its phenotypic display. For example in the South Asian 
population the metabolic component is more apparent (49, 50), in both indigenous 
and immigrant populations (51, 52). This propensity correlates with the exponential 
rise in type 2 diabetes within this population in recent times (53). A very clear variation 
in metabolic risk is evident in different Indian populations: Western United States (US) 
society (17.4%), urban India (13.6%) and rural India (8.4%) (54). Despite having milder 
features of HA, more pronounced insulin resistance is seen in young South Asian 
women compared with older obese white women (55). Central obesity appears to be 
one of the best discriminators for metabolic features of PCOS. Interestingly, SHBG 
often viewed as a surrogate marker for insulin resistance is lower in South Asian 
women compared with white women (55). Another interesting comparison uses the 
often overlooked feature of acanthosis nigricans. When present, it signifies a greater 
metabolic risk in both South Asian (irrespective of geographical location) and 
indigenous Thai women (56). Hispanic populations also demonstrate a higher insulin 
resistance alongside increased obesity (57).Variation in the metabolic component is 
apparent within white populations. Lower reported levels are seen in Turkish, Czech 
and south Italian women (2-8%) whereas 43-47% prevalence is seen in American 
women (58). Different environmental, migration and lifestyle confounders obviously 
contribute to this variation. Removing geographical factors, African-American and 
white-American women, have similar clinical manifestations of PCOS with respect to 




increased metabolic demands with increased central obesity, hypertension and 
mortality.     
 
1.2.6 Genetics 
Without doubt, as evidenced by the familial association of PCOS, a genetic component 
underpins this highly complex and variable condition. The interplay between 
environment and underlying genetic inheritance is hard to unpick, due to the multiple 
phenotypic presentations of the syndrome. Kosova and Urbanek (60) highlight the 
challenges facing scientists whilst trying to identify susceptibility genes. Phenotypic 
heterogeneity, environmental confounders, small sample size and limitations of the 
commonly used candidate gene analysis methods are but a few of these challenges. It 
has been well documented that family clusters of PCOS exist. This extends to all of the 
main components of PCOS with an increased propensity for HA and T2DM within first-
degree relatives of either sex (61, 62). With the advance in genetic studies, the 
feasibility of genome-wide association studies (GWAS) is promising in the identification 
of novel genes associated with PCOS (60).  The use of candidate gene analysis within 
PCOS research has highlighted a number of potential susceptibility gene foci such as 
Fibrillin-3 (FBN-3) (60, 63), insulin and insulin receptor genes (64, 65) and the fat and 
obesity associated gene (FTO) (66-68). Unfortunately, often due to small sample size 
and heterogeneous presentation, these studies have failed to be easily replicated. The 
first publication of GWAS in PCOS originates from China (69). Three distinct regions 
were identified: chromosome 2p16.3 (containing the Luteinising 
hormone/choriogonadotrophin receptor gene), chromosome 2p21 (containing the 
Thyroid adenoma associated gene) and chromosome 9q33.3 (containing the DENN 
domain-containing protein 1a gene, DENND1A). The latter gene’s involvement has had 
successful replication in European (70, 71) populations allowing plausible recognition 
as a PCOS susceptibility gene. Single nucleotide polymorphisms (SNPs) in the Thyroid 
adenoma associated gene have been linked to T2DM, whilst DENND1A encodes a 





1.3 Diagnosis of Polycystic Ovary Syndrome 
 
1.3.1 Current diagnostic criteria PCOS 
Despite an extensive literature, the diagnostic criteria for PCOS remain a subject of 
debate within scientific and clinical circles. Stein and Leventhal (72) first described the 
collection of symptoms  (enlarged ovaries, amenorrhoea, infertility and hirsutism) 
recognised currently as features of PCOS. In 1990, the National Institute of Health (NIH) 
defined the condition as the presence of chronic anovulation and HA (73). A joint 
meeting between the European Society of Human Reproduction and Embryology 
(ESHRE) and the American Society for Reproductive Medicine (ASRM) published the 
Rotterdam consensus in 2003. To reach diagnosis, 2 out of 3 criteria should be met. 
These include oligo- or anovulation, clinical and/or biochemical HA and polycystic 
ovarian morphology (PCOM). Subsequently, it has been proposed that more emphasis 
should be placed on HA with its presence absolutely necessary for diagnosis (8). 
Table ‎1-1 outlines the 3 proposed definitions of PCOS. The most recent meeting of the 
NIH suggested the continued use of the Rotterdam criteria with focus on the variable 
phenotypic picture of those with PCOS (74).  
 
Table ‎1-1 - Diagnostic criteria for polycystic ovary syndrome 








2. oligo-/ anovulation 
3. exclusion related 
disorders 
To include 2 of the 
following with exclusion 
of related disorders: 
1. oligo/an-ovulation 




3. polycystic ovaries 
 
To include all: 















1.3.2 Diagnosis of polycystic ovarian morphology  
Ultrasound has provided the ability to define an individual’s ovarian dimensions and 
follicle count, using a relatively acceptable and safe method. The accepted definition 
for PCOM is at least 1 ovary demonstrating a volume greater than 10cm³ or 12 or more 
follicles 2-9mm (75). Using this definition >75% of women with PCOS will have PCOM 
(8). The significance of PCOM in an apparently normal women without PCOS, divides 
opinion. PCOM alone has been reported in >20% of women (76-78).  Some believe it is 
a normal variant of ovarian morphology (79), whilst others consider it a mild 
phenotype of PCOS (80, 81). Johnstone et al (79) evaluated a Caucasian female 
population with regular cycles, with and without PCOM (n=257). Although a significant 
increase was seen in mean testosterone level in the PCOM group, this remained within 
the upper limit of the normal range. No difference was seen in metabolic parameters 
including insulin, fasting glucose and lipid profiles. They concluded PCOM alone should 
not be considered a marker for metabolic dysfunction or cardiovascular risk. This last 
point is supported by a review by Moran and Teede (82). The review concludes that if 
PCOS diagnosis is reached using PCOM and either hyperandrogenism or anovulation, 
the metabolic disturbance is less severe than if both HA and anovulation are present. 
In contrast, Dewailly et al (83) showed PCOM to be a marker of HA using principal 
component analysis. They believe that the use of follicle number as a surrogate for HA 
bridges the gap between the Rotterdam criteria and the Androgen excess groups 
criteria outlined above.  Having PCOM alone has not been shown to have any 
detrimental effect on overall fertility (84) but gonadotrophin stimulation 
characteristics are similar to those with PCOS, with respect to oestradiol concentration 
and number of oocytes retrieved (85). It is accepted that ovarian reserve declines with 
age. This also applies to the finding of PCOM (79). Use of age-specific ranges for PCOM, 
have been recommended but not yet quantified (76). The opposite end of the age 
spectrum, adolescence, also questions the significance of PCOM in healthy volunteers 
(86). Advances in ultrasound technology and sensitivity, has challenged the validity of 
the PCOM definition. The ability to accurately measure smaller follicles is evident in 




elevate the follicle number used in diagnosis. Dewailly et al (87), found that when 
comparing a non-PCOM non-PCOS population with a PCOS population, a follicle 
number of >19 provided the best compromise between sensitivity (87%) and specificity 
(83%) in identifying PCOM. Excluding those with asymptomatic PCOM may artificially 
strengthen this level, as it is not a true reflection of the population, particularly if 
PCOM is regarded as a normal ovarian phenotype. If women with PCOM alone are 
considered as a separate population, then excluding this ovarian morphology removes 
a sub-group that imposes bias on the true diagnostic threshold for PCOS. More recent 
work (88) suggests a threshold of 25 follicles is a better indicator to define PCOM. The 
operator’s ability should not be overlooked as both inter and intra-observer variation 
are recognised as confounding factors in ultrasonography (89).  A mere 51% 
agreement between 4 experienced observers and 63-74% agreement with their own 
findings, highlight this inconsistency (90).  
 
Figure ‎1-4 - Old and new ultrasound technology (87) 
 
 
The majority of the literature concentrates on follicle number in reference to PCOM. 
Increased ovarian volume is less common, but remains a recognised diagnostic feature. 
Johnstone et al (79) suggest that unlike follicle number, the proportion of women with 
increased ovarian volumes does not trend downward with increasing age. Nor do they 




is the only feature considered. Recommendation to scan when there is ovarian 
quiescence negates the effect of a dominant follicle on the overall ovarian volume. The 
findings of increased stromal volume and vascularity may also underpin part of the 
pathogenesis of both the PCOM and PCOS. Suggested inclusion of 3 dimensional 
ultrasound may also improve diagnostic ability for PCOM (91, 92).          
 
1.3.3 Diagnosis of hyperandrogenism 
The use of clinical and biochemical HA diagnostics as a means to assign PCOS, have 
been besieged with problems related to optimum diagnostic level, assay design and 
standardisation of often subjective measurements. Despite published scoring 
symptoms for hirsutism such as that proposed by Ferriman and Gallwey (93), there are 
wide discrepancies between patient and physician scores (94) as well as between  
physician scores alone (95). Acne is also a common finding in women of reproductive 
years, making its relative importance in PCOS diagnosis questionable (8). Assessment 
of biochemical HA is no less difficult due to the types of assay and multiple androgen 
tests available (96). Barth et al (97) summarise the biological and analytical variables 
that can influence serum testosterone concentrations. The development of liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) (98) has been shown to 
surpass the standard radioimmunoassay (RIA) methods used, as it limits laboratory 
variation (99). Using a variation of this method, the reference level for women without 
PCOS is <1.8nmol/l (100). Testing the diagnostic performance of testosterone, using 
receiver operator characteristics, in a consecutive cohort of fertility patients, the area 
under the curve (AUC) was 0.75. Interestingly, the AUC for the discarded criterion of 
raised LH: FSH was very similar at 0.72.         
In summary, PCOS diagnosis remains a debated topic. Lack of clarity in definition, 
variability in laboratory measurements and subjectivity in clinical observations allows 
the debate to continue. Use of ultrasound allows pictorial evidence of ovarian function, 
revealing a spectrum of disorder from normal variant to metabolic representation. The 
importance of PCOM in a ‘normal’ population remains unknown despite much 




threshold for diagnosis has been questioned. However other pelvic pathologies can be 
identified at the time of investigation and ease of assisted reproductive techniques 
assessed. Historical use of less robust testosterone measurements has left a 
hyperandrogenism definition vague. More accurate methods such as mass 
spectrometry may help to alleviate this ambiguity.  There remains clear need for 
further less subjective criteria for the identification of PCOS. 
 
1.4  Anti-Müllerian Hormone Physiology 
Anti-Müllerian Hormone is a member of a large family of regulatory proteins labelled 
as the transforming growth factor beta (TGF-β) superfamily, named after its originally 
discovered member TGF-β1 (101). These proteins have a wide range of actions 
including roles in cell growth, differentiation and apoptosis. Despite the range of 
peptides incorporated under the TGF-β superfamily umbrella, the method of cell 
signalling is essentially uniform. The ligand e.g. AMH binds to a specific ‘type II 
receptor’ dimer found in the cell membrane (Figure ‎1-5). This receptor is a 
serine/threonine receptor kinase (102). This then allows recruitment and 
phosphorylation of a ‘type I receptor’ dimer to form a heterotetrameric complex with 
the ligand. Once activated, the type I receptor phosphorylates a collection of 
intracellular proteins, related to the Drosphilia gene Mothers against dpp (MAD) and 
now with more genes identified, dubbed ‘Smads’.  Binding of co-Smads within an R/Co-
Smad complex, transduce the TGF-β signal into the nucleus where they act as 






Figure ‎1-5 The AMH receptor 
 
The AMH ligand binds to a type II receptor in the cell membrane, which in turn recruits a type I receptor 
dimer within the cell. Once recruited the type I receptor binds intracellular proteins, which transduce 
the signal into the nucleus. This allows downstream expression of the AMH ligand.   
 
In humans, the AMH gene has been located on chromosome 19p13.3 (105), with 5 
exons encoding a protein of 560 amino acids. The human AMH II receptor gene is 
located on chromosome 12 (106). The specific type I receptors remain elusive but 
potential candidates include bone morphogenetic proteins which activate specific 
SMADs (107). Prior to secretion AMH undergoes glycosylation and dimerization to 
form two identical linked 70 kDa monomers. Each of these subunits has a ‘mature’ C-
terminal and a ‘pro’ N-terminal (see Figure ‎1-6).  Cleavage occurs between these two 
ends during cytoplasmic transit but remain in contact via a non-covalent bond, 
resulting in a 140kDa complex in circulation. The biologically active part of the AMH 
molecule resides in the ‘mature’ region but requires the N-terminal to maintain this 
activity (108). This is in contrast to other members of the TGF-β family e.g.  TGF-β, who 
when both parts are associated remains latent (108). Although it has been shown that 




reveals greater inhibition when both parts of the AMH molecule are in association. This 
is likely to represent the location of the binding site on the C-terminal.  
 
Figure ‎1-6 The Anti-Müllerian Hormone protein 
 
AMH protein formed of 2 identical monomers. Plasmin cleavage site highlighted, but fragments remain 
in association via non-covalent bonds. Both monomers remain in contact via disulphide bonds. 
 
1.4.1 AMH in males 
Although the genetic sex of an individual is predetermined by the inheritance of either 
an X or a Y chromosome from the paternal line, initial morphological appearance of 
the embryological gonads is indistinguishable between sexes. Post gonad formation, 
the crucial event in male sex differentiation is the expression of the SRY gene (sex 
determining region of the Y chromosome), allowing transformation of the gonad 
supporting cells to differentiate in to Sertoli cells (109). Once testicular differentiation 
has occurred, testicular hormone secretion promotes masculinisation of the embryo to 
generate the male phenotype. These hormones include androgens, Insulin-like-3 




Müllerian Inhibiting Substance). Expression of AMH occurs shortly after SRY gene 
expression and leads to regression of the Müllerian ducts, which were pre-destined to 
form the uterus, fallopian tubes and proximal vagina. This degeneration occurs via the 
direct effect of AMH on the mesenchymal tissue surrounding the ducts. This tissue 
contains the AMH-receptor type II needed to effect the cranial-caudal regression of 
the Müllerian system. Defects in the pathway or lack of the type II receptor lead to 
Persistent Müllerian Duct Syndrome seen in adult males. Normally, the postnatal 
decline in male AMH concentration runs in parallel with the initiation of 
spermatogenesis and increasing testicular testosterone production. Over expression in 
the adult can produce Leydig cell abnormalities and interfere with testosterone 
production. However, evidence in support of an AMH-induced suppression of 
CYP450c17, the gene necessary for testosterone biosynthesis, exists (110). These 
findings support the theory that AMH retains an inhibitory autocrine/paracrine role in 
the adult male steroidogenesis pathway (109). Use of AMH measurement for male 
infertility assessment is limited when compared with its role in the investigation of the 
female. The serum concentration of AMH does not seem to be have any predictive 
capacity on In vitro fertilisation (IVF) or intra cytoplasmic sperm injection (ICSI)  
outcome nor does it reliably differentiate between fertile or infertile males (111). In 
the case of non-obstructive azoospermic males undergoing testicular sperm extraction, 
AMH did not predict success (112).  
 
1.4.2 Physiology of AMH 
The main physiological effects of AMH have been shown in both animal and human 
studies. AMH plays an inhibitory role on both the recruitment of primordial follicles 
and prior to final selection of the dominant follicle. It has also been suggested that 
AMH acts as the ‘gatekeeper’ of follicular oestrogen production (113). Anti-Müllerian 
Hormone expression is specific to the granulosa cells of pre-antral and antral follicles. 
When the follicle reaches the FSH-dependant growth stage, AMH expression drops. A 
number of studies have shown a steep decline in AMH expression as follicles reach 




cumulus cells (117, 118). Atretic follicles lack expression of AMH (119). AMH null-mice 
show increased oocyte degeneration and follicular atresia (120). Insight into the role of 
AMH during folliculogenesis has been provided by studies of AMH-knockout mice (121). 
Although fertile, in the absence of AMH, the mice have a depleted primordial pool and 
reduced reproductive lifespan due to their lack of inhibitory control from AMH and 
accelerated recruitment from the primordial pool (121, 122). Histological work on 
ovarian tissue, confirms the inhibitory effect of AMH on the transition from the 
primordial to primary follicle (123-125). Carlsson et al (124) evaluated the effect of 
different AMH concentrations on human ovarian tissue growth in vitro. Specimens 
cultured in the highest concentrations of AMH showed no difference in primordial 
follicle count compared with the non-cultured sections. Specimens incubated in low 
concentrations of AMH showed significant initiation of follicular growth and depleted 
primordial follicle count. Interestingly, AMH exposure also inhibited the stimulatory 
effect of several other growth factors on primordial follicle recruitment, including basic 
fibroblast growth factor (bFGF), kit ligand (KITL) and keratinocyte growth factor (KGF) 
(125). Both the in vivo and in vitro studies highlight the ability of AMH to reduce the 
follicle’s sensitivity to FSH (34, 126). A further hypothesis involves the ability of raised 
FSH to down regulate AMH and AMH receptor expression within the granulosa cells, 
effectively releasing the ‘brake’ on folliculogenesis (127). Human work confirms a 
significant inverse relationship between FSH and AMH (128). 
The concept of AMH as the gatekeeper of follicular oestrogen production is supported 
by a number of studies, summarised by Dewailly et al (113). Anti-Müllerian Hormone 
ensures little oestrogen is produced from the antral follicles, until the dominant follicle 
has been selected. At this point, a shift occurs from a low-oestrogen producing state to 
one of increasing oestrogen production. This differential regulation of AMH by 
oestrogen and vice versa, has been shown through the interaction of the AMH 
promoter region and the oestrogen beta receptor (129). A number of studies support 
the inhibitory role of AMH on aromatase action prior to selection of the dominant 
follicle (130, 131). An intra-follicular inverse relationship exists between AMH, 




(132, 133). The inverse relationship between aromatase and AMH is also seen in the 
oocyte cumulus complex of pre-ovulatory follicles in sheep (134). 
     
1.4.3 The effect of age 
Dataset analysis has integrated a number of studies, incorporating birth to menopause, 
with the aim to represent ‘normal’ female population changes in relation to AMH (135, 
136). Analysis of this model describes 4 distinct stages of circulating AMH, with 
correlation to non-growing follicle (NGF) recruitment. This NGF population (which 
peaks at 20-22 weeks fetal gestation  (137))  should be considered the true reflection 
of ovarian reserve. There are no available direct methods to assess this number in 
clinical practice, which lead to indirect methods such as AMH testing. Levels of AMH 
increase through childhood (stage 1), fluctuate at puberty (stage 2) and have a 
secondary increase to a peak at 25 years (stage 3). The final stage, over 25yrs of age, 
shows parallel reduction in both AMH and the NGF population. The dynamics of AMH 
in relation to the resting pool of follicles in stage 4, allow the reliable use of AMH as an 
ovarian reserve marker, unlike the 3 earlier stages when the NGF population is still 
changing (see Figure ‎1-7).  






1.4.4 Menstrual variation in AMH 
An AMH test can be performed at any point within the menstrual cycle because there 
appears to be little variation in an individual, within or between cycles. This is due to a 
relatively stable pre-antral to early antral follicle pool and the reduced production of 
AMH by larger follicles on their approach to ovulation (128, 138). Studies that have 
tracked AMH profiles in individuals have generally found no significant differences 
across the reproductive cycle (128, 139). Minor fluctuations do occur although there is 
little consensus on when or if these peak in each individual cycle (128, 140). Further 
review suggests that although a potentially significant difference in AMH concentration 
may occur within the cycle, this is smaller than inter-cycle variability and as such it is 
not clinically significant (141). Two prospective studies have evaluated and agreed on 
inter-menstrual cycle variability in AMH concentration (138, 142). The majority of the 
variability was due to between-subject variation with only 11% of the variability 
secondary to individual fluctuations. Conversely, Hadlow et al (143) have shown a 
clinically significant difference in AMH values taken at different stages of the cycle, 
with a negative trend from follicular to luteal phase. The maximum change was found 
to be 7.9pmol/L, with over half of the subjects having their ovarian reserve reclassified. 
It must be noted this study was on a very small sample size.   
An interesting hypothesis from Sowers et al (144), depicts two different patterns of 
AMH dynamics. This is based on AMH level and not the chronological age of the 
patient. Lower AMH values, showed less variation and correlated with shorter cycle 
lengths. This was termed the ‘ageing’ ovary, in comparison to the ‘young’ ovary, 
characterised by higher mean AMH values and significant variations within the 
menstrual cycle. Others have shown that age also correlates with the ‘young vs. ageing’ 
ovary patterns (145).  
    
1.4.5 Factors affecting AMH 
Contradictory evidence is published for factors that may alter AMH, which is 




no impact of obesity on AMH per se (146-148) whilst others suggest a negative 
correlation with increasing BMI (149, 150). Piouka et al showed a significant inverse 
relationship with AMH in obesity, irrespective of ovulatory status (151). La Marca et al 
(152) discussed this finding in a study of a ‘normal’ population of regular cycling 
women. A significant decline in AMH was seen with raised BMI (r:-0.1; p=0.03). This 
was confounded by the stronger relationship that increasing age has with increasing 
BMI. 
  
Table ‎1-2 Factors affecting AMH 
FACTOR Negative effect No effect Positive 
effect 





Smoking Negative correlation (153, 
154) 









No effect (159, 
160) 
na 
Pregnancy Negative correlation (161, 
162) 
No effect (163) na 
Ethnicity Reduced AMH in African / 







Smoking, often considered an accelerant of decline in ovarian reserve, is regularly 
assessed as a covariate in trials. La Marca et al (152) found no difference between 
smoking and non-smoking groups, although they acknowledge the limitation of not 
establishing an accurate  smoking history of their subjects. These findings corroborate 




of 137. Alternatively, from an older population, up to a 44% drop in AMH was seen in 
active smokers (166) with no relation to dose or duration of smoking. Passive smoking 
or prenatal exposure to cigarette smoke had no effect on systemic AMH. There is 
conflicting evidence for the impact of passive smoking on ovarian reserve and time of 
menopause (167, 168).  
In contrast, use of agents to suppress ovulation such as the oral contraceptive pill or 
GnRH analogues may reduce AMH with time (156, 157). Others report no change in 
level with 6 months use despite a significant reduction in ovarian volume and follicle 
count (159, 160). Kallio et al (158) suggested that with continuous use of a combined 
hormonal contraceptive, regardless of mode of treatment delivery, there was a 
significant suppression of AMH relative to individual baseline values off hormonal 
contraceptives (AMH 3.88±3 vs. 1.91±1.5 ng/mL; p<0.001). There were similar 
reductions in FSH, LH, inhibin B and oestradiol (169). These authors suggest that an 
inhibition of the early FSH-dependent follicular growth associated with continuous 
hormonal contraceptive use may reduce AMH production through reduction in 
number of antral follicles releasing AMH.  This may even impact on the earlier stages 
of folliculogenesis. Furthermore, ovarian androgen suppression by such contraceptive 
use may also reduce promotion of antral follicle growth, therefore impacting on AMH 
production (169).     
It has been reported that serum AMH concentrations fall during pregnancy, which is a 
situation of prolonged ovarian quiescence (in terms of large antral follicle growth) and 
suppressed FSH secretion. Postnatal recovery of  AMH is then seen (161). A significant 
reduction is seen in AMH during the second and third trimester. The first trimester 
correlates with the non-pregnant value taken ~4.5 months after delivery. Obesity also 
showed an inverse relationship with AMH which correlated at all stages of pregnancy 
with the early pregnancy BMI (161).  In contrast, an earlier study by La Marca et al (163) 
suggested no change in AMH during pregnancy, although the study design did not 
track individual values through a pregnancy but employed a cross sectional method of 
analysis. Both studies (161, 163)  conclude that early follicular activity is not abolished 
in pregnancy due to the presence of detectable AMH throughout. Furthermore, 




available to support early folliculogenesis but not enough for late antral follicle support 
(170). Nelson et al (161) suggest a plausible evolutionary hypothesis, that reduced 
AMH and ovarian quiescence help to prevent multiple pregnancies and asynchronous 
gestations, supported by the rapid recovery of AMH in the early postnatal period.   
Variance between ethnicity and AMH is the subject of much debate. A significant 
proportion of the published work on AMH comes from homogenous cohorts of women 
with little variation in ethnicity. Disappointingly in some of the largest study cohorts 
ethnic background is not recorded (171). A study looking at AMH decline in a cohort of 
809 American women enrolled in the World Interagency Human Immunodeficiency 
Virus (HIV) study used multivariate linear regression to establish if there was any 
difference in AMH decline between white, black or Hispanic women (164). By 
controlling for confounding factors such as age, BMI, smoking and HIV status, black 
women were found to have a significantly lower AMH level than white (25.2% lower; 
p=0.37). Hispanic women also had a lower AMH although this did not reach 
significance (24.6%; p=0.63).  
 
1.4.6 Other uses for AMH 
Ovarian reserve testing has traditionally employed a serum FSH plus dynamic tests 
such as the GnRH and Clomiphene Citrate stimulation tests (172). With the 
development of high resolution ultrasound, accurate antral follicle counts (AFC) can be 
made. A single AMH test may limit observer variability (138), but with the many 
problems associated with AMH measurements (173), many believe AFC may be as 
good as AMH as an index of ovarian reserve and so the 2 indices should be used in 
combination (174). In contrast, recent evidence suggests that AMH is superior to AFC 
in predicting ovarian response to controlled ovarian stimulation (175). The ability to 
not only quantify the ovarian reserve, but also reveal the quality of the reserve 
remains a difficult proposition. Atretic follicles produce less AMH (120) but are still 
registered within the AFC. In contrast, the larger antral follicles are more likely to 
respond to gonadotrophins and therefore predict ovarian response (176). Predicting 




ratio between the pre-ovulatory follicle count and baseline AFC, which shows a 
negative and independent relationship with AMH (177).       
Anti-Müllerian Hormone has been promoted as a test to predict and tailor treatment 
for superovulation (178). Within ART, its value has been proposed  for the prediction of 
oocyte yield and to a lesser extent live birth rate, allowing individualisation of 
treatment (179, 180).  Adoption of safer strategies for superovulation such as the 
antagonist cycle can limit the iatrogenic complication of OHSS (181).  Improving patient 
expectations at the lower extreme of reproductive potential may have psychological 
benefit (182).  Age remains the single most important prognostic factor in achieving a 
successful pregnancy, despite the quantitative merits of AMH as an assessment of 
ovarian reserve (183, 184). Conflicting evidence questions the relevance of low AMH 
on untested fecundability (150, 185).  Some clinicians have used the detection of very 
low AMH to deny patients infertility treatment. Although oocyte yield, live birth and 
treatment success is undoubtedly reduced with reducing AMH, pregnancy can 
nonetheless be achieved even in those women with a very low serum AMH 
concentration (186, 187). This treatment limiting strategy therefore seems unjustified 
and raises ethical questions.   
Assessment of the toxic consequences of oncological treatment on the ovary and 
ovarian tissue using AMH measurement is gaining momentum. Indeed, depending on 
the chemotherapy regimen used, recovery of ovarian function can be tracked by AMH 
(188). In both pre and post-pubertal girls treated with chemotherapy, initial detectable 
levels of AMH showed a progressive decline during the course of treatment. For some 
the levels recovered to near pre-treatment levels by 12 months following completion 
of treatment. Unfortunately those treated with alkylating agents show little recovery 
in comparison with those with non-alkylating agents (189). The alkylating agents are 
not cell-cycle specific and damage both resting and growing follicles. Furthermore, the 
damage is rapid, with apoptotic indicators detectable within 12 hours of injection of 
the alkylating agent, Cyclophosphamide (190). A significant reduction in primordial 
follicle density has been demonstrated by 48 hours following treatment initiation. 
Further longitudinal data is required to establish if the AMH recovery patterns reflect 




are significantly raised, suggesting it may have a use as a potential tumour marker 
(191). At the opposite end of the ovarian spectrum to PCOS, AMH has been shown to 
be useful in establishing premature ovarian insufficiency (POI) (192-194). In women 
with Turner’s syndrome, a recognised cause of POI, karyotypes with a poor probability 
of fertility (e.g. 45XO, 45XO/46XY, 46X del(Xq)) had a lower level of serum AMH 
compared with karyotypes that had a fair probability (e.g. 45XO/46XX, 46X del (Xp)) 
and of whom went through spontaneous puberty (192). Histological work has shown 
normal AMH expression in POI pre-antral follicles but a reduced expression in the early 
antral stages, reflecting a possible defect in antral development (194). Furthermore, 
serum AMH was detectable in women who had >15 AMH immuno-positive follicles 
unlike those who had <5 immuno-positive follicles. Serum AMH testing could be used 
to predict the presence of persistent follicles (194). 
Prediction of age of menopause using AMH remains contentious. Complex genetic 
patterns have emerged controlling the age of menopause, including variants in the 
AMH receptor gene, which have been implicated in initial follicle recruitment (195, 
196). A novel interaction between SNPs on both the AMH gene and AMH receptor 
gene (AMHR2) has been identified (196). The SNP for the AMH gene alone has been 
found to be unrelated to age of natural menopause (197), but in unison with the SNP 
for the AMHR2 there is an apparent negative impact on ovarian ageing, including when 
controlling for parity, smoking and BMI (196). A proposed mechanism for this involves 
the SNP for the AMH gene, which influences the expression of mRNAs (198). 
Furthermore, this mutation can have a protein damaging function (199). It is suggested 
that AMH can be highly predictive of the onset of menopause when combined with 
age. Levels become undetectable approximately 5 years prior to the menopause (200) . 
Broer et al (201) have developed a nomogram based on AMH and age to predict this 
stage of life. The age ranges are noticeably wide and incorporate the vast majority of 
years surrounding the average age of menopause. It is therefore questionable whether 
this provides any clinically useful further information to women contemplating 
delaying motherhood as suggested in this study. Evidence related to maternal age of 




into menopause before the age of 45 years (8.6% decline per year vs. 3.2% decline if 
the maternal mother was over 55 years at time of menopause) (202).  
Endometriosis, a condition of abnormal proliferation and apoptotic regulation of 
endometrial cells distant to the uterine cavity, is implicated as a potential ovarian 
cause of infertility (203). Surgical treatment for endometriomata can have a significant 
negative impact on AMH, especially in bilateral cases (204). A novel therapeutic 
approach to harness the inhibitory role of AMH is under research (205). An intact 
AMH/AMHR2 pathway has been identified within human endometrial stromal cells. 
Activation of this pathway in vitro reduces cell viability through increased programmed 
cell death (205). Potential mechanisms for AMH as an adjuvant therapeutic treatment 
have also been identified in ovarian and cervical cancer lines (206, 207). There is 
increasing expression of the AMHR2 from benign ovarian tumours to borderline lesions, 
especially in the non-epithelial tumours (206). Inhibition of ovarian cancer cell growth 
has been shown via lengthening of the G₁ phase of cancer cells (208). A similar effect 
has been shown in cervical cancer with induction of the tumour suppressor proteins 
p16, p130 and p107 (209). In contrast, some evidence suggests that ovarian stromal 
tumours may be refractory to the anti-proliferative actions of the AMH protein, 
producing their own bioactive AMH (206). An explanation for this could be defective 
type 1 receptors blocking AMH signalling (210).  
            
1.5 Anti-Müllerian Hormone As A Diagnostic Test For PCOS 
The concept of using AMH as a diagnostic tool for PCOS is not new. Predating the last 
decade, studies report higher than normal levels of AMH in both serum and follicular 
fluid in women who meet the different criteria for the diagnosis of PCOS compared 
with controls. Both Cook et al (211)  and Fallat et al (212) demonstrated higher 
systemic levels of AMH in comparison with normal controls and women with different 
infertility aetiologies. A polycystic ovary has an increased cohort of antral follicles (213). 
The ratio of median AMH to AFC has been quoted as a 0.2ng/mL increase per follicle 




demonstrate that although there is a similar increase in serum AMH with AFC between 
PCOS and non-PCOS women, those with PCOS have a consistently higher AMH level 
(difference 2.05 ± 0.26 ng/mL). In contrast, Pellat et al (215) show AMH production is 
increased in anovulatory polycystic ovaries compared with ovulatory polycystic ovaries 
(215). Indeed, granulosa cells from women with PCOS secrete more AMH in vitro than 
those with normal ovaries (215). This was demonstrated from work with granulosa 
cells plated at the same density of cell/plate in all 3 types of ovary. The mean AMH 
production/ granulosa cell (other descriptive statistics such as standard deviation (SD) 
were not specified) was 0.37ng/mL, 1.56ng/mL and 27.4ng/mL for normal, ovulatory-
PCO and anovulatory PCO’s respectively. From this study, it should however be noted 
that the normal ovarian tissue was from an older population of women. It is well 
recognised that AMH declines with age, but also that those with normal ovaries have a 
steeper rate of decline in AMH (214). This may have exaggerated the observed 
difference in granulosa cell AMH production. Not only is AMH over-expressed in the 
granulosa cells from polycystic ovaries, so too is its type II receptor. This positive 
correlation includes AMH, AMHR2 and also FSH receptor expression, which could 
reflect follicle maturation abnormalities (216). Excessive production of AMH may 
therefore lead to disordered follicular growth and excess androgen production in PCOS 
(2). The exact cause of elevated AMH in PCO follicles is unknown, but it is plausible 
that androgens may regulate AMH production as reviewed by Dewailly et al (113). 
There appears to be an intrinsic defect in PCO thecal cells that leads to overproduction 
of androgens (36). Androgen and AMH levels appear to have a positive correlation 
(217). Indeed, animal studies have shown that androgens induce growth of pre-antral 
follicles (218) which in turn produce more AMH. In contrast, there is evidence that 
androgen supplementation reduces AMH production (219, 220). Theoretically, this 
could be due to androgens forcing small-antral follicles to produce less AMH and 
reduce the overall AMH concentration (220). Prolonged androgen suppression does 
not appear to have effect on AMH production (221).  
Interestingly, morphological comparisons have been made between primordial 
recruitment in women with polycystic ovaries and AMH-null mice. The AMH-null mice 




due to lack of inhibitory control from AMH and accelerated follicular recruitment from 
the primordial pool (121, 122). In contrast, disordered folliculogenesis in PCOS is not 
purely confined to the antral stage. A hypothesis supported by histological studies 
purports that primordial follicle recruitment is accelerated leading to an increased 
primary/pre-antral population (222). Reduced AMH expression determined by 
immuno-histochemical staining is shown in the primordial follicle and pre-granulosa 
cells of anovulatory polycystic ovaries in comparison with the normal ovary. Stubbs et 
al (222) do not comment on the potential confounding factor of obesity in this study. If 
indeed obesity leads to reduced AMH expression (151), it should be noted that the 
anovulatory polycystic ovaries in the aforementioned study  (222) came from a 
significantly elevated BMI  cohort (34.1kg/m² standard error mean (SEM) 4.5) when 
compared with either the ovulatory PCO (23.6kg/m² SEM 1.2) or normal ovarian 
(22.6kg/m² SEM 1.7) groups.      
A study to ascertain the cause of secondary amenorrhoea (223) again highlighted AMH 
use in ovarian reserve assessment. Patients were grouped according to the main 
causes of secondary amenorrhoea (PCOS, POI and hypogonadotrophic hypogonadism). 
There was a clear correlation with AMH and the PCOS group. No difference in AMH 
was seen between the regular cycling control group and the hypogonadotrophic 
hypogonadal group. Unsurprisingly, AMH was lowest or undetectable within the 
ovarian failure cohort.    
 
1.5.1 Polycystic ovarian morphology and AMH 
There is debate about the use of a single AMH measurement to replace the ultrasound 
assessment of PCOM. A strong correlation between the AFC and AMH exists (87). 
Table ‎1-3  catalogues a variety of cut off values proposed in the literature to diagnose 
the polycystic ovary and PCOS.  It is clearly evident that a consensus has not been 
reached. Iliodromiti et al (224) conducted a meta-analysis to aggregate data on the 
diagnostic power of AMH in the diagnosis of PCOS. The extracted data demonstrates 
specificity and sensitivity for a PCOS diagnosis of 79.4% and 82.8%, respectively, using 




to define PCOS in the studies included in the meta-analysis. The majority of diagnostic 
studies have selected patients from gynaecology or infertility clinics. This has the 
potential to overestimate the performance characteristics of the test.  Studies that 
have used controls from the general population (225, 226) have found similar AMH cut 
off values with no associated reduction in sensitivity or specificity, negating any serious 
effect of selection bias. As highlighted in the meta-analysis detailed earlier (224), there 
is considerable debate over the equivalence of different AMH measurements 
quantified by different assays; thus making meaningful comparisons across studies of 
AMH and PCOM questionable. For example, the significant difference between the 
Diagnostic Systems Laboratories (DSL) and Immunotech (IOT) / Generation II (Gen II) 
assay values, hamper the comparison between studies (227).  To date relatively few 
studies have used the Gen II assay (228, 229). In contrast, the work of Dewailly et al (87) 
has adopted a retrospective design, analysing records from a subset of infertile 
patients excluding women with unexplained infertility or endometriosis. Interestingly, 
unlike others this study attempts to categorise women using cluster analysis. They 
separate the non-PCOS non-PCOM women from the asymptomatic PCOM group. 
Eliminating the latter removes a potential cohort of women who could be considered 
to have a silent form of PCOS (230). This ‘silent’ assumption is not accepted by all who 
consider PCOM as a normal variant of ovarian morphology (79). On this highly selected 
population, Dewailly et al (87) use receiver operator characteristic (ROC) curves to 
establish the best PCOS diagnostic levels for AMH (as measured using the IOT assay), 
follicle number and ovarian volume of 35pmol/l, 19 and 7ml, respectively. Their data 
provides an interchangeable value for either follicle number or AMH for PCOS 
diagnosis. The AUC is 0.973 for AMH, providing strong evidence for its suitability as a 
diagnostic test for PCOS. More recent work from Dewailly et al (231) follows a similar 
design comparing PCOS patients, using the stricter NIH criteria, against ‘normal’ 
patients without using PCOM within diagnosis. The study population is small, at 59 
subjects, with a high proportion of PCOS women. Using ROC curve analysis (AUC 0.97) 







Table ‎1-3 - AMH values in PCOS diagnosis 
IOT: Immunotech, DSL: diagnostic systems laboratory, GEN II: generation II assay, na: not applicable 
Author Type Study Number Category Type 
Assay 
Result AMH pmol/L 
(7.14 x ng/ml) 
Casadei et al 
2013 (8) 
Prospective study n = 59 
Infertility 
PCOS/OA or HA/ Asymptomatic  IOT AMH >33pmol/L for PCOS  (+ 13 follicles) 33 
Homburg et al 
2013 (228) 
Prospective study n = 234 
Infertility  
PCOS/PCOM/Normal 
Significant difference between groups  
DSL / 
GEN II 
AMH 48pmol/l LH >6IU/L 82.6% PCOS 48 




n = 111  
Community / Clinic 
PCOS/ Premature ovarian failure / healthy 
volunteers 
DSL 3.5ng/ml Sensitivity 74% Specificity 79% 24.99 




n = 262 
Preterm / Term Birth   
Rotterdam & Androgen XS  
PCOM/OA/HA 
DSL AMH >20pmol/l 
Replace PCOM with AMH 
20 








IOT AMH > 7.82ng/ml 
Sensitivity 75.9% Specificity 86.8% 
55.83 
Li et al 2012 
(233) 
Prospective n = 131 PCOS 
 
PCOS +/- hyperandrogenamia DSL AMH 4.23ng/ml for PCOS with HA 30.2 




n=102 Non-PCOM/Asymp PCOM/PCOS 
with/without response to androgen testing 
GEN II AMH >6.2ng/mL for PCOS vs non-PCOM; 








n = 128 Non-PCOM non-PCOS vs. Hyperandrogenic 
oligo-anovulation 
IOT >35pmol/L for PCOM ( plus AFC >19) 35 
Skalba et al 2011 
(148) 
Prospective n = 87 (+ 50 control)  Metabolic clinic and relations IOT Normal weight/obese PCOS (9.6±3.5 vs 
11.2±4.5ng/mL) vs non-pcos (2.5±.8 vs 
2.3±0.7ng/mL) 
na 
Pigny et al 2006 
(234) 
Prospective n = 73 (+ control 96) IVF patients – PCOS/controls IOT ROC curve  
60pmol/L sensitivity 67% specificity 92% 
60 
La Marca  et al 
2004 (235) 
Prospective n = 14 (PCOS) + 15 
matched controls 
PCOS/Normal IOT PCOS vs Normal 





The best compromise between sensitivity (95%) and specificity (95%) for PCOM 
diagnosis was found with a value of 33pmol/L. Both of the French studies (87, 231) 
propose very similar diagnostic AMH levels to that which is derived from the meta-
analysis (using a 7.14 conversion factor from ng/mL to pmol/L, 33.6pmol/L) (224). In 
marked contrast, a number of studies contest the sensitivity of AMH in predicting 
PCOS despite good specificity (228, 229, 234). It is of note, that these studies include 
women with asymptomatic PCOM in their study cohort. Rosenfield et al (229) used 
age-matched volunteers and PCOS cohorts to delineate between the individual with no 
evidence of PCOM, the individual with a PCO, atypical PCOS (no hyper-response to 17-
hydroxyprogesterone (17-OHP)) and finally typical PCOS (17-OHP hyper-response to 
GnRH agonist). An AMH (Gen II assay) value of >6.2ng/mL discriminated between a 
non-PCO and the other 3 groups with a 95% specificity. The sensitivity in discriminating 
between the non-PCO group from typical PCOS remains high (81%), but drops to as 
low as 32% if a PCO is found. A ROC analysis indicated that a considerably higher AMH 
(>10.7ng/mL) was needed to discriminate between the asymptomatic PCO and PCOS 
with 96% specificity, but sensitivity remained low. Homburg et al (228) support these 
findings in a similar study design using patients presenting to an infertility clinic. Three 
groups were identified (controls with no evidence of a PCO/asymptomatic 
PCOM/PCOS). An AMH >48pmol/l (Gen II assay) had a predictive capacity for 
diagnosing PCOS with a 98.2% specificity and 60% sensitivity. The inclusion of LH levels 
of > 6IU/L in the analysis, improved the predictive capacity of AMH for PCOS to 82.6%. 
This study supports the hypothesis that a finding of asymptomatic PCOM represents a 
separate cohort of women, midway between those with a normal ovary and PCOS (80).      
The capacity of AMH measurement to predict PCOS has been shown to be less reliable 
in adolescents, who have a lower sensitivity and specificity for diagnosis (236). The 
reasons for this may be due to the higher incidence of menstrual irregularities (237) 
and to the multi-follicular appearance of ovaries (238) often seen in this population. 
Mortensen et al (86) suggest that the finding of a polycystic ovary (based on ovarian 
volume) in an asymptomatic adolescent is a variant of normal ovarian morphology. 
They acknowledge that 40% of adolescent girls appeared to have a subclinical ovarian 




17-OHP response to a GnRH agonist, akin to that seen in PCOS. The difficulties seen in 
establishing a diagnostic AMH level in adolescent girls is understandable, when 
considering the different phases of NGF recruitment and AMH as reported by Kelsey et 
al (136). 
 
1.5.2 LH, insulin resistance, hyperandrogenemia and AMH 
A demonstrable significant positive correlation exists between serum concentration of 
LH and AMH (151). AMH and LH levels are increased in lean PCOS women relative to 
those who are obese. A positive correlation can be demonstrated between insulin 
resistance, anovulation and hyperandrogenaemia (87, 239). The factors involved in this 
link are however complex. The LH-mediated stimulation of androgen secretion from 
the ovaries is augmented by insulin and insulin-like growth factors, leading to 
increased androgen production. A significant positive correlation has been shown 
between the homeostasis model assessment (HOMA), a measure of basal insulin 
resistance, and AMH level (r =0.621; p<.05) (235).  This notion is supported by in vitro 
evidence. A study comparing granulosa cell growth and AMH production in vitro when 
cultured independently with either FSH or LH, showed no effect of the gonadotrophins 
on AMH secretion by cells from the normal human ovary. From the polycystic ovary, 
AMH production was inhibited by FSH but significantly elevated by LH (215). This 
correlation may provide an explanation of the failure of anovulation PCOS phenotypes 
to produce a dominant follicle. The relationship between LH and AMH appears 
independent of antral follicle number as serum AMH levels are higher in anovulatory 
women with hyperandrogenaemia without PCOM when compared with ovulatory 
women with PCOM in combination with raised androgens (73, 240). Increased LH pulse 
frequency and amplitude (2) and premature sensitisation to LH (241), contribute to 
follicular arrest (240).  Furthermore, there is a reported loss of LH-induced down 
regulation of the AMH type II receptor within the granulosa cells  of anovulatory 
women with PCOS compared with  granulosa cells from women who are normal or 





Studies of treatments aimed at reducing insulin resistance have looked at the effect of 
treatment on AMH concentration. Protracted (>4 month) use of the insulin sensitising 
agent metformin is correlated with a reduction in AMH levels, where as a rapid 
reduction in androstenedione levels is seen within weeks of commencement of 
metformin treatment. Fleming et al (242) hypothesised that this lag time is due to the 
time required to recruit a cohort of follicles under a normalised insulin drive. The study 
in question does not acknowledge the significant reduction in BMI which occurred 
within the 8 month period or in deed any correlation between weight loss and AMH. 
Another group confirmed the lack of change in AMH with short term metformin 
treatment (8 weeks) (243). Further work, showed a differential reduction in AMH 
concentrations with metformin if hyperinsulinaemia existed in the patients from the 
outset unlike those women who were normo-insulinaemic (244). An increase in AMH 
in PCOS with a combination of diet and exercise and orlistat despite reduced 
testosterone and insulin resistance indices has also been reported (245). Other work 
by the same group showed a reduction in AMH with diet and weight loss following 
Sibutramine administration (246). 
The use of AMH as a surrogate marker for HA has been proposed (83). Also, AMH has 
the ability to distinguish between the asymptomatic individual without a polycystic 
ovary and an individual with PCOS with HA (151). The work of Li et al (233) support this 
argument by asserting that AMH should only be used for diagnosing PCOS in women 
with HA due to the relatively improved sensitivity and specificity for this subgroup 
(HA+ 4.23ng/mL  (DSL assay) sensitivity 82% specificity 64%; HA- 3.76ng/mL sensitivity 
64% specificity 62%). Notably, the specificity remained poor in this study, unlike other 
findings which have been discussed previously (228, 229), where a correlation 
between AMH and androgens has been demonstrable regardless of PCOS status (214). 
It has been suggested that the term ‘PCO-like abnormalities’ may be more appropriate 
as the third criterion of the Rotterdam classification (247).  
In summary, the diagnostic utility of AMH for identifying PCOS has generated many 
opinions and has various suggested cut-off values. The wide variation in recommended 
AMH levels and the debate over its diagnostic capacity, indicate that further work is 




ability to apply these values to the general population are needed. The elimination of 
specific cohorts of patients in many of the published studies e.g. asymptomatic PCOM, 
has led to falsely strengthened evidence for the diagnostic use of AMH in PCOS. Given 
the discrepancy between the different AMH assays, more data must be generated 
using the Beckman Coulter Generation II assay, to further validate the diagnostic value 
of AMH before an international standard can be established.  
      
1.6 Ovarian Hyperstimulation Syndrome 
The condition of OHSS is a potentially avoidable iatrogenic endpoint of ovulation 
induction for assisted conception therapy. The condition has a higher incidence in 
women with PCOS (248). It is most frequently created by exogenous administration of 
gonadotrophins and is accentuated by pregnancy (249). Vasoactive products released 
from stimulated ovaries generate increased capillary permeability. Fluid shifts from the 
vascular compartment into the third space, resulting in intravascular dehydration. 
Severe manifestations of OHSS include hepato-renal disturbance, thrombosis, adult 
respiratory distress syndrome and even death. Symptoms of OHSS progress from mild 
abdominal distension and nausea to oliguria, ascites and haematological disturbance. 
Hospital admission is needed in severe cases. Careful fluid balance and 
thromboprophylaxis is imperative. Early OHSS is related to exogenous Human 
Chorionic Gonadotrophin (hCG). Ovarian hyperstimulation syndrome presenting or 
continuing after this is often due to endogenous hCG from pregnancy and can follow a 
protracted course (250, 251). The angiogenic molecule vascular endothelial growth 
factor (VEGF) is thought to mediate the relationship between hCG and OHSS (see 
Figure ‎1-8) (252, 253).  This molecule is an endothelial cell mitogen promoting 
increased vascular permeability and new vessel formation (252, 254). The expression 
of VEGF has been demonstrated in both granulosa lutein and thecal ovarian cells (255). 
Furthermore, soluble forms have been found in follicular fluid and ascites in those with 
OHSS (253, 256). Within the luteal phase, an increase in VEGF occurs, playing a pivotal 
role in ovarian folliculogenesis (257). There is an increased expression of VEGF in 




ovary (255), with enhanced blood flow (258) and overexpression of VEGF, may 
contribute to failed diversion of blood between follicles and enhanced androgen 
steroidogenesis (252). A number of SNPs have been identified in the VEGF gene, that 
are associated with PCOS (254). Furthermore, insulin has been demonstrated to 
augment VEGF secretion (259), which is a fundamental feature of PCOS. Unfortunately, 
although modulation of insulin levels with metformin has been shown to reduce VEGF 
by some authors (260), this has not been replicated by others (261).  
         
Figure ‎1-8 Ovarian hyperstimulation and vascular endothelial growth factor.  
 
Exogenous and endogenous hCG stimulate secretion of VEGF which increases vascular permeability. In 
those with PCOS, an increased concentration of VEGF occurs with altered patterns of VEGF receptor 
expression and signal transduction.    
 
The action of VEGF is via 2 endothelial tyrosine kinase receptors. The first receptor is 
expressed in 2 forms, which can either transduce or prevent signal transduction. The 
combined effect of these differing forms mediates the angiogenic properties of VEGF 




who develop OHSS, who therefore have an increased bioavailability of VEGF (253). It is 
plausible that women with PCOS who experience OHSS, may have increased serum 
and follicular concentrations of VEGF secondary to an increased population of 
granulosa lutein cells and an enhanced secretory ability by the granulosa cells in 
question (259). A reduction in follicular VEGF has been shown in those with PCOS 
treated with an antagonist cycle compared with an agonist treatment IVF cycle (263).  
The complication of OHSS has not been eliminated in modern assisted conception 
practice, despite multiple risk reduction strategies. However, maternal death from an 
IVF cycle or pregnancy is rare. A report from the Netherlands (264), states that 
6/100,000 women died  from a cause directly related  to IVF treatment between 1984-
2008. Three of these 6 deaths were related to OHSS, of whom 2 had PCOS. Seventeen 
deaths were directly related to the IVF pregnancy (42.5/100,000) which was higher 
than the general maternal mortality in this country. Although the overall incidence of 
death related to IVF is low, historical reporting of cases of mortality has been sporadic. 
Significant morbidity may also be under-reported. The risk of both venous and more 
serious arterial thrombosis is increased in assisted reproductive technologies (ART) and 
OHSS. Presentation is often unusual such as the upper extremities, making recognition 
and clinical management hard (265). An estimated 0.08-0.11% of treatment cycles are 
affected by a venous-thromboembolic event. Although low this represents a 10-fold 
increase in thromboembolic events in women of reproductive age (266).  
The overall incidence of severe OHSS, requiring hospital admission is low (0.5-2%). 
Clinically significant moderate to severe OHSS affects 1-10% of IVF cycles (248), whilst 
milder forms can effect 33% of cycles. Women with PCOS or PCOM are at increased 
risk of OHSS due to the sizeable cohort of antral follicles that are responsive to FSH 
contained within the polycystic ovary (267, 268). Once the response threshold for the 
individual is breached, the follicular response may be exuberant, tipping the balance 
towards OHSS. A study from Oxford (269), reported a clinically significant increase in 
incidence of severe OHSS in women undergoing their first IVF cycle based on ovarian 
morphology: normal ovaries (2.7%), PCOM (12.6%) and PCOS (15.4%). Managing and 




cohort of otherwise ‘well-women’.  Table ‎1-4  summarises the main strategies that 
have been implemented to date and their effectiveness. 
 
Table ‎1-4 - OHSS reduction strategies 
Strategy Effect  
Low dose 
Stimulation 
Use individualised, low dose FSH stimulation (270). Use 




Competitive binding to GnRH receptors. Significant 
reduction in OHSS and cycle cancellation when compared 




Oral biguanide. Significant reduction in OHSS and 




Use of Progesterone in luteal phase as alternative to 




Dopamine agonist. Use for secondary prevention of 
moderate OHSS (OR 0.40 95% CI 0.20-0.77). No 




Limited evidence for use of albumin or hydroxyethyl starch 




Withholding gonadotrophins whilst maintain pituitary 
suppression prior  to ovulation trigger e.g. hCG – No 
evidence of benefit (275). Reduction in pregnancy 
outcome with extended coasting (276) 
 
In Vitro Maturation 
 
Avoidance of gonadotrophins eliminates OHSS risk (277). 
Reduced clinical pregnancy and live birth rate. 
 
Freeze all cycles 
 
Prevention of late OHSS by prevention of exposure to 
endogenous hCG (278). 
 
Agonist trigger in 
Antagonist cycle 
Use of GnRH agonist to produce endogenous LH surge 
(shorter half life when compared to exogenous hCG). 
Concern regarding inadequate luteal phase support with 
reduced live birth rate (279).  
 
 
1.7 The Antagonist IVF Cycle 
Prevention of the premature surge of LH and subsequent ovulation is a key element 
for successful controlled ovarian stimulation. Classically, this was prevented by a GnRH 
agonist (280). During the course of this protocol, after initial stimulation, down 
regulation of the GnRH receptors lead to pituitary suppression over a minimum of 
seven days (281). The drawbacks to this type of therapy include ovarian cyst formation, 




widespread uptake of GnRH agonists for controlled ovarian stimulation, the incidence 
of OHSS has increased 6-fold (282) due to the synchronisation of follicle development 
and the high doses of gonadotrophin used to stimulate Graafian follicle development. 
The agonist approach has increased pregnancy rates through increased oocyte and 
embryo creation compared to the older regimens using clomiphene citrate rather than 
necessarily improving embryo quality (283).  In contrast to GnRH agonist therapy, 
treatment with the GnRH antagonist competitively binds to the GnRH receptor, 
producing its effect within hours of administration (281, 284). The aim, similar to that 
of the agonist, is to promote synchronous oocyte maturation and prevent follicle 
maturation arrest by premature luteinisation (281). Early use of the GnRH antagonist 
was hampered by anaphylactoid reactions. Based on the structure of porcine GnRH, 
structural modifications led to the development of Nal-Arg and Detrilex. Although 
these had good anti-ovulatory properties, they also had potent histamine–releasing 
properties (285). Further pharmaceutical development produced compounds without 
these unwanted side effects, allowing for the safe use of the antagonist (286). 
Early reviews of antagonist cycles were not favourable with regard to clinical 
pregnancy. The first Cochrane review (287) cited 5 randomised controlled trials (RCTs) 
comparing the antagonist cycle with the long agonist cycle. There was no difference in 
rates of OHSS (Relative Risk (RR) 0.51; Odds Ratio (OR) 0.79; 95% Confidence Interval 
(CI)  0.22-1.18). Significantly fewer clinical pregnancies were seen with the antagonist 
cycle (OR 0.79; 95% CI 0.63-0.99). Subsequently, 2 reviews disagreed. Al-Inany et al 
(288) maintained that the antagonist cycle had a lower clinical pregnancy rate. Rates of 
OHSS were significantly reduced with the antagonist cycle (RR 0.61, 95% CI 0.42 to 0.89 
P = 0.01) with less use of techniques such as coasting or cycle cancellation. Kolibianakis 
et al asserted that the type of GnRH analogue used for pituitary suppression did not 
affect the pregnancy outcome (289). The most recent Cochrane review (181) 
concluded that there is no difference in live birth or ongoing pregnancy rate between 
the analogues used (28 RCTs; OR 0.87, 95% CI 0.77 to 1.00). In the most recent 
Cochrane review, antagonist protocols have been shown to significantly reduce the 
risk of OHSS compared with agonist protocols (29 RCTs OR 0.43 95% CI 0.33-0.57) (181). 




likely (Risk Difference (RD) -0.10 95% CI -0.14 to -0.07 p < 0.00001). Cycle cancellation 
due to OHSS, was significantly more likely with an agonist (OR 0.5 CI 0.33-0.76 
p=0.001). When the entire population was reviewed the absolute risk reduction was 4% 
with a corresponding number needed to harm of 25. In lay-man’s terms, for every 25 
women treated with an agonist 1 more person is likely to develop OHSS (181). The 
antagonist approach has been acknowledged within National Institute Clinical 
Excellence (NICE) guidance to have a lower rate of OHSS. The agonist approach is only 
recommended for those likely to have a low response (290).  
Further benefit of using antagonist cycles during assisted conception treatment is that 
it allows use of a GnRH agonist trigger for final oocyte maturation instead of hCG. The 
GnRH agonist displaces the antagonist from the pituitary receptor, resulting in a 
gonadotrophin flare response. The released LH drives oocyte nuclear maturation, 
although there is a substantial reduction in surge duration (291). Live birth rates have 
however been disappointing. The 2011 Cochrane review (279) concludes that the 
agonist trigger should not be employed routinely due to a reduced live birth rate (OR 
0.44, 95% CI 0.29 to 0.68; 4 RCTs). The benefit of this alternative trigger is the further 
reduction in OHSS compared with hCG trigger (OR 0.10, 95% CI 0.01 to 0.82; 5 RCTs). It 
is well documented that hCG has a longer half-life and supports the formation of 
numerous corpora lutea compared with LH and so maintains a higher level of 
oestradiol and thus increased risk of OHSS than LH per se (292, 293). In women at high 
risk of OHSS, the reduction of OHSS risk therefore counterbalances in part the reduced 
birth rate. Further consideration is needed for optimal luteal phase support, if the 
agonist trigger is going to be used routinely to treat patients undergoing antagonist 
cycles.  
 
1.7.1 Antagonist cycle in PCOS 
The outcome of IVF in women with PCOS has been reviewed (269, 294). The overall 
cancellation rate of cycles is increased in PCOS. There is an increased oocyte yield, with 
lower total fertilisation but similar number of embryos available for transfer. The 




findings agree with the majority, some disagree. Engmann et al (295) suggest that 
women with PCOM without symptoms of PCOS, have a higher clinical pregnancy rate 
compared to those with normal ovaries.  
A meta-analysis (296) comparing outcomes between the antagonist and agonist cycle 
in PCOS agrees with others regarding the risk of OHSS (297). The overall risk of 
moderate to severe OHSS is reduced with the antagonist cycle using pooled data (RR 
0.60 95% CI 0.48-0.76 p<0.0001). Due to inconsistent classification of severity of OHSS, 
without data aggregation there was no difference between the cycles reporting severe 
OHSS alone. The authors conclude that reduction in severe OHSS following antagonist 
cycles in women with PCOS should be viewed with caution due to inconclusive results.  
Like other studies (289, 298, 299) a shorter duration of stimulation and a lower total 
dose of gonadotrophin was used in the antagonist cycle. There was no difference in 
oestradiol on day of hCG, number of oocytes retrieved, cycle cancellation, clinical 
pregnancy rate (RR1.01 95% CI 0.88-1.15) or miscarriage rate (RR 0.79 95% CI 0.49-
1.28).   
A theory for the higher OHSS rate in the agonist cycle despite similar oocyte yield has 
been suggested (251). An increased dose of gonadotrophin is required to overcome 
the pre-treatment blockade of endogenous FSH following pituitary suppression (300). 
Normally, the ovulatory follicle(s) cohort selection commences at the start of the cycle. 
GnRH agonist down regulation may interfere with this selection process, reducing 
atresia of small antral follicles and allowing more midsized follicles to be generated 
(301). Another interpretation is that following down regulation the low/basal levels of 
FSH remain sufficient to support the growth of multiple small antral follicles up to the 
2mm gonadotrophin dependent stage (302).  During controlled ovarian stimulation, 
large doses of gonadotrophin allow this sizeable cohort to respond on mass creating 
the outcome of OHSS.       




1.8 Insulin Sensitising Agents 
The action of insulin sensitising agents could reasonably be a viable treatment for 
PCOS. Addressing the ovarian insulin imbalance could break the cycle of 
hyperinsulinaemia and HA that is pivotal to the pathogenesis of PCOS (303). Debate 
surrounds the automatic treatment for insulin resistance for those with PCOS (20, 304, 
305). A consensus prevails that these agents should only be used when impaired 
glucose tolerance is seen. Interestingly, metformin use in adolescents with PCOS may 
attenuate disease progression (306).  Some evidence suggests that early use of 
metformin in high risk women e.g. low birth weight / precocious puberty, may limit 
onset of hirsutism and androgen excess. It has been suggested that there may be a 
critical window of development prior to the onset of menarche, that if targeted is 
more effective than treating post-menarche (307). At present the prescribing of 
metformin in adolescent girls remains unlicensed (308); however an RCT addressing 
quality of life in the adolescent found no improvement with metformin when 
compared to placebo (309).  
The vast majority of literature focuses on metformin, discussed below. Other insulin 
sensitisers have been reviewed. An improvement in ovulation and HA has been shown 
with Thiazolidinediones (Glitazones). This family of drugs are a selective ligand of the 
nuclear transcription factor peroxisomes proliferator activated receptor γ. In Type II 
diabetics, blood sugar levels are lowered, unlike non-diabetics, where only a lowering 
of insulin is seen. Promising evidence for Troglitazone suggested improvement in all 
parameters of PCOS (310). Clinical use was aborted due to the significant risk of 
hepatotoxicity, leading to the agent being withdrawn from the market. Other 
Glitazones (Rosiglitazone/Pioglitazone) have a reduced hepatic effect but remain 
category C (animal studies have shown adverse effect on fetus but benefits may 
outweigh risk of drug use), according to the Food and Drug administration (FDA) due to 
animal fetal growth restriction (311). The unwanted side effect of weight gain further 
negates any drug benefit in PCOS women. D-Chiro-Inositol, a buckwheat derivative, 
also has insulin sensitising properties. Initial work suggested an improvement in 
ovulation, androgen profile and plasma triglyceride concentrations (312). However, 





1.8.1 The pharmacology of  metformin 
Metformin is a member of the oral biguanide family of oral anti-diabetic drugs (313). 
The compound is produced from a heating reaction between equal amounts of 
dimethylamine hydrochloride and 2-cyanoguanidine. Figure ‎1-9 shows the structure of 
metformin which has a molecular formula of C4H11N5 • HCL. Under fasting conditions, 
the bioavailability of metformin is 50-60%. Renal tubular secretion occurs with a 








The main modes of action of metformin include: 
 Suppression of hepatic glucose production 
 Reduced intestinal absorption of glucose 
 Increased peripheral glucose uptake and utilisation, improving insulin 
sensitivity 
 
1.8.2 Metformin safety profile 
Metformin readily crosses the placenta in healthy pregnancies and those complicated 
by gestational diabetes (315). A 10 year retrospective review of the use of metformin 
and glibenclamide in early pregnancy, show no association with fetal anomaly; unlike 
the independent association with elevated mean glycated haemoglobin (316). These 
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increase in congenital malformation. Pregnant women with PCOS are at increased risk 
of pre-eclampsia. Despite early work suggesting an association between metformin 
and pre-eclampsia (318), further literature showed no ill effect (319). They also 
showed a protective effect against the development of gestational diabetes (GDM). In 
women who had had a previous pregnancy complicated by GDM, the metformin group 
had a further 14% GDM pregnancies compared with 40% of those without metformin 
(p=0.004). Similar findings have been reported (320). Use of metformin is often limited 
by patient compliance due to frequent gastrointestinal side effects (321). 
 
1.8.3 The action of metformin on the ovary 
The effect of metformin on follicular steroidogenesis seems to be two fold: (i) it has an 
indirect effect of reduced insulin excess on the ovary; and (ii) it has a direct effect on 
the ovary itself (322). Clinical data has shown a reduction in the CYP450c17 activity 
(323). A direct suppression of androstenedione has been found with a preferential 
suppression of 17,20-lyase over 17αhydroxylase activity (324).  See Figure ‎1-3  for an 
outline of the steroid pathway within the ovary. De Leo et al also showed an increase 
in IGFBP1 following metformin treatment, reducing the active availability of IGF- 1 in 
vivo (43). The evidence for androgen reduction is perhaps more robust, than of either 
insulin concentration or SHBG (242, 325). Teissier et al (326), suggest that the follicular 
endocrine microenvironment was critically important for oocyte quality. In mouse 
models, elevated androgens have been reported to generate more meiotically 
incompetent oocytes (327) particularly in response to higher concentrations of either 
androstendione or testosterone (328). Mechanisms for this effect included elevated 
follicular fluid oestradiol levels and chromosome displacement on the metaphase plate. 
The poor oocyte quality recorded in hyperandrogenic women with PCOS has 
contributed to this hypothesis (329). In contrast, it has been suggested that pre-
treatment supplementation of women undergoing ART treatment with testosterone 
may improve follicle growth by increasing granulosa cell FSH receptor levels and 
improving FSH sensitivity. Furthermore, testosterone pre-treatment may induce 




opposing views may in part be related to the type of androgen in question (331). The 
action of metformin may modulate FSH-stimulated aromatase activity within the 
granulosa cells, so reducing the circulating oestradiol concentration (21). Further work 
has shown an inhibition of insulin-stimulated aromatase mRNA expression due to 
silencing of key promoters, via the MEK/ERK pathway (332). These authors have also 
shown that metformin increases the translocation of the GLUT-4 to the plasma 
membrane of human granulosa luteal cells, improving glucose uptake (333). 
Regardless of its direct effect on ovarian cells, the treatment response to metformin is 
hampered by obesity. Indeed, an inverse relationship exists between BMI and 
metformin treatment efficacy (334). This may explain the varied results obtained with 
treatment dependant on trial selection criteria, particularly in the morbidly obese 
(335). 
 
1.8.4 Clinical use of metformin for the treatment of women with 
PCOS 
Early studies suggested an improvement in reproductive function and possible benefit 
to long-term health when insulin sensitisers were used to treat women with PCOS 
(336). Large prospective, randomized studies have, however, failed to demonstrate a 
consistent benefit of metformin. Indeed, metformin is not effective at achieving 
weight loss. Although some biochemical parameters may improve this does not 
translate into a significant benefit in outcomes, whether for the dermatological 
manifestations of hyperandrogenism (337) or the enhancement of fertility (338). A 
prospective randomized, double blind, placebo-controlled multicenter study evaluated 
the combined effect of metformin and lifestyle modification on obese anovulatory 
women (BMI > 30 kg/m2) with PCOS (339) . Individualized patient assessment by a 
research dietitian set sustainable realistic goals with an average reduction of energy 
intake of 500 kcal per day. Both the metformin-treated and placebo groups managed 
to lose similar amounts of weight. An improved menstrual cycle was observed in those 
who lost weight but did not differ between the two arms of the study, reinforcing the 




The use of metformin combined with clomiphene citrate (CC) has been evaluated 
(313). In a Dutch multicenter trial 228 women with PCOS were randomly allocated to 
either: CC plus metformin or CC plus placebo (340). There was no significant difference 
in rates of ovulation (metformin 64% vs. without 72%), ongoing pregnancy (40% vs 
46%) or spontaneous miscarriage (12% vs 11%). More women discontinued therapy in 
the metformin group (16% vs 5%) due to gastrointestinal side effects. The largest 
study, named The Pregnancy in Polycystic Ovary Syndrome (PPCOS) trial, sponsored by 
the NIH in North America enrolled 626 anovulatory women with PCOS (341). 
Randomization to 3 different treatment arms occurred for a total of 6 cycles or 30 
weeks and included: a) metformin 1000 mg twice daily plus placebo, b) CC 50 mg day 
3–7 of cycle plus placebo, or c) combined metformin 1000 mg twice daily plus CC 50 
mg/day (days 3–7). Live birth rates (LBRs) were 7.2% (15/208), 22.5% (47/209), and 
26.8% (56/209), respectively. An increased pregnancy loss rate was seen in the 
metformin-alone group (40.0% vs 22.6% vs. 25.5%, respectively). The results of this 
study may not be applicable to all women with PCOS as the average BMI was greater 
than 35. Dose escalation of metformin did not show significant improvement in 
features of insulin resistance (342). 
The latest Cochrane review on metformin and ovulation induction in women with 
PCOS included 38 trials with a total of 3495 participants (ranging from 16 to 626 per 
study) (338). Trial duration ranged from 4 to 48 weeks with a median daily dose of 
metformin of 1500mg. Pregnancy was reported by most trials, but rarely live birth 
rates. Although metformin was effective in achieving ovulation in women with PCOS 
(metformin vs. placebo OR 1.81 (95% CI 1.13 to 2.93) and metformin plus CC vs. CC 
alone OR 1.74 (95% CI 1.5 to 2.0)), these benefits were not translated into LBRs (7 
RCTs, 907 participants; OR 1.16 95% CI 0.85 to 1.56) (Figure ‎1-10). Live birth rates were 
significantly better in obese women with PCOS taking clomiphene than those taking 
metformin alone (2 RCTs, 500 participants; OR 0.30 95% CI 0.17 to 0.52 (341, 343)). For 
women with CC-resistance, it was suggested that the combined use of CC with 
metformin would improve the chance of ovulation although the numbers of women 
studied were relatively small and the data did not translate into an increased live birth 




with metformin (5 RCTs, 318 participants; OR 4.27, 95% CI 2.4 to 7.59), but no serious 
adverse effects were reported. Therefore, the benefit of metformin in women with 
anovulatory PCOS appears to be limited. Furthermore, the review did not demonstrate 
any benefit from metformin in improving weight loss, insulin sensitivity or lipid profiles 
(338).   
 
Figure ‎1-10 - Metformin combined with clomiphene compared to clomiphene alone (338) 
 
 
In contrast, a large study from Finland recorded an increased chance of pregnancy 
from 40.4% to 53.6% (OR 1.61, 95%CI 1.13-2.29) with metformin treatment.  A total of 
329 women received either metformin (1500mg-2000mg/day) or placebo for 3 months 
prior to fertility treatment and then during fertility treatment and up to 12 weeks of 
gestation if a conception occurred (344).  Obese women seemed to gain the greatest 
benefit from metformin. Although there was no reduction in miscarriage rate, live 
birth rate was significantly increased in those who received metformin (41.9% vs 





1.8.5 The use of metformin in IVF treatment cycles 
The insulin sensitizing properties of metformin are deemed a risk prevention strategy 
for OHSS in women with PCOS but not PCOM alone (345). One of the largest RCTs to 
compare metformin versus placebo in IVF cycles in women with PCOS, randomised 101 
consecutive cycles (260). Metformin at a dose of 850mg twice a day was used for a 
period of roughly 4 weeks prior to egg collection, within a conventional long GnRH 
agonist protocol. No differences between placebo and metformin for total FSH dose 
(1300units vs. 1200units, p=0.94), number of oocytes retrieved (16.2±7 vs. 17.3±7.4) or 
overall fertilisation rate (52.9% vs 54.9% p=0.641) were recorded. However, a 
significant increase in clinical pregnancy rate (CPR) beyond 12 weeks (38.5% vs. 16.3%, 
p<0.05) was seen with a significant reduction in cases of severe OHSS (3.8% vs. 20.4% 
p= 0.02), even when age, BMI and total FSH dose were taken into account. Work by 
Kjotrod et al (346) found similar benefits in the pregnancy rate; lean women with PCOS 
had a higher live birth rate. In a further study by the same group, a total of 150 
patients were randomised to receive either 2000mg/day of metformin or placebo for 
12 weeks prior to IVF treatment. The live birth rate was significantly higher in the 
metformin group (48.6 versus 32.0; 95% CI: 1.1 to 32.2; P = 0.0383) (347). A similar 
reduction in OHSS was seen in a subsequent Cochrane review (OR 0.27 95% CI 0.16-
0.47) (348) and meta-analysis (349). Further studies, have shown an increased total 
dose of stimulation required with added metformin but a lower oestradiol 
concentration on day of hCG trigger (350).  
Historically, the GnRH agonist cycle has been used to treat infertility but the 
development of the GnRH antagonist has seen significant reduction in OHSS. A single 
small trial has used metformin in such a cycle. Although underpowered for OHSS 
reduction, a trend towards reduced incidence is encouraging (351). 40 patients were 
randomised to either 2 months pre-treatment of 1500mg/day of metformin prior to 
commencing an IVF cycle or to simply starting IVF. A statistically significant reduction in 
number of ampoules of FSH used (18±6 vs. 24±8 p<0.05) and oestradiol concentration 
on the day of hCG (2400±600 vs. 3370±900 p<0.05) were noted. Although no 
differences in embryo quality or oocyte yield were observed, an improvement in 




fewer cycles were cancelled after metformin treatment and there was a lower 
incidence of OHSS.  
An underlying factor in the development of OHSS is VEGF (see Figure ‎1-8). This 
glycoprotein acts to induce vascular permeability and regulates physiological and 
pathological angiogenesis, as discussed in Chapter 1.5.  Insulin increases expression of 
VEGF within vascular smooth muscle via the PI3-K pathway and nitrous oxide pathway 
(352). By reducing insulin secretion, metformin may attenuate VEGF release and 
therefore reduce OHSS risk (349). A significant reduction in VEGF was shown by Tang 
et al (260) within the metformin treatment group of their study.  
The benefits of metformin therapy may extend into subsequent frozen embryo 
transfer cycles. A retrospective study highlighted that for those women who had used 
metformin within fresh assisted conception treatment cycles, in their subsequent 
frozen cycle they had a significantly improved live birth rate (28.6% vs. 12.3%). This 
was most significant in women who had a ‘freeze all’ fresh attempt due to OHSS risk, 
whereby a 9-fold increase in live birth was seen (353). Although there was no apparent 
difference in embryo quality, a potential improvement in the hormonal milieu 
surrounding the follicles provided by metformin may lead to a metabolic improvement 
in the embryo. Furthermore, there was a trend for improved freeze-thaw survival of 
embryos in metformin treated fresh cycles. The improved follicular environment could 
influence the ability of the oocyte to enhance early embryo development and viability 
prior to zygotic genome activation (353, 354). It is highly unlikely that there would be 
any residual impact on uterine environment from metformin use in previous cycles on 
subsequent frozen cycles, especially given the average 8 month duration between 
cryopreservation and thaw.   
 
1.9  In Vitro Maturation Of Oocytes 
In vitro fertilisation techniques have many potential drawbacks when they are applied 
to the treatment of women with PCOS and PCOM. High cost, intense monitoring and 




to the gonadotrophin dose, stimulation length and underlying infertility aetiology.  In 
vitro maturation of oocytes has been proposed as a patient friendly alternative to 
conventional therapies that will eliminate OHSS in women with PCOS undergoing 
infertility treatment. The potential benefit of IVM in the treatment of PCOS would 
seem clear, as it avoids the excessive ovarian stimulation required to retrieve multiple 
mature oocytes during conventional ART cycles. Edwards et al (355) described the 
successful fertilisation of in vitro matured oocytes. Subsequent reports of pregnancy 
are abundant. Cha (356) achieved a healthy triplet pregnancy in a woman with primary 
ovary failure. Trounson (357) showed potential for  successful pregnancy in women 
with anovulatory PCOS. Recent literature suggests clinical pregnancy rates of 20-48% 
can be achieved (358-360). Despite a wealth of literature regarding IVM, high quality 
evidence in the form of RCTs comparing IVM against a standard IVF protocol in PCOS is 
sparse. The most recent Cochrane review (361) highlighted that no completed RCTs 
could be included. The authors highlighted 3 on going registered studies (362-364) 
addressing this question although recruitment had yet to start or had been suspended 
in at least 2 of the trials. 
In vitro maturation involves immature egg collection followed by a period of laboratory 
‘maturation’.  This should not be confused with the technique of in vitro follicle culture, 
whereby the follicle and oocyte architecture and interactions are maintained in 
extended culture in either bi-dimensional or three-dimensional in vitro culture systems 
(365-367). During IVM oocytes are cultured for approximately 24-48hrs only. When 
meiotic maturation is completed the oocytes can be fertilised, usually adopting ICSI. 
Oocyte maturation covers the recommencement and completion of the first meiotic 
division of the presumptive gamete to metaphase II (MII) as is manifest by the 
extrusion of the first polar body. This progression would normally occur prior to 
ovulation in vivo. Cytoplasmic maturation must accompany meiotic maturation to 
allow appropriate fertilization and to support early embryo development up until 
embryonic genome activation (368). Not all germinal vesicle (GV) oocytes progress 
either through germinal vesicle breakdown to metaphase I (MI) or on to MII. The 




cell-oocyte interaction, that mimic maturation in vivo in order to a produce a fertile 
gamete (368).  
To understand the intricate system of oocyte maturation it is prudent to understand 
the lifecycle of the oocyte housed within the follicular structure (see Figure ‎1-11). The 
stock of primordial follicles formed between 5 - 9 months gestation, constitutes the 
ovarian reserve. This supply of oocytes services the entire reproductive lifespan of the 
individual. Folliculogenesis is the term used to describe primordial follicle recruitment 
into the pool of growing follicles; this process ends in either ovulation or atresia. In 
humans, this process can take up to 6-9 months to complete (30). Two distinct phases 
of folliculogenesis are described. The pre-antral (gonadotrophin-independent) stage of 
follicle development incorporates the growth and differentiation of the oocyte which 
accompanies the transition from the primordial to secondary follicle.  The antral 
(gonadotrophin-dependant) stage describes the growth and formation of the antral 
follicle that is under the control of FSH, LH and multiple growth factors produced from 
both the oocyte and its surrounding somatic cells (369). The primordial follicle contains 
a small oocyte (~25μm diameter) surrounded by a single layer of squamous granulosa 
cells contained within a basal lamina. The histological hallmarks of the activation of 
primordial growth include the transition from squamous to cuboidal granulosa cells 
alongside oocyte growth. Evidence suggests that the oocyte itself has significant 
control over the activation and growth of primordial follicles (370). Two major 
signalling pathways are involved. These are the restraining phosphatidyl inositol 3-OH-
kinase (PI3K)-AKT-Foxo3a (371) and activating pathway mammalian target of 
rapamycin (mTOR) (372). Furthermore, oocyte and granulosa cell derived proteins are 
also crucial regulators of primordial follicle survival and recruitment. Oocyte derived 
proteins include helix-loop-helix transcription factors and homeobox transcription 
factors that regulate expression of downstream genes including growth differentiation 
factor-9 (GDF-9) and bone morphogenetic protein-15 (BMP-15). These proteins 
promote granulosa cell proliferation (30, 373). Kit ligand produced by the granulosa 
cells interacts with the c-kit tyrosine kinase receptor on the oocyte which promotes 
growth and primordial follicle activation (374). Factors separate to the oocyte-




to primary oocyte. These include stromal produced KGF (also known as fibroblast 
growth factor-7), BMP-4, and BMP-7 (375, 376). In addition, AMH produced from 
growing antral follicles feeds back locally with the ovary to inhibit primordial 
recruitment (124).   
 
Figure ‎1-11 Folliculogenesis from primordial to antral follicle 
 
Transition from primordial follicle (squamous granulosa cells surrounding an oocyte) to primary follicle 
(zona pellucida present and cuboidal granulosa cells). Increasing layers of granulosa cells with the 
appearance of theca represent the secondary follicle before antrum formation and the antral follicle. 
GC: Granulosa cells O: oocyte BL: basal lamina ZP: zona pellucida TC: thecal cells CT: connective tissue 
 
The primary follicle is recognised by 1 or more cuboidal granulosa cells arranged in a 
single layer around the oocyte. Expression of the FSH receptor commences with FSH 
being required for progression of follicle growth through the pre-antral stages (302). In 
concert, the oocyte dramatically increases in size to ~120μm developing the zona 




oocyte genome. The highly transcriptionally active oocyte generates enough protein 
and mRNA to support immediate growth, maturation and subsequent embryo 
development (30). During the primary stage, intimate interdigitating intracellular 
connections are made between oocyte and granulosa cell (377). Within these 
connections, gap junctions facilitate transport of metabolites and signalling molecules 
which ultimately allow the resumption of meiosis (378). The secondary follicle is 
recognised by an increased number of granulosa cells forming multiple layers around 
the oocyte with the acquisition of a thecal layer (30). The granulosa cell layers change 
from simple cuboidal to a stratified columnar epithelium arrangement. Oocyte derived 
GDF-9 and BMP-15 are critical for this transition (379). The thecal layer differentiates 
through the secondary follicle stage to include a theca externa (smooth muscle cells) 
and theca interna. Alongside the thecal layer formation, new vessel formation occurs 
allowing a circulation of nutrients and gonadotrophins (380). By the end of the pre-
antral stage, if an oocyte is removed from the follicular environment it has the 
potential to resume meiosis (381). It is widely recognised that cAMP plays a pivotal 
role in preventing meiotic resumption (382). High levels of oocyte derived cAMP are 
maintained by activation of a G –protein coupled receptor. Cyclic guanosine 
monophosphate (cGMP) transits via the gap junctions from the cumulus cells and 
inhibits phosphodiesterase 3A (PDE3A). This in turn prevents PDE3A-mediated 
cleavage of cAMP, maintaining meiotic arrest as shown in mice (383).  
The antral follicle is characterised by the formation of a cavity filled with follicular fluid. 
It provides the medium that surrounds both granulosa cells and oocyte and through 
which regulatory proteins must pass through (384). The quantity of follicular fluid 
determines the size of the follicle. A dominant follicle has extensive proliferation of 
granulosa cells, thecal cells and follicular fluid compared with atretic follicles which 
rarely grow past the medium follicle size (30). The spatial organisation of the granulosa 
cells in relation to the oocyte, lead to 3 distinct subtypes: the membrana, peri-antral 
area and the cumulus oophorus. Receptors for FSH are expressed within all 3 subtypes, 
but the membrana also express aromatase and LH receptors (30). Oocyte morphogens 
including GDF-9 and BMP-15 function as gradient signals to enable the differentiation 




that FSH acts as a pro-survival factor for follicles inhibiting apoptosis (385). In a highly 
orchestrated symphony of gonadotrophins, growth factors and signalling pathways 
(30), during the follicular phase of each menstrual cycle the dominant follicle responds 
to the pre-ovulatory surge by resuming meiosis. Following the LH surge, the mural 
granulosa mediate cAMP production which reduces cGMP production and leads to 
closure of gap junctions (386). A reduction in cGMP entering the oocyte enables PDE3A 
to activate and cleave cAMP and therefore allow meiotic resumption. Following 
ovulation, the luteinised granulosa cells and theca cells undergo remodelling to form 
the corpus luteum, the cells retain a high capacity to produce progesterone and 
oestradiol to support an implanted pregnancy (30).  
 
1.9.1 Clinical application of IVM 
Women with PCOM or PCOS are prime candidates for IVM as their naturally occurring 
large cohort of antral follicles provides a large reservoir of follicles for collection, 
increasing oocyte yield and potential embryo production. Trounson (357) showed a 
significantly increased oocyte retrieval between a PCO (15.3 oocytes) and non-PCO 
ovary (2.8 oocytes). No difference in yield was seen in anovulatory or ovulatory PCOS. 
Indeed, the majority of studies only consider women with polycystic ovaries as 
candidates for IVM. While women with normal ovarian morphology could receive IVM, 
the success rates from conventional ART cycles far outweigh that what can be attained 
through IVM. Jaroudi et al (387) employed IVM to avoid cycle cancellation in those at 
risk of OHSS following a long protocol IVF cycle. The majority of these women had 
demonstrable PCOM. Human chorionic gonadotrophin was withheld and oocyte 
retrieval completed. Of 21 cycles, 20 retrieved oocytes (average 8.1 oocytes per cycle) 
with a 70.8% maturation rate; of these 17 cycles had on average 2.6 embryos 
transferred (44 embryos per 17 cycles) which resulted in  a clinical pregnancy rate of 
9.5%. The other potential use of IVM is in fertility preservation. For some fertility 
preservation patients the protracted time frames of IVF/ICSI cycles are not appropriate 
(388) and/or supraphysiological doses of gonadotrophins may aggravate hormone 




partner and for whom IVF/ICSI treatments are not appropriate, ovarian tissue 
preservation and subsequent in vitro culture followed by IVM or the collection and 
maturation of oocytes for vitrification may be the better treatment option e.g. Turner’s 
syndrome (391). 
Despite the availability of oocytes for retrieval, oocyte quality may be reduced in 
women with polycystic ovaries. For example, in vitro matured oocytes collected from 
regular cycling women versus anovulatory women, showed a higher maturation and 
embryo development rate (392). There was no difference in embryo development 
between unstimulated and super-ovulated regular cycling women (368, 392). However, 
the initial CPRs were unsatisfactory at 1-2% (356, 357, 393). By changing the 
gonadotrophin priming and timing strategies, success rates of IVM now range from 16-
40%. In 2008, Suikkari et al (394) reviewed the published LBR of 671 IVM cycles from 
which 108 children were born, and reported a 16.1% birth rate. The Oxford Fertility 
Unit (358) have compared matched PCOS/PCO women undergoing IVM or IVF. The LBR 
for these 2 groups of patients is 15.9% and 26.2 % respectively. Other studies have 
reported exceptionally high clinical pregnancy rates (43.9%) and live births (42.4%) 
(359). The latter group (359) adopted an FSH/LH only priming strategy, reduced oocyte 
culture duration (24-26 hours) and single blastocyst transfer compared with the former 
group (358) who used hCG priming pre oocyte retrieval and extended oocyte 
maturation up to 48hrs. Both used similar endometrial priming strategies based 
around oral oestradiol and vaginal progesterone supplementation.  
 
1.9.2 Gonadotrophin priming 
Early work (395) improved oocyte retrieval and maturation potential with a truncated 
course of FSH. An increased follicle number ≥4mm (11.7±1.2 vs. 7.6±1.2 p=0.039), 
oocyte yield (7.5±1.2 vs. 5.2±1.3) and meiotic progression to  MII were seen following 
6 days of FSH pre-treatment (71.1% vs. 43.5% p <0.05). Further clinical work (396) 
found similar outcomes in women with PCOS. There was no difference in oocyte yield 




gonadotrophin priming (59% 92/156 vs. 44% 36/81 p<0.05). Indeed, implantation only 
occurred in women who had been primed with FSH before oocyte retrieval (21.6% 
8/37). It is plausible that the gonadotrophin priming may influence the endometrial 
receptivity through increased follicular oestradiol production, although no difference 
was seen in endometrial thickness between the primed and non-primed group. In 
support of this idea, a significant increase in serum oestradiol was measured prior to 
oocyte aspiration.   
During ART treatments hCG is routinely used 35-37 hours prior to oocyte harvest to 
trigger oocyte nuclear maturation. This strategy has also been adopted in IVM. For 
example, a Canadian RCT (397) randomised 24 IVM cycles to receive either no priming 
or 10000IU of hCG, 36 hours prior to oocyte retrieval. No difference was seen in oocyte 
yield but maturation was significantly improved with priming (84.3% vs. 69.1% p <0.05). 
Speed to maturation was improved at 12 hours (8.8±3.6% vs. 0%) and 24 hours 
(78.2±7.1% vs. 4.9±2.5% p<0.001). Other studies have shown lower maturation rates 
(398).  An increased dose of hCG did not improve maturation but reduced  fertilisation 
(399). It can however be questioned whether the use of an hCG trigger in vivo really 
represents IVM or whether this strategy more closely reflects a minimal stimulation 
IVF treatment cycle.  
The combined effect of FSH priming in vivo and the use of hCG as trigger is debated. 
Lin  et al (400) found the addition of FSH to hCG primed cycles did not improve oocyte 
maturation, fertilisation or clinical pregnancy rate. Son et al (401) showed no 
difference in total maturation or fertilisation rate using both methods. At oocyte 
retrieval, MII oocytes were collected in the hCG primed group (11.4% vs. 0%) with 
more cumulus expansion. Higher CPRs were seen (39.1% with hCG priming vs. 25% 
with FSH priming vs. 22.2% with no priming). In mouse studies (402), the benefit of 
hCG over FSH priming was not confirmed.  More recent work by Junk et al (359) has 
used FSH alone, with  a maturation rate of 69.7% and fertilisation of 71.4%. Blastocyst 





1.9.3 In vitro maturation cycle planning 
The optimum timing for oocyte collection during IVM cycles is unclear. Resumption of 
meiosis in oocytes from larger follicles (9-15mm diameter; 34.5%) is significantly higher 
than in oocytes from smaller follicles (3-4mm; 8.8%) (403). Larger oocytes display 
higher maturation rates (86-105µm vs. 106-125µm; 22.2% vs. 60.0%) (404). 
Endometrial thickness > 5mm and the presence of no dominant follicle >10mm 
or >14mm at the time of harvest are the most common planning factors. This evidence 
has led to oocyte collections for IVM being conducted on day 9-16 of the cycle in PCOS 
women. Apparent discordancy exists with regard to the effect a dominant follicle has 
on IVM outcome. In 1999, an RCT suggested that the presence of a follicle of > 10mm, 
led to a significantly reduced blastocyst rate (56.5% vs. 35.7%) (405). In contrast, more 
recent work suggested higher success rates if a dominant follicle was present. A 
retrospective review (406), using an endometrium thickness of >6mm to time hCG 
priming, grouped collections into 3 (dominant follicle <10mm/10-14mm/14mm). No 
significant difference was seen in oocyte maturation, fertilisation or cleavage rates 
following IVM but embryos transferred from group 2 had a significantly increased CPR. 
Further work has also shown comparable embryo quality, between oocytes from 
<10mm and >10mm follicles (407). This observation is important for those women with 
anovulatory PCOS who may not produce a follicle greater than 10mm without 
stimulation. 
Endometrial preparation is a major limiting feature of IVM cycles. Supplementary 
oestradiol and progesterone are routinely used as gonadotrophin priming seems to 
have little impact on the endometrial thickness (395, 400). A strategy that improves 
the synchrony between the endometrium and embryo has been a frozen embryo 
transfer (FET) cycle. Unfortunately IVM outcomes do not seem to improve with FET, 
with a significantly reduced survival of zygotes and cleavage stage embryos being 
recorded;  most pronounced in women with PCOS (408).  The clinical pregnancy rate 
following freeze-thaw IVM transfers was 6.7% compared to the centres’ standard 
freeze-thaw IVF cycles (24%) and ICSI cycles (20%). More recent work shows 
comparable survival and cleavage between vitrified oocytes matured in vitro or in vivo 




rate using vitrified and warmed embryos instead of a freshly transferred embryos after 
IVM (31.8% vs. 9.4% p<0.03). These authors attribute this result to optimised 
endometrium prior to transfer. Furthermore, it has been suggested that vitrification 
rather than slow freezing is optimal for more sensitive in vitro matured oocytes or 
embryos. A possible reason for this is less cellular trauma caused by ice crystal 
formation in slow freezing methods (411).  A further detrimental effect of IVM is the 
potential for extended culture to induce hardening of the zona pellucida (412). 
Consequently, the majority of centres conducting IVM use ICSI to bypass this 
phenomenon. A retrospective analysis (412) has compared IVM-IVF vs. IVM-ICSI. 
Although fertilisation was significantly improved (69.3% vs. 37.7%), implantation (14.8% 
vs. 24.2%) and clinical pregnancy rate was significantly better with IVF alone; this 
finding was most distinct in those women with PCOS.  
It is clear from the literature, that consensus on the optimum protocol for IVM 
treatment has yet to be reached. This is discussed in more detail in Chapter 3, 
including an overview of the published protocols and outcomes for the majority of IVM 
treatments published worldwide for women with PCOS. The majority of centres use 
hCG priming with fewer adopting gonadotrophin stimulation. Clinical pregnancy and 
live birth rates continue to show a wide variation. This could in part be related to the 
variability in the average number of embryos transferred. The legal boundaries within 
the United Kingdom limit a maximum of 2 embryos for transfer in the populations 
concerned, whilst many studies outside the UK transfer more. 
 
1.9.4  Safety aspects of the clinical treatment of PCOS with IVM   
IVM is safer for the women with respect to OHSS when compared to IVF. Gremeau et 
al (358) report no episodes of OHSS in a case-controlled study. 8.2% of IVF cases had 
moderate–severe OHSS requiring hospital admission. Interestingly, these authors 
noted that of the 97 IVM cycles, 27% had previously either had OHSS or had cycles 
abandoned due to OHSS; highlighting the high risk group being treated. Other studies 




With any experimental treatment regarding an unborn child, safety is of paramount 
importance. Data available for the safety of the child following IVM is relatively limited. 
A Finnish team (414) reported on 46 infants born from IVM, of which 20.9% of the 
mothers had PCO. Preterm birth rate, birth weight and major malformation rate were 
all within the national average range. Increased minor developmental delay was seen 
at 1 year (19 vs. 10%) but equalized by 2 years. A small comparative study showed no 
developmental or growth delay (415). Canadian data showed no increased risk of 
abnormality when compared with the risk for conventional IVF/ICSI. Other studies 
have displayed higher abnormality (416, 417), preterm birth and lower birth weight 
rates (418) when ART is implemented. Interestingly, a higher birth weight with IVM has 
been reported which links to commercial animal studies with ‘large offspring syndrome’ 
(419, 420). Whether the type of ART treatment or the underlying infertility cause, the 
risk to mother and child should not be overlooked (421). 
 
1.9.5 Epigenetics and chromosomal abnormality following IVM 
Epigenetic disruption and imprinting disorders are of concern following the 
manipulation and extended culture of gamete and embryo during assisted conception. 
Angelman and Beckwith-Wiedemann syndromes have been associated with ART and 
specifically with the use of ICSI (422, 423).  This incidence could be due to the 
maturation process or level of gonadotrophin stimulation. Khoueiry et al (424) 
observed an increased disruption in stimulated IVF oocytes when compared to natural 
cycle oocytes. Methylation is part of the epigenetic marking to allow parent-of-origin 
gene expression. By exposing the oocytes to gonadotrophins, fewer GV and MI oocytes 
were methylated after 28 hours of in vitro culture. A limited number of studies have 
compared the rate of aneuploidy in different assisted conception techniques. A non-
significant increase in aneuploidy rates in IVM embryos was seen when compared with 
IVF controls (60 vs. 33%) (425). Yakut et al (426) display higher aneuploidy in certain 
chromosomes (11,13,15,21,22) after IVM  in comparison to in vivo maturation. 
Oocytes from PCOS patients (427) confirm mice studies (428), with a significant 




oocytes (43.7%; 33.3%) when compared to in vivo matured oocytes (13.6%; 9.1%). 
Contrasting work from Vieira et al (429) who compare non-obese in vitro matured 
oocytes from standard IVF cycles found no significant difference in IVM rates or 
meiotic abnormalities between women with PCOS and other infertility causes. 
Microarray analysis of oocytes shows some persistent immature gene expression in 
IVM-MII oocytes that bears resemblance to GV oocytes. This molecular immaturity 
may play a part in the lower potential of IVM embryos (430). Gene expression is also 
altered in the cumulus complexes of IVM oocytes with up-regulation of genes involved 
in deoxyribonucleic acid (DNA) replication and repair (431). 
OHSS remains a significant risk despite practical methods already in place, aimed at 
reducing the iatrogenic complication. Any further reduction in this risk should be 
sought. Metformin has the potential to provide a simple adjuvant solution. The drug 
has an established safety record and is easy to administer. Establishing if it offers 
further benefit in an antagonist cycle will complete the ‘jigsaw’ for metformin 
management and IVF.  Similarly, IVM is a possible alternative treatment option for high 
risk women, limiting the exposure to gonadotrophins which potentiate the effect of 
OHSS. For this to be a viable treatment, efficacy and optimisation of the IVM protocol 
needs to be attained. Useful comparisons between standard IVF treatment and IVM 




1.10 Aims & Objectives 
The overarching aim of the work presented in this thesis was to evaluate the efficacy 
of risk reduction strategies for the treatment of women with PCOS who are undergoing 
assisted conception. The evidence presented in this literature review highlights the 
rapid advancement in the science and technology in assisted conception. It is therefore 
necessary to use the new information to improve potential treatment. On this basis it 
is possible to hypothesise that: 
“The diagnosis and management of treatment strategies for PCOS should be re-
evaluated in light of the advances in understanding of AMH and the development and 
adaptation of treatment modalities such as metformin and IVM, to improve the 
outcome and management of risk for women with PCOS who undergo ART treatment”.  
Three inter-linked aims tested this hypothesis. These were:  
Aim 1: AMH has clinical utility as a diagnostic test for PCOS and can be used as a 
marker of severity of the condition. 
This hypothesis is addressed in Chapter 2. The aims of this chapter were:  
(i) To conduct a diagnostic study for PCOS on a prospective consecutive series 
of women presenting to the Infertility clinic using the AMH Gen II assay. 
(ii) To evaluate the use of AMH as a substitute for the Rotterdam criteria of 
PCOS as a means to diagnose the phenotypic presentations of PCOS. 
(iii) To evaluate the impact of age on the diagnostic utility of AMH 
measurements in women with PCOS. 
(iv) To define the cut-off levels for AMH in the diagnostic pathway of PCOS 
 
Aim 2: Metformin treatment can significantly reduce the risk of OHSS in women with 
PCOS undergoing a GnRH antagonist treatment cycle. 




(i) To conduct an appropriately powered RCT to evaluate the use of metformin as 
an adjunct in an antagonist IVF treatment cycle with the aim of OHSS reduction 
in women with PCOS. 
(ii) To establish if metformin had any impact on ovarian stimulation, embryo 
development and clinical treatment outcome within an antagonist cycle.  
 
Aim 3: IVM is an effective alternative to a standard IVF assisted conception cycle for 
those with PCOS who wish to avoid OHSS. 
The aims of Chapter 4 were: 
(i) To conduct a pilot study to optimise conditions for the use of IVM as a 
treatment strategy in women with PCOS, as a prelude to conducting a full RCT 
to evaluate the efficacy of IVM as a strategy to treat women with PCOS or 
PCOM. 
(ii) To conduct a cost analysis of IVM as a treatment for PCOS compared with a 









2 Chapter 2 
Anti-Müllerian Hormone As A Diagnostic Tool For 
Polycystic Ovary Syndrome 
 
2.1 Introduction 
Anti-Müllerian Hormone has an extensive literature base. Its origin, physiology and 
history have been discussed in detail within Chapter 1 section 1.3. The focus of this 
chapter is therefore to assess the diagnostic potential of AMH within the context of 
treatments for women with PCOS and furthermore to evaluate its ability to reflect the 
severity of disease in individuals. A wide literature is already available highlighting the 
increased systemic level of AMH in women with PCOS. Despite this, there is little 
consensus on the best reference range to use in the diagnosis of PCOS or what variable 
AMH correlates with the most closely. Whether it is purely a reflection of AMH 
production from the small antral follicles or also the interplay between underlying 
ovarian hyperandrogenism and anovulation will be discussed.  
Targeted assay development, directed at some or all parts of the AMH molecule, has 
led to the development of a series of AMH assays. The current AMH assay has seen the 
commercial acquisition of the two previously available assays DSL and IOT under the 
ownership of Beckmann Coulter (Beckmann Coulter (UK) Ltd, High Wycombe). 
Beckman Coulter has subsequently enhanced their AMH assay (Generation II). 
Historically, a number of epitopes have been used to measure AMH levels (432-434). 
Through this process, the optimal detection antibodies were ascertained (F2B/7A and 
F2B/12H) and were subsequently used within 1 of the first commercially produced 
assays by DSL. This assay targeted both the pro-region and mature region of the AMH 
molecule. With extended exposure the first antibody will also bind to the mature 
region of the molecule (see Figure ‎1-6). This ability negates any effect of proteolysis 
within the sample. An interesting point is the ability for these antibodies to detect not 




Calibration standards have varied through the history of the AMH assay. The IOT 
standard has been made in heat-inactivated bovine calf serum, using native AMH and 
has been adopted into the AMH GEN II assay. With only a single commercial assay 
available presently (227), impetus to create an international standard has lost 
momentum, despite the obvious need for such a universally accepted standard. The 
details of the assay remain proprietary information of Beckman Coulter. With the 
varying standards, results also vary. Although a significant correlation exists between 
the DSL and IOT samples, given the primary endpoint measurement, it is important to 
be aware of the units and normal range for each assay. Traditionally DSL uses pmol/l 
and IOT uses ng/ml. A simple multiplication conversion would not be appropriate as 
the different antibodies bind the AMH molecule differently and therefore the two 
assays do not exhibit a true linear relationship. Furthermore, values with the older DSL 
assay were initially approximately 40% lower than either the IOT or GEN II assay (435). 
More recent data has suggested that this difference may no longer exist, as there has 
been a systematic shift in assay calibration (436).  The amalgamation of the antibodies 
from the DSL assay with the calibration standards of the IOT assay, have produced the 
only commercial assay now available from Beckman Coulter. Although care is needed 
when comparing studies retrospectively, from now the comparison of discriminatory 
cut off levels for normal ranges and discriminators of ovarian function should be easier 
and more reproducible (227).  
Many Assisted Conception Clinics may not offer in house testing for AMH due to cost 
and the need for additional equipment and so they send specimens by post to external 
laboratories for analysis. Preparation, handling and storage of the samples affect the 
viability of the sample and the validity of the result. For example, a potential 31% 
increase in AMH has been seen with storage of whole blood at 20°C over a 3.5 day 
period (437) where as there is a  more modest variability if it is stored at 4°C. These 
findings are supported by others (438). Negligible change occurs if serum separation is 
carried out within 3 hours of sample collection regardless of the subsequent 
temperature storage. These findings lead the authors to suggest an ‘enzymic 
breakdown phenomenon’ occurs if there is direct contact between blood cells and 




laboratories even though data reproducibility is good within a laboratory. This may be 
of relevance clinically when comparing results from different laboratories (439). Trust 
in the assay has also been negatively affected by technical updates from Beckman-
Coulter, suggesting complement interference and dilution may have an effect on the 
sample value.    
The ability to predict a women’s potential fertility at any given age has led to the 
generation of a number of statistical models to assess this parameter (171, 440, 441). 
These studies have had varying cohort sizes and backgrounds. Some of the largest 
studies have originated from Glasgow, UK (171, 442). The data suggests a non-linear 
quadratic equation provides the best model for correlating age and AMH decline. All of 
the models used within these studies tended to underestimate the natural log of AMH 
at the older age of the reproductive spectrum. Overall quadratic regression was best 
within the 25-45 years age bracket. Initially, the older DSL assay was used to generate 
the regression models (171), but more recently a similar nomogram has been 
produced for the GEN II (Figure 2-1). Good inter-assay agreement with the newer GEN 
II assay has been established concurrently by members of the same team (436). 
However,  the only variable to be assessed within this nomogram was age and no 
consideration was given to other fertility based pathologies such as the presence of 
polycystic ovaries. The transatlantic external validation of this initial nomogram has 
provided evidence for its generalised predictive capacity (442). Despite a clearly 
different cohort of women, still from an infertile population, the quadratic relationship 




Figure 2-1 Comparison of AMH nomograms for age using DSL and GEN II assay (436) 
 
 
Nelson et al (442) have challenged the scientific accuracy of other nomograms 
generated at a similar time to their own work due to their reduced sample size and 
AMH assay amalgamation (440, 443). Seifer et al (444) provide an alternative statistical 
hypothesis through a large dataset (17,120) showing a stepwise reduction in AMH with 
age. A mean reduction of 0.2ng/ml/year up to age 35 was seen, with further reduction 
to 0.1ng/mL/year thereafter. This study includes all women even at extremes of 
reproductive age, whom as a group were excluded by Nelson (171). These 
inclusion/exclusion criteria may reflect the differences in relationship seen between 
AMH and age. All studies acknowledge that sub-groups of patients have not been 
investigated. A nomogram specific for ethnicity and presence of polycystic ovaries 
would be a useful research tool.       
The unification of different assays to form the single Generation II (Beckmann Coulter) 
assay has provided a stepping stone towards an international standard needed in this 
field. The inherent difficulties in combining data from different assays should be laid to 
rest. Few publications to date (only 2 (228, 229)) have used the Gen II assay in PCOS 
diagnosis. The present study therefore aims to provide further statistically relevant 
information to aid the interpretation and dissemination of evidence in support of the 
use of AMH measurements in the diagnosis of PCOS. Neither of the aforementioned 
studies (228, 229), used a clearly defined consecutive series. A prospective consecutive 




accuracy study (445). For example, the entire group of patients that the test would 
routinely be carried out on. In the case of AMH testing this may be either in the 
secondary or tertiary clinical setting. This is to ensure that the outcome of such a study 
has good clinical applicability.  Instigating restrictions in eligibility or not including all 
women within a given time period may subject the study findings to bias. Two 
examples of such bias include limited challenge bias (446) and bias created from 
diagnostic case control (445, 447). The former type relates, for example, to exclusion 
of more difficult cases. In doing this, there may be expected to be a lower number of 
false positive or false negative results enhancing the specificity and sensitivity of the 
study outcome. Studies which select the populations to study using 2 separate 
selection processes (sampling of those with the target condition and healthy controls) 
can overestimate the diagnostic performance. A well designed consecutive series 
therefore provides a  superior study design for diagnostic studies and is needed for the 
validation of the AMH Gen II assay in relation to PCOS.      
 
The aims of this chapter were:  
(i) To conduct a diagnostic study for PCOS on a prospective, consecutive series 
of women presenting to the Infertility clinic using the AMH Gen II assay. 
(ii) To evaluate the use of AMH as a substitute for the Rotterdam criteria of 
PCOS. 
(iii) To evaluate the utility of AMH in diagnosing the phenotypic presentations 
of PCOS. 
(iv) To evaluate the impact of age on the diagnostic utility of AMH in PCOS. 






2.2 Materials And Methods 
 
2.2.1 Eligibility criteria and baseline investigations 
Formal ethical approval (ethics reference 12/LO/0679) for this project was granted 
from Leeds West Ethics committee. All patients attending an appointment at Leeds 
Centre for Reproductive Medicine (LCRM) in either outpatient or treatment clinics 
were eligible. The only exclusion criteria, was active current hormonal treatment. An 
information sheet regarding the trial was supplied with verbal discussion during the 
appointment with the doctor/designated research nurse.  If the patient wished to take 
part written consent was completed, allowing a sample of blood to be taken and 
stored, alongside routine blood tests. Consent was gained to access the patients’ 
record to allow a concise history to be recorded.  
Consecutive patients within the LCRM registrar outpatient clinics were asked to take 
part. Patients were also included from the ‘LCRM treatment’ clinic. These patients had 
completed baseline investigations and were due to commence ART treatments. These 
treatments included ovulation induction or in vitro fertilisation with or without ICSI. 
Patients were only recruited at the starting point of their treatment cycle prior to 
hormone administration. These patients were assigned a ‘Treatment’ code to separate 
them from the ‘Outpatient’ group. The number of patients who declined or were not 
eligible for recruitment was not recorded.  
The case notes were reviewed to compile a relevant history for each patient. This 
included: age, BMI (kg/m²), ethnic background, duration of infertility, cause of 
infertility, menstrual cycle, patient reported symptoms of acne or hirsutism, 
ultrasound ovarian volumes, ultrasound antral follicle count and the requested blood 
tests as discussed next. Although symptoms of hyperandrogenism were not formally 
quantified, a patient’s subjective perception of either acne or hirsutism was recorded. 
The routine clinical serum investigations (see Table 2-1) were completed with the 




1-3 of the menstrual cycle. These included FSH / LH / Oestradiol / Testosterone / 
Androstenedione / SHBG. Thyroid function tests (TFTs) and prolactin levels were 
evaluated to rule out other endocrine pathology that may affect the menstrual cycle. 
Blood samples were taken by the routine phlebotomy services and samples processed 
by blood sciences staff. In most instances, samples were separated and serum 
analysed within 12-18 hours of collection (although this was not formally evaluated). 
Samples for oestradiol, testosterone, androstenedione and SHBG were stored frozen (-
20°C) and analysed in the Supra-Regional Assay Service (SAS) laboratory at Leeds 
(http://www.sas-centre.org/centres/hormones/leeds). A further aliquot of serum was 
stored for AMH analysis. If an early menstrual phase test was not possible, for example 
due to patient geographical location, systemic AMH concentration was measured 
randomly in the cycle (141) and the correctly timed hormonal profile within the last 6 
months was recorded. Leeds Centre for Reproductive Medicine is a tertiary centre for 
reproductive treatment with a treatment radius of several hundred miles. To allow 
sample storage without delay or to avoid difficulties with transport, samples were 
taken at the clinic appointment and stored at -20°C; the stage of the menstrual cycle 
was noted.  
A baseline trans-vaginal ultrasound was completed as routine either at LCRM or Leeds 
General Infirmary (LGI). The scan was usually done at random through the women’s 
menstrual cycle due to availability of scanning appointments within the hospital. 
Machines used included a Philips HD15 and Philips HD11XE with a C8-4V trans-vaginal 
probe (Philips healthcare, the Netherlands). Baseline scans were completed by trained 
ultrasonographers or radiologists. The day of the menstrual cycle was noted. Ovarian 
volume was measured using 2 perpendicular planes of direction through the ovary. 
The volume was calculated using the formula V = 0.526 x length x height x width. The 
total number of follicles 2-9mm was recorded, alongside any dominant follicles or 
cystic structures that could affect the ovarian volume. If the number of follicles 






Table 2-1 Serum blood tests 








Gonadotrophins Siemens Advia Centaur 





phases: FSH 1-8 









7.9 cv 6.5% 
/ 45.5 cv 
2.9% 




Oestradiol In house 
radioimmunoassay (RIA) 













MS) Leeds SAS 
laboratory 
Female adult 
<1.8 nmol/L  
In house 
calibrations 
0.8 cv 5.3% 





MS (Leeds SAS 
laboratory) 
1.4 - 7.4 nmol/L In house 
calibrations 
3.5 cv 6.5% 
/ 
8.7 cv 6.8% 
SHBG Siemens Immulite 2000 
& Siemens reagents 
Female adult 
18-114 nmol/L 
WHO 95/560 5 cv 5.7% / 






Siemens Advia Centaur 
& Siemens reagents 
TSH 0.2-6.0 
mU/L 






0.7 cv 3.0% / 
26.4 cv 4.4% 
11.9 cv 5.7% 
/ 45.7 cv 
3.7% 
Prolactin Siemens Advia Centaur 





  IS 75/537 153 cv 2.6% 
/  
907 cv 3.3% 
 
A diagnosis of PCOS was given if 2 out of 3 criteria were met, as outlined within the 
Rotterdam consensus for PCOS (449). Criteria include: oligo-/anovulation, clinical 
and/or biochemical features of HA and PCOM. Anovulation was defined as the 




As previously stated no formal method to assess clinical hyperandrogenism was 
undertaken and records relied on the patients’ perception to provide this information. 
Biochemical HA was assessed by measuring serum testosterone by tandem mass 
spectrometry. A value greater than >1.8nmol/L defined laboratory HA.  
 
2.2.2 AMH analysis 
One additional serum gel separator tube was taken from the patient. Samples were 
transported as whole blood from Seacroft Hospital to the central laboratories at either 
St James’ University Hospital or the LGI. They were centrifuged on arrival at the central 
laboratory within a maximum 9 hours from sampling.  The separated serum was stored 
in aliquots ready for batch analysis at -20˚C. Storage time was less than 18 months. 
Although some samples had been processed prior to June 2013, due to a field safety 
notice (FSN 20434-3) issued by Beckmann Coulter, all samples were subsequently 
reanalysed using the amended protocol. This led to an additional step whereby the 
sample was mixed with AMH Gen II assay buffer. This was instigated due to 
complement interference in fresh or freshly frozen undiluted samples producing 
results up to 70% lower than expected.  
Anti-Müllerian Hormone generation II enzyme linked immunosorbent assay (ELISA) 
was obtained from Beckman Coulter (High Wycombe, Buckinghamshire, UK). This 
assay is an enzymatically amplified two-site immunoassay. The method was not 
calibrated against any international standard. Liquid calibrators provided by Beckmann 
Coulter were traceable to their working standards. The 7 AMH Gen II calibrators were 
labelled ‘A-G’; with ‘A’ containing 0ng/mL of AMH and ‘B-G’ containing defined 
concentrations of bovine AMH in bovine serum with sodium azide. These were 
prepared into 100ul aliquots and frozen. Once thawed ready for use, the aliquot was 
stable for 7 days stored 2 to 8°c. One set of quality controls (QC) were provided, 
containing a low and high concentration of bovine AMH in bovine serum with sodium 
azide. These were run at the beginning and end of each run, with the same storage and 
stability as the calibrators. Internal quality control checked that results were within 2 









All calibrators, QC and patient samples were run in duplicate. Up to 96 samples could 
be run at once including 37 ‘unknowns’ (patient samples) run in duplicate. All analyses 
were performed by Ms Nicola Calder in the Research and Development (R&D) 
department of Blood Sciences, Pathology, Leeds Teaching Hospitals Trust (LTHT). The 
quality control data included: QC 1 mean 20.6pmol/L, inter assay CV 8.2%; QC 2 mean 
66.2pmol/L, inter assay CV 12.3%. The stepwise process of the AMH assay is outlined 
in Figure 2-2. 
 
2.2.3 Statistical analysis  
Data was processed using IBM SPSS 21 statistics package (IBM Corporation, New York, 
USA). Descriptive statistics included mean, SD, median and interquartile range (IQR) 
and geometric mean plus 95% CI. Continuous data was tested for normality using the 
Kolmogorov-Smirnov test. If data were positively skewed, a log transformation was 
used where appropriate to allow parametric tests to be completed (Testosterone, 
Androstenedione, Prolactin and AMH). Data were then back transformed and 
presented as the geometric mean with 95% confidence intervals. Data that were 
normally distributed were analysed by Student’s t-test and one-way Analysis of 
variance (ANOVA). Parametric data are presented as mean and SD (age). Data that 
were not normally distributed including following log transformation, was analysed 
using Mann-Whitney and Kruskal-Wallis tests. This data is presented as median and 
the IQR (BMI, FSH, LH and SHBG); contingency tables were employed where necessary 
with Chi-squared statistic and Fisher’s Exact test.  Although the p value of <0.05 is 
often adopted as the cut off significance level in medical research, for this chapter 
p<0.01 was considered significant. This was to limit error artificially created by 
performing multiple significance tests, thereby reducing the type 1 error rate (450). 
With AMH as the dependant variable, multiple regression was used to establish if the 
individual Rotterdam criteria for PCOS were independent predictors of AMH. All 
statistical results were presented in a comparable manner with other published 




A ROC curve (451) was used to assess the diagnostic value of AMH as a means to 
diagnose PCOS (sensitivity plotted against 1-specificity). The performance of AMH was 
quantified by calculating the AUC with a 95% confidence interval. An ideal test would 
have had an AUC of 1 whereas a value of 0.5 shows no diagnostic ability greater than 
chance. In simple form, an optimal test will have a curve that runs close to the top left 
hand corner of the graph. Youden’s index is often used in conjunction with ROC curves. 
The Youden’s index (J) is a function of sensitivity and specificity, frequently used to 
evaluate the overall effectiveness of a diagnostic test (452). It is advantageous over 
AUC by providing a single threshold diagnostic value which maximises the sensitivity 
and specificity of the test. The values range from 0 to 1. One implies a perfect test 
(with no false negatives or positives) and close to 0 implies a test of limited value.  The 
J value is the maximum vertical distance on the ROC curve from the diagonal line of 
chance, with the intersection on the curve providing the optimal cut off value of the 
test (see Figure 2-3). The J value is defined over all the cut points (c) as: 
J = maximum [sensitivity (c) + specificity (c) – 1} 
 
Figure 2-3 Example of a receiver operator characteristic curve, depicting the maximal 
vertical position from the diagonal line (J) with the area under the curve (AUC) including 






With the suggested AMH values generated from the study, a series of substitutions 
were then carried out on the consecutive group of women. The substitutions involved 
all of the individual criteria of PCOS (Rotterdam) and reclassified the population of 
women with PCOS. Repeated substitutions were then carried out with a higher value 
of AMH if a significant deviation (over-classification) in the numbers occurred. Fisher’s 
exact test was used to assess if there were significant differences in proportions of 
women diagnosed with PCOS using AMH in lieu of the standard Rotterdam criteria.   
 
2.3 Results 
Between June 2012 and May 2013, 383 patients consented to have their AMH blood 
test taken for research alongside their routine investigations. Figure 2-4 outlines how 
the patients were recruited and the number of complete results obtained. There were 
253 complete (all diagnostic results available) sets of results, grouped as a consecutive 
series from the outpatient clinic setting and also from the treatment clinic. All 
diagnostic performance testing used the consecutively recruited outpatient group to 
ensure results obtained from the study were representative of the population studied. 
Descriptive results used the entire dataset. Disappointingly, the remaining 130 patients 
did not have either an AMH test taken and stored or diagnostic tests completed. These 
patients were therefore excluded from the study analysis. It was also apparent that 
despite requesting specific information on the baseline ultrasound (total antral follicle 
count), a variety of reporting styles occurred. The majority of ultra-sonographers 
reported the entire antral follicle count, but there was a common occurrence for a 
report to state multiple/12 or more/ polycystic appearance of ovaries. For the purpose 
of this study, these cases have been labelled as having 24 follicles if both ovaries were 
involved. This may have underestimated the total number of follicles present and 








2.3.1  Patient demographics categorised by PCOS status 
Patients meeting the Rotterdam diagnostic criteria for PCOS comprised 40% of the 
study population. Table 2-2 tabulates the differences in both AMH and baseline 
variables for women with PCOS, PCOM and normal ovarian morphology. Women 
presenting with PCOS were significantly younger (p<0.01) than those with normal 
ovaries with a lower mean FSH. LH, Androstenedione and Testosterone were 




with isolated PCOM were significantly younger than those with normal ovaries but 
similar in age to those with PCOS. Those with PCOM also had a significantly increased 
(p<0.01) androstendione, testosterone and AMH compared with those with normal 
ovaries. Only 5 instances of deranged TFTs were found which were evenly spaced 
through the groups. Figure 2-5 depicts the increase in median AMH through the 3 
categories, with PCOM being situated part way between normal ovaries and PCOS.     
 
Figure 2-5 AMH concentration categorised by polycystic ovary morphology 















A vs. B A vs. C B vs. C Overall 
significance 
value (p) 
Age (Years) 33.2 ± 4.3 30.9 ± 4.5 29.6 ± 4.8 2.3, 0.7-3.9, 
0.02³ 





BMI (kg/m²) 25 (22.4-27.5) 23.8 (21.0-27.7) 26 (22.0-29.0) 1.2, 0.14⁴ -1.0, 0.20⁴ -2.2, 0.03⁴ 0.07² 
FSH (iu/L) 7.6 (6.2-9.3)  6.3 (5.2-7.7) 6.2 (5.2-7.6) 1.3, 0.001⁴ 1.4, <0.01⁴ 0.1, 0.94⁴ <0.01² 
LH (iu/L) 4.9 (3.4-6.3) 5.1 (3.5-6.9) 6.7 (4.4-10.2) -0.2, 0.49⁴ -1.8, <0.01⁴ -1.6, <0.01⁴ <0.01² 
SHBG 
(nmol/L) 
56 (39.3-79.0) 62 (48.8-79.5) 47 (29.3-68.5) -6.0, 0.60⁴ 9.0, 0.01⁴ 15.0, 0.02⁴ <0.01² 
Testosterone 
(nmol/L)* 








































Mean ± SD, Median (IQR), *Back transformed Geometric mean (95% CI)  
¹ANOVA ²Kruskal-wallis test ³T test (mean difference (95% CI difference), significance level) ⁴Mann-Whitney U test (median difference, significance level) ⁵T test 




2.3.2 Factors affecting AMH  
There was no significant association (p>0.05) between AMH and BMI. The AMH value 
did not change by BMI category within normal, PCOM or PCOS women (Figure 2-6). 
The lack of association was confirmed by linear regression, using AMH as the 
dependant variable (0.46, -0.7 – 1.6 95% CI, p=0.43). There were clear correlations 
between the individual criteria of PCOS (Rotterdam criteria) and serum AMH 
concentration (Figure 2-7). All of these associations were significant (p<0.01). The AMH 
concentration increased with follicle number and ovarian volume, with the highest 
values attributable to what would be classified as PCOM (24 plus follicles). With both 
evidence of hyperandrogenism (Figure 2-7) and increasing cycle length (Figure 2-7D) a 
significant (p <0.01) increase in AMH concentration was seen. Table 2-3 used multiple 
regression to show the independent variables used to diagnose PCOS were related to 
AMH level. Testosterone, PCOM and cycles >3 months remain significant predictors of 
AMH when controlling for BMI. This outcome remains correct whether the log 
transformed or the raw data were used. Although there were correlations between the 
predictor variables, none of these correlated highly.  
 
Table 2-3 Multiple regression: Dependant variable log (AMH) 
  Unstandardized  coefficient  
Model  B (slope) 95% CI for B Significance 
level 
1  (constant) 1.13 1.08 – 1.19 <0.01 
 PCOM 0.56 0.48 – 0.63 <0.01 
2 (constant) 1.16 1.10 – 1.21 <0.01 
 PCOM 0.44 0.36 – 0.51 <0.01 
 Log ₁₀ Testosterone 0.54 0.37 – 0.70 <0.01 
 Normal vs. >3 month 
cycles 
0.12 0.00 – 0.23 0.04 
 Normal vs. <3 month 
cycles 
0.07 -0.02 – 0.15 0.14 
Note R² = 0.46 for model 1; ∆R² = 0.10 for step 2 (p<0.001)   






Figure 2-6 Anti-Mullerian hormone and body mass index. A: Anti-Mullerian hormone by PCOS status categorised by body mass index; B: Anti-Mullerian 







Figure 2-7 AMH serum concentration and individual criteria of PCOS (Rotterdam) A: Total follicle number B: Combined ovarian volume C: Features of 





Within this study population, the timing of the AMH test within the menstrual cycle 
was recorded (Figure 2-8). If it was taken within a 35 day cycle, there was no difference 
in AMH value when grouped by early follicular, late follicular and secretory phases. If 
taken after 35 days since the last menstrual period then there was a significantly 
higher AMH (0.54, 0.37-0.78, p=0.001). Of the study population, 29 patients were 
excluded from this calculation as the menstrual timing was not recorded.  
 
Figure 2-8 AMH concentration by timing of test in menstrual cycle between women with 











Ethnicity (Figure 2-9) and parity (Figure 2-10) were the final 2 parameters reviewed. 
Separating the population according to ethnicity, generally into Black, White or South 
Asian revealed no significant difference in systemic AMH concentrations (p=0.14). 
When the two largest populations (White and South Asian) were compared, although 
there was a difference in geometric mean (26.9 (23.7–30.5 95% CI) pmol/L vs. 35.0 
(25.3-48.6 95% CI) pmol/L) of serum AMH, this was not significant (0.8, 0.6-1.1, p=0.13). 
Likewise with parity, there was no difference in serum AMH concentration whether a 
woman had had a successful pregnancy or not (1.2, 0.3-1.8, p=0.23).  
 
Figure 2-9 Anti-Müllerian Hormone concentration comparison between the White and 








Figure 2-10 AMH concentration categorised by parity and Polycystic Ovary Syndrome. 
 
 
2.3.3  Phenotypes of PCOS and corresponding AMH 
Serum AMH level was significantly (p<0.01) associated with the different phenotypic 
presentations of PCOS (Figure 2-11). Those with all 3 components (PCOM, HA and OA) 
had the highest value when compared with those with HA and OA only (72.7 (61.0-86.7 
95%CI))pmol/L vs 28.4 (6.0-134.9 95%CI)pmol/L; 0.4, 0.2-0.8, p=0.005). No difference 
was seen between those who had PCOM and either OA or HA (41.4 (31.4-54.5 95%CI) 
pmol/L vs. 44.7 (33.6-59.5 95%CI)pmol/L; 0.9, 0.6-1.4, p=0.69). The OA/HA group was 
too small (n=4) to draw a useful comparison between the non-PCOS group. Significant 
variation occurred across the groups in BMI and testosterone. Those with all 3 
components had a heavier and more androgenic profile. Overall, any PCOS phenotype 





Figure 2-11 AMH concentration by phenotype of Polycystic Ovary Syndrome 
 
 
Table 2-4 Comparison of demographics by Polycystic Ovary Syndrome phenotype (OA: 













s P-value   
Overall  
P-value 
Age (Years) 32.7 ± 4.5 28.8 ± 5.3 31.0 ± 4.8 30.0 ± 5.3 28.6 ± 4.4 0.19¹ <0.01¹ 













(24.0 – 29.8) 
0.05² <0.01² 
FSH (iu/L) 7.2  
(5.6 – 8.8) 
7.0  
(5.0 - 9.0) 
6.1  
(4.8 - 7.9) 
6.3  
(5.7 – 7.7) 
6.3  





(0.8 - 0.9) 
2.2 
(0.5 – 10.1) 
1.0 
(0.9 – 1.2) 
1.2 
(1.0 – 1.5) 
1.8 






(3.8 – 4.4) 
6.4  
(2.9 – 14.0) 
5.4  
(4.3 – 6.7) 
5.4 
(4.4 – 6.7) 
6.3 

















(61.0 – 86.7) 
<0.01¹ <0.01¹ 





2.3.4  Diagnostic performance of AMH 
Figure 2-12 presents a ROC curve using different hormonal tests to diagnose PCOS 
within the consecutive study population. When selecting AMH this has the best AUC of 
the group (0.84). This is in contrast to LH and an increased LH: FSH ratio (a variable 
traditionally used in PCOS diagnosis) which had an AUC of 0.64 which reflects a limited 
diagnostic value. Testosterone concentration was below AMH in terms of diagnostic 
value. This diagnostic performance for Testosterone will be artificially strengthened as 
it has been one of the criteria used in the PCOS diagnosis. Within this study population 
there was a higher than average prevalence of PCOS at 41% compared with that 
documented in the literature.  
 
Figure 2-12 Diagnostic performance of AMH (0.84), antral follicle count (0.72), 
testosterone (0.74) and androstenedione (0.65) in PCOS using a receiver operator 
characteristic curve with the corresponding AUC values 
 





Further analysis of the different components of PCOS using the ROC curve, reflects the 
higher diagnostic potential of AMH compared with either Testosterone or FSH (Table 
2-5). The AUC for AMH is >0.75 for cycles longer than 3 months, biochemical HA and 
PCOM. There was little difference between the AUC for clinical and biochemical HA 
when comparing AMH and Testosterone.  
 
Table 2-5 Diagnostic performance using area under the curve values for AMH, 
Testosterone and FSH for components of Rotterdam criteria plus 95% confidence 
intervals 




0.71 (0.62 – 0.79) 
0.67 (0.58 – 0.76) 
0.85 (0.78 – 0.92) 
0.74 (0.66 – 0.82) 
0.66 (0.58 – 0.75) 
0.99 (0.98 – 1.00) 
0.45 (0.36 – 0.54) 
0.47 (0.38 – 0.56) 
0.45 (0.35 - 0.56) 
Cycles  
- >35 days 
- >3 months 
 
0.62 (0.51 – 0.72) 
0.75 (0.65 – 0.86) 
 
0.59 (0.48 – 0.70) 
0.72 (0.60 – 0.83) 
 
0.45 (0.35 – 0.56) 
0.43 (0.31 – 0.55) 
PCOM 0.90 (0.84 – 0.95) 0.73 (0.65 – 0.81) 0.33 (0.24 – 0.41) 
PCOS 0.84 (0.78 – 0.90) 0.74 (0.66 – 0.82) 0.38 (0.29 – 0.46) 
 
2.3.5 Suggested AMH cut-off values 
Using Youden’s index (detailed within the statistical methods), the following tables 
(Tables 2-6 – 2-8) provide rationale for the best serum AMH threshold value to use to 
distinguish between women with normal ovaries, PCOM and PCOS.   
 
Table 2-6 AMH cut-off values with corresponding sensitivity and specificity for normal 






PCOM Sensitivity Specificity Youden’s Index 
(J) 
10 51 27 0.96 0.26 0.22 
15 37 27 0.96 0.46 0.42 
20 18 26 0.93 0.74 0.67 
22.5 12 24 0.86 0.83 0.69 
25 8 22 0.79 0.88 0.67 
30 5 20 0.71 0.93 0.64 
35 5 18 0.64 0.93 0.57 






Table 2-7 AMH cut-off values for distinguishing between PCOM and PCOS (orange 
shading= best value) 
AMH cut-off 
(pmol/L) 
PCOM PCOS Sensitivity Specificity Youden’s Index 
(J) 
25 22 60 0.90 0.21 0.11 
30 20 58 0.87 0.29 0.16 
35 18 55 0.82 0.36 0.18 
40 18 49 0.73 0.36 0.09 
42.5 16 45 0.67 0.43 0.10 
45 12 45 0.67 0.57 0.24 
47.5 11 40 0.60 0.61 0.21 
50 10 35 0.52 0.64 0.16 
 
Table 2-8 AMH cut-off values for distinguishing PCOS from non-PCOS (orange shading = 
best value) 
AMH cut-off (pmol/L) Sensitivity Specificity Youden’s 
Index 
25 0.90 0.69 0.59 
28 0.89 0.72 0.60 
29 0.88 0.73 0.61 
30 0.87 0.74 0.61 
31 0.84 0.76 0.60 
35 0.81 0.76 0.57 
 
 
Using the values of 29pmol/L and 45pmol/L as suggested AMH cut off values for 
diagnosis, a series of substitutions for PCOS criterion were made (see Table 2-9). An 
AMH value of 29pmol/L could be swapped with PCOM, without any significant changes 
(p>0.05) in the number of women diagnosed with PCOS. If 29pmol/L was used 
alongside PCOM for substitutions of either OA or HA PCOS was over diagnosed. 
Increasing the AMH limit to 45pmol/L eliminated this problem. Therefore a proposed 
29pmol/L is optimal for PCOM and 45pmol/L for either OA or HA, if the other 






Table 2-9 Fisher's Exact: Substituting AMH for different PCOS criteria  
Substitutions Actual count (n=164) Significance levels 
OA/PCOM vs. OA/AMH (29pmol/L) 17 vs. 12 p = 0.44 
HA/PCOM vs. HA/AMH (29pmol/L) 16 vs. 17 p = 1.00 
HA/OA/PCOM vs. HA/OA/AMH (29pmol/L)  32 vs. 33 p = 1.00 
BioHA/OA vs. BioHA/AMH (29pmol/L) 1 vs. 2 p = 1.00 
OA/BioHA vs. OA/AMH (29pmol/L) 1 vs. 3 p = 0.62 
PCOM/OA vs. PCOM/AMH (29pmol/L) 17 vs. 35 P  = 0.01 
PCOM/OA vs. PCOM/AMH (45pmol/L) 22 vs. 17 p = 0.50 
PCOM/HA vs. PCOM/AMH (29pmol/L) 16 vs. 35 p < 0.001 
PCOM/HA vs. PCOM/AMH (45pmol/L) 16 vs. 22 p = 0.39 
PCOM/BioHA vs. PCOM/AMH (29pmol/L) 4 vs. 35 p < 0.001 
PCOM/BioHA vs. PCOM/AMH (45pmol/L) 4 vs. 22 P < 0.001 
 
2.3.6 Diagnostic performance of AMH for PCOS by age 
In relation to patient age in women with PCOS, AMH had a higher diagnostic potential 
(Figure 2-13) in the older age groups. The youngest group has the lowest AUC. Overall 
there was a highly significant difference in AMH concentration between the non PCOS 
and PCOS group within each age bracket (as shown in Table 2-10). Although 
approaching significance (p=0.05), the downward trend in the non-PCOS AMH level 
was not significant across the age groups. There was no significant difference in AMH 
for those with PCOS in each age group, although the numbers in each group were 
small. There was also no difference in BMI by age or PCOS status. There was a 






Figure 2-13 Diagnostic performance of AMH for PCOS per age group (with the respective 
AUC beneath chart) 
 
AMH1: age ≤ 25yrs (0.74),  AMH2: age 26-30yrs (0.85), AMH3a: age ≥31yrs (0.83) 






Table 2-10 Comparison of AMH, BMI and Testosterone by age group and PCOS status 
 Age group 
(Years) 
Non–PCOS 





















28.1 (16.1 - 48.8) 65.3(48.1 -88.7) 0.4 (0.3 -0.8) 
<0.01⁴ 
0.05³  0.13³ 
 26-30 
(n=73) 







16.1 (13.5 -19.2) 43.7 (33.3 – 
57.4) 
0.4 (0.3 - 0.5) 
<0.01⁴ 
  
 >35  
(n=51) 
15.2 (11.8 – 19.5) 45.4 (29.6 – 
69.6) 
0.3 (0.2- 0.6) 
<0.01⁴ 
  
BMI (kg/m²) ≤25  25.51 (21 – 30.4) 28 (24-32) 0.15¹ 0.27²  0.06² 
 26-30 26 (22 – 29.1) 26 (23-29) 0.91¹   
 31-35 24.6 (22 – 26) 24 (21-28) 0.89¹   
 >35 24 (22.2 -27.1) 24 (21.8 – 31) 0.67¹   
Testosterone 
(nmol/L)* 
≤25  1.1 (0.8 – 1.4) 1.7 (1.3-2.2) 0.6 (0.4 – 1.0) 
0.04⁴ 
<0.01³ 0.05³ 
 26-30 1.0 (0.9 - 1.2) 1.5 (1.3 – 1.7) 0.7 (0.6 – 0.9) 
<0.01⁴ 
  
 31-35 0.8 (0.8 - 0.9) 1.3 (1.1 – 1.5) 0.7 (0.6 – 0.8) 
<0.01⁴ 
  
 >35 0.8 (0.7-0.8) 1.0 (0.7 – 1.4) 0.8 (0.6 – 1.1) 
0.09⁴ 
  
*Geometric mean (95% CI) or median (IQR) ¹Mann Whitney U test ²Kruskal Wallis ³ANOVA ⁴T test (ratio 






2.4  Discussion            
This study has shown that a large proportion of women meet the Rotterdam criteria 
for PCOS within the infertility clinic setting. Women with PCOS often present at a 
younger age, with an increased androgenic profile. Isolated PCOM represents a group 
of women mid-way between those with normal ovaries and PCOS. This finding is 
reflected in the serum AMH concentration. Body mass index has little association with 
the value of AMH. For those with PCOS, AMH reflects the severity of the condition. The 
highest levels are seen in those with the full constellation of symptoms including OA, 
HA and PCOM. All of the Rotterdam diagnostic criteria for PCOS are independent 
predictors of the AMH value. Furthermore, AMH can be used as a substitution for any 
of these features. It has diagnostic value that is maintained with age.      
 
2.4.1  AMH and hyperandrogenism 
This study supports the correlation between anovulation (240, 453), 
hyperandrogenism (83, 151) and AMH. The significant differences (p<0.01) seen in 
AMH between elongated cycle length, particularly greater than 3 months apart and 
evidence of HA, whether clinical or biochemical, are symbolised in Figure 2-7. In this 
simple representation, the effect of each factor independently or together i.e. PCOM, 
OA and HA are not incorporated but provide a good starting position to evaluate AMH 
as a diagnostic tool in PCOS. Using multiple regression within the current study, 
Testosterone, the visualisation of PCOM and oligo-ovulation are all independent 
predictors of AMH when adjusted for BMI. This holds for the entire population and the 
PCOS group. This agrees with Eldar-Geva et al (217), who found an independent 
relationship between the AMH level and both the number of small antral follicles and 
serum androgen (testosterone) level. In contrast, Pigny et al (454), found that by using 
multiple regression analysis the association between serum androgen and AMH was 
no longer significant when controlling for the number of 2-5mm follicles. Further 





provided by Chen et al (455). These authors found via multiple regression with follicle 
number per ovary as the dependant variable, that only the free androgen index and 
AMH level maintained a significant independent relationship with follicle number. As 
outlined below it would seem reasonable to assume that the correlation is also true 
between AMH and serum androgen.  
It is timely to remember the histological findings of earlier work (456). Women with 
PCOS have the same primordial pool size, with a larger number of growing follicles but 
also an increased population of atretic follicles. To explain this finding, AMH has been 
implicated in 2 stages of follicle activity leading to PCOS (151).  Excessive follicle 
recruitment from the primordial pool is followed by increased attrition and ultimately 
defective selection of the lead follicle, culminating in anovulation. The inhibitory role 
of AMH in follicle recruitment (121) is deficient despite an elevated level of the 
hormone. New evidence, suggests that there is significantly less 
immunohistochemistry staining of AMH in the primordial and transitional follicles of 
anovulatory PCO women (222). This data supports the view that AMH operates in a 
paracrine fashion, whereby growing follicles locally inhibit the recruitment and growth 
initiation of adjacent primordial follicles. The relative deficiency of AMH surrounding 
the primordial follicles in anovulatory PCO women leads to reduced inhibition of 
primordial follicle recruitment. Furthermore, AMH reduces follicle sensitivity to FSH, 
inhibiting FSH-induced pre-antral growth (126). The theory of AMH acting as the ‘gate 
keeper’ of follicular oestrogen production should also be considered (113). The time of 
follicle selection corresponds with a declining intra-follicular expression of AMH in 
follicles >8mm (114). There is also a transition from a low to high oestrogen producing 
state. Oestrogen orchestrates this decline in AMH via the interaction between the 
oestrogen receptor β and the AMH promoter region (457). Evidence to support the 
gate keeper theory suggests that there is an inhibition of aromatase activity (113) by 
AMH. This ensures that there is limited oestrogen production from the small antral 
follicles, which allows direct communication between the ovary and pituitary in the 





Although the exact causative factors leading to PCOS are unknown; the intra-ovarian 
environment, in particular the androgen concentration within it, is thought to play a 
role (2). Porcine work has demonstrated mitogenic effects of androgens on the 
granulosa cells via the androgen receptor, potentiating the follicle growth-promoting 
effects (458).  A convincing argument for the role of androgens in this process, 
predating birth, is outlined by Homburg (459). Exposure to androgens in utero may re-
programme the fetus, although these effects may not be apparent until later in life, as 
seen in studies using prenatally androgenised female rhesus monkeys (460). The 
gonadotrophin LH influences this androgenic environment by driving androgen 
production through the binding of thecal LH receptors. Granulosa cells from 
follicles >10mm (i.e. after acquisition of LH receptors) from a PCO cultured with LH 
generate a 4-fold increase in  AMH production, augmenting the anovulatory problem 
(215). Granulosa cells cultured with LH from normal ovaries only produced a modest 
rise in AMH production. In addition, it has been suggested that granulosa cells from 
those with PCOS gain LH responsiveness at a smaller follicular size than normal ovaries 
(461). Further work on luteinised granulosa cells (post hCG), show an over expression 
of AMH and AMH-receptor II in anovulatory PCO women which is not seen in normal 
ovaries, in response to LH (129). The current study shows a significant correlation 
exists between AMH and LH (p<0.01) which may potentiate the effects of both of the 
hormones. Hyperinsulinaemia and insulin resistance (IR) may act as a ‘second-hit’ on 
the already dysregulated system by amplification of the intra-ovarian 
hyperandrogenism (2). Formal insulin resistance testing was not performed as part of 
this study. 
A method to reconcile the opinions on PCOS definition (7, 462, 463) was suggested by 
Dewailly et al (83). These authors use principal component analysis to highlight that 
similar information can be captured by different variables. The outcome of this study 
aggregated AMH, AFC, LH, testosterone, androstendione and free androgen index (FAI). 
They suggest that a single ovarian anomaly can be summarised by ovarian androgen 





AMH or AFC can act as a surrogate marker for either. The strong correlation seen 
between testosterone and AMH supports this theory. Interestingly, Dewailly et al (83) 
suggest a more appropriate androgen to use in general diagnosis is androstenedione 
over testosterone. This may be in part due to the secretion of androstendione by the 
theca cells and conversion to testosterone peripherally (464). Within the current study, 
both androstenedione and testosterone remained significant independent predictors 
of AMH during multiple regression. Further analysis helps with the often subjective 
topic of ‘clinical HA’. Regression suggests that AMH is a better predictor than either 
testosterone or androstenedione. 
The importance of the HA/AMH correlation is potentially relevant to the long-term 
sequelae of PCOS. It is thought that women with PCOS have an increased long term 
risk of cardiovascular and metabolic disease, often related to, if not caused by, obesity 
and insulin resistance. Shaw et al (465) outline an increased postmenopausal risk of 
angiographic coronary artery disease and reduced cardiovascular disease free survival 
if there is a positive history of irregular menses and biochemical evidence of HA. 
Furthermore, Wild et al (466) show that women with the metabolic syndrome prior to 
starting hormone replacement therapy (HRT) are more likely to experience adverse 
cardiovascular events during the course of treatment. This group of authors suggest 
individual risk stratification should be observed prior to commencing HRT.  A raised 
AMH as a marker for HA could help counsel patients to make life adjustments to 
modify these long term risks. Conversely, Bleil et al (467) suggest that accelerated 
ovarian aging with a reduced AMH level may in fact predict an increased 
cardiovascular risk. The phenotypic presentations of PCOS may not all share the same 
cardiovascular risk (82, 468). It is suggested that those who have OA and PCOM but 
normal androgen profile have minimal increased risk to the normal population. The 
reduced AMH in this population compared with the most ‘severe’ form (OA/HA/PCOM) 
in the current data could reflect the reduced long term risks (Figure 2-11). As 
suggested later, the diagnostic performance of AMH with age increases. Further 





2.4.2  AMH and PCOM 
The well documented positive correlation between AFC (138, 454, 469) and AMH is 
clearly replicated within this trial (see Figure 2-7). This correlation is confirmed with 
the high AUC of 0.90 for AMH diagnostics for PCOM alone (see Table 2-5). This AUC is 
in fact the highest value for all separate criteria for PCOS. Such a significant parallel has 
led many to suggest that AMH can replace or act as an alternative for AFC (87, 232, 
234, 455). As previously discussed, Dewailly et al (83) showed that AFC and AMH are 
strong markers of an ovarian anomaly. Sahmay et al (470) argued that PCOM is the 
most effective factor affecting serum AMH levels. The editorial by Raine-Fenning (471) 
summarises this argument, with the stance that AMH and an ultrasound scan (USS) 
‘are unlikely to offer mutually exclusive information’. Although the proposed cut-off 
values in our study were formulated on the current data, using an AMH of 29pmol/l as 
a substitute for PCOM, we found no difference via Fisher’s exact analysis between the 
proportions of women diagnosed with different combinations of PCOS (Table 2-9). This 
finding continues when substituting AMH for OA or HA, when either of the latter two 
factors is present. If PCOM is the constant factor, there is a significant difference in 
proportions using an AMH of 29pmol/L. If the value is increased to 45pmol/L (as 
recommended to delineate between PCOM and PCOS in this study  (Table 2-7) there is 
no longer a difference. The exception to this is if combining PCOM with biochemical HA 
or AMH.  This raises a novel possibility in the diagnostic process; a 2-tier process for 
AMH substitution. For purely PCOM substitution the lower level could be used; but if 
substitution for either OA or HA when USS is the only feature, the higher threshold 
should be used. This would support the findings of Dewailly et al (83).    
With improvements in ultrasound technology there have been recommendations to 
increase the threshold follicle number for the diagnosis of PCOM (76, 87, 472) to 
prevent over diagnosis. This is perhaps reflected in those exhibiting PCOM within the 
PCOS population studied here (98 of 102 women with PCOS had PCOM). A consensus 
on whether the new threshold should be 25 follicles (88) or even doubled to 28 





may be eradicated by automated follicle counts (474). In the context of AFC, AMH 
quantification offers an attractive option to be used in conjunction with AFC data or 
individually  for the diagnosis of PCOS, as long as ongoing assay stability problems can 
be resolved (173).  
 
2.4.3  Phenotypic presentation 
A formal gradation of PCOS severity has been postulated. The ability to do this can 
pose a problem due to the subjective nature of some of the components of diagnosis 
e.g. clinical hyperandrogenism. Although formal scoring systems are available for the 
latter issue, these may be academic when evaluating the patients’ perception of the 
problem. Use of a simple diagnostic test in these situations may be of value to 
biochemically reflect the severity of condition and tailor treatments, such as 
gonadotrophin stimulation. 
As seen in Figure 2-11, AMH is significantly affected by the different phenotypes of 
PCOS. Evidently those displaying all 3 factors have an increased AMH; this situation in 
itself could be deemed the most severe. This agrees with much of the published data 
(151, 229, 470, 475). Sahmay et al (470) found that those with HA/OA/PCOM showed a 
3-fold increase in circulating AMH compared to those with OA/HA only. They found a 
non-significant marginal elevation in AMH in the PCOM/OA vs. PCOM/HA group. No 
difference was seen in BMI or testosterone across the 4 phenotypes. This differs from 
the current study where the reverse is seen, with a significant difference in BMI and 
testosterone by phenotype, but interestingly not androstendione. Although the data 
was not significant (p>0.05), having HA correlates with an increased AMH. 
Considerable variation was seen in both the BMI and testosterone levels, with the 
HA/OA/PCOM group being heavier and more androgenic than the other phenotypes. 
Piouka et al (151) agree with the current data and suggest that the lowest AMH level 
by phenotype (OA/PCOM) reflects the least severe form of the syndrome. Those in 





metabolic abnormalities. Controversially, some believe it not part of the PCOS 
spectrum (462). The conclusions surrounding the relative placing of the ‘classical’ 
OA/HA phenotype (73) from the current study are limited due to the small group size 
(n=4). 
 
2.4.4  Timing of test 
AMH variation within the menstrual cycle has been discussed in detail in chapter 1.3.4. 
Table 2-11 reflects this discussion providing the contradictory evidence surrounding 
intra-cycle variation. As suggested by Streuli et al, although individual variation will 
occur, this is unlikely to be clinically significant (141). Furthermore, it has been 
suggested that the intra-cycle variability in serum AMH concentration is less than that 
found in the antral follicle count (138). Two different AMH patterns related to AMH 
level, termed the ‘ageing’ or ‘young’ ovary, suggested by Sowers et al (144) may also 
be relevant. More recent studies provide further support for this phenomenon (145, 
477). This theory is particularly pertinent to women with PCOS who are recognised to 
have elevated AMH levels and therefore may display more intra-cycle variation in their 
serum AMH levels. It should be noted that any true biological inter-cycle variability 
may also be eclipsed by assay measurement variation (173). 
A diagnostic test should be easy to implement in the clinical setting. For example, it 
has long been recognised that FSH is menstrual cycle stage dependant and can have 
wide inter-cycle variability. This complicates the ease of use of the test, often 
necessitating repetition of samples to provide an estimate of ovarian reserve and tailor 
treatment protocols. From the current study data (Figure 2-8), no significant difference 
was seen between the AMH values whether taken in the early follicular (day 1-5), mid 
follicular (day 6-14) or secretory (day 15-35) phases (p=0.459). The similarity is 
maintained when either the PCOS population (p=0.735) or non-PCOS group (p=0.403) 





Table 2-11 Intra-cycle variation of serum AMH concentration 
Author Assay Study group Significant difference No significant 
difference 
La Marca et 
al (128) 
(2006) 
IOT n =12 18-24yrs 
regular cycle 
 No significant change 
throughout cycle 
Hehenkamp 
et al (478) 
(2006) 
DSL n =44 fertile regular 
cycle 
 No consistent 
fluctuation throughout 
cycle compared with 




DSL n =20 18-35yrs 
regular cycles 
 No significant variation 
in cycle 
Wunder et al 
(140) (2008) 
DSL n =36 20-32yrs 
regular cycles 
Significant variation – highest 
in late follicular compared 
with time of ovulation or early 
luteal phase 
 
Streuli et al 
(141) (2009) 
IOT n =10 regular 
cycles. Mean age 
24.1yrs 
Small but significant drop in 
AMH in early luteal phase 
Smaller than inter-




et al (138) 
(2010) 
DSL n=44 regular cycles 
25-46yrs 
 Less intra-cycle 
variation than antral 
follicle count 
Sowers et al 
(144) (2010) 
DSL n =20 regular cycles 
30-40yrs 
Significant variation follicular 
phase in higher AMH levels 
‘young‎ovary’.‎Little‎variation‎









Significant variation in intra-
cycle variation which should 
be taken into account when 






DSL 2 groups: 




In later reproductive life 
variable changes between 
follicular and luteal phase 
No change in AMH 





DSL n=44 regular 
menstruating 
women 25-46yrs 
Substantial fluctuations in 
young individuals 
 
Hadlow et al 
(143) (2013) 
GEN II n =12 non-PCOS 
regular cycles 29-
43yrs with at least 1 
result‎‘adequate‎
ovarian‎reserve’‎‎ 
Significant variation in AMH – 
negative trend from follicular 
to luteal phase. Maximum 







n =20 age 30-40yrs 
regular cycles non-
PCOS 
Significant variation in higher 
AMH levels – biphasic peaks 
mid-follicular and mid-luteal 
No variation lower 
AMH levels 
Kissell et al 
(482) (2014) 
GEN II n =259 cycles 21-35 
average age 27yrs 
Significant variation in AMH 
in both ovulatory and 
sporadically anovulatory 
cycles. Drop at time 
ovulation. 
Level of variation not 
clinically relevant – can 
test at any time point 
 
A highly significant difference was seen if an AMH was taken outside of a regular 35 





PCOS, in particular cycle length, and AMH. If the non-PCOS group are analysed, there is 
no significant difference (p>0.05) in AMH level irrespective of time to test (p=0.426), 
although the number of patients in the >35 day cycle group is small at only 4.  
The ability to undertake AMH measurement without constraints of cycle timing is 
favourable for the diagnostic application of AMH. Many clinics currently rely on distant 
services to process the sample, requiring the sample to be taken at set locations. Add 
to this the geographical catchment area each clinic covers, and the convenience of 
opportunistic testing is clear. Although the individual variation in AMH value through 
the cycle has not been tracked within this study, the overall non-significant changes in 
mean AMH agree with the consensus of AMH stability within the cycle (128, 139). It is 
possible to speculate that the wider range of AMH seen in women with PCOS may also 
reflect intra-cycle variability. None of the aforementioned studies (Table 2-11) have 
focussed on this group of women, who may have a more exaggerated or stable intra-
cycle variation. This, however, does not seem clinically relevant as suggested 
differences in AMH would not alter the ovarian reserve classification or indeed 
treatment options. For example, if 7.9pmol/L is the true intra-cycle variation, as 
suggested by Hadlow et al (143), this would have little impact on the median serum 
AMH 50pmol/l found in the current PCOS population.    
 
2.4.5  Parity and ethnicity 
It has been suggested that AMH could act as a predictor of LBR for IVF cycles or other 
assisted reproductive techniques (179, 483). Retrospective review of the parity of 
women enrolled, revealed no significant difference in mean AMH (see Figure 2-10). 
This supports the theory that there is only modest predictive value for live birth. Li et al 
(483) suggest that using a model including age and AMH versus using age alone, only a 
further 2% had an accurate prediction. They use logistic regression, with the outcome 
that neither AMH nor AFC are significant predictors of LBR. Similar diagnostic potential 





0.65 (233) and 0.62 (179). Neither of these values shows strong diagnostic 
performance. An interesting trend was seen when the non-PCOS group were analysed 
separately with a difference in serum AMH concentration between those without living 
children/never pregnant and those with children (p=0.041). The latter group was on 
average >9pmol/L lower than the other 2 groups with a mean value of 15.3pmol/L. The 
majority of studies suggest that those with a higher AMH have an increased chance of 
live birth. The observation in this study is only likely to represent the case mix 
presenting to the fertility clinic, particularly as other factors have not been included in 
this analysis such as age and reasons other than PCOS for infertility.  
Conclusions on the effect of ethnicity on AMH cannot be drawn from the current data, 
due to the relatively small numbers within the minority groups. The largest group, 
from Pakistan (n=22) had a mean AMH of 48.2pmol/l. When compared with the white 
Caucasian population mean of 41.0pmol/L, there was no significant difference in AMH 
value or the proportion of those presenting with PCOS in either group. These low 
numbers do not help to decipher the case selection presenting to an infertility clinic. 
For example, it may only represent a higher morbidity group from the smaller number 
minority accessing tertiary healthcare within the United Kingdom. 
 
2.4.6  Recommended diagnostic level 
The cut-off value for a test to define a condition is a repeated question. It is important 
to remember that the test performance will depend on the prevalence of the disease 
i.e. PCOS in the population studied. Using both ROC curves and Youden’s index, 
suggested values have been generated from this data as outlined in Tables 2-6 – 2-8. 
The diagnostic ability of AMH in PCOS is high with an AUC of 0.84 as previously 
discussed. The best compromise between sensitivity and specificity suggest that values 
of 22.5pmol/L and 45pmol/L delineate the normal ovary from PCOM and PCOM from 
PCOS respectively. The group of patients used within this study are in some ways 





229). There are no selected or matched controls, representing an entirely consecutive 
group of women presenting to an infertility clinic. Case control studies have the 
potential to overestimate the performance characteristics of a diagnostic test (224). 
The proportion of women with PCOS is similar to that presented by Homburg et al 
(228). Emphasis is placed on creating 3 important subgroups, labelling PCOM as its 
own entity. As discussed in chapter 1.2.2 , there is a 2 sided argument as to whether 
PCOM is a silent form of PCOS or normal variant. If the current consecutive population 
is used, a suggested value of 29pmol/L could be used to diagnose PCOS from normal 
women. This is much lower than that suggested by either of the 2 studies using the 
generation II assay and may represent the case control effect. Meta-analysis produces 
a similar result (4.7ng/mL) to the current recommendation (4.06ng/mL) (224).  The 
value suggested to separate PCOM from PCOS is very similar to Homburg et al (228) in 
sensitivity (67% vs. 60%). Unlike the latter trial, my suggested value also has a 
relatively low specificity (57%). This again is dissimilar to the other discussed trials 
which all maintain higher specificity (224, 228). Not all trials quote high specificity; for 
example Li et al (233) provide very similar values to our study. The lower specificity can 
be explained by the significant overlap of the PCOM population with the PCOS group 
as seen in Figure 2-5, which can create a higher number of false positives. If the PCOM 
population are removed the corresponding specificity of the test using 45pmol/L is 
significantly elevated (94.2%). The ROC curve is also improved with an AUC of 0.92.  
Although on paper this may look a better test, it has been produced from a selected 
cohort rather than representing the true population. Having a lower specificity is less 
concerning in the context of individualising fertility treatment for high risk women. 
Cautious use of gonadotrophins for those with increased AMH levels is a safe 
recommendation, universally accepted.  
The combination of 2 tests in diagnostics i.e. AMH and LH has the potential to 
introduce more error by combining error rates alongside the true effects of the tests. 
Implementing the suggested combination of AMH (using my suggested 45pmol/L) and 





For the purpose of diagnosis of PCOS, a balance between sensitivity and specificity is 
therefore the best compromise and would suggest using a simpler method of testing 
with a single test only.  
 
2.4.7  Age effect on AMH in PCOS          
The downward trend in AMH with age has been well documented reflecting reduced 
ovarian reserve (171, 444). The majority of the suggested age nomograms for AMH do 
not focus on PCOS. More recent literature focuses on this sub-group. Wiser et al (484) 
have produced a nomogram for the AFC in PCOS. Their retrospective review shows a 
slower decline in AFC with age in women with PCOS. They further quantify this decline 
as 0.8 follicles/year in PCOS and 1.7 follicles/year in non-PCOS (p<0.001). The data 
within my study, in agreement with others (485), shows a significant difference in all 
age brackets between those with PCOS and those without. Although not significant, 
the downward trend in the non-PCOS group is increased compared with the PCOS 
group, suggesting a more rapid decline in AMH. This correlates well with the 
aforementioned AFC nomogram (484). The limitation of my data apart from small 
numbers is the lack of longitudinal data. Limited longitudinal data is available on this 
topic. Tehrani et al (486) present a 10 year longitudinal dataset averaging 3 
consecutive measurements on individuals. The decline in AMH in PCOS is more gradual 
than the consistent reduction in the non-PCOS group. They hypothesise that the 
average age of menopause is 2 years later due to this phenomenon. Hwang et al (475) 
agree with the slower decline in AMH with age. They found a maintained AMH until 35 
years of age in PCOS, unlike those with normal menstruation. An estimated 
extrapolation from the AMH nomogram suggested by Nelson et al (436), allows the 
current mean serum AMH values to be plotted at different ages (see Figure 2-14). 
Although a formal nomogram has yet to be produced for those with PCOS, the general 
trend seems to tally well. It would be useful to evaluate this further with larger data 





Figure 2-14 Mean AMH concentration by age in those with PCOS plotted on an 




The statistical performance of AMH seemingly improves with advancing age, when 
ROC curve analysis is applied (see Figure 2-13). If the AUC for the <25 years group is 
compared with the >35 year group it is noticeably different (0.74 vs. 0.91). Although 
simple explanations can be assigned to this, it remains relevant when used for 
diagnosis of PCOS and the underlying pathophysiology. A significant positive 
correlation exists between AFC and AMH. Younger women have an elevated AFC which 
is not related to PCOM or PCOS. There is also a greater preponderance of PCOM 
without the other manifestations of PCOS. Referring back to Chapter 1.3.3, it is known 
that AMH increases through adolescence into the early 20’s reaching a peak at ~25 
years. This will muddy the scientific waters when using such an age dependant test 
within diagnostics.   
The other relevant feature in the ROC curve finding is the cohort used in the study. The 





low . The phenotypic presentation of PCOS alters with advancing age, with many 
women attaining a regular menstrual cycle (487-489) and a decline in HA (490). 
Women presenting with PCOS are often younger and many will have achieved a 
pregnancy before the advanced years (13). This speculates that those who do present 
later have a potentially more pronounced form of PCOS and therefore may have an 
increased serum concentration of AMH. All of these factors contribute to the 
strengthened diagnostic finding in older women. Supporting other studies (490-492), 
there is a significant decline in biochemical hyperandrogenaemia with age (see Table 
2-10). Unlike other studies, there is no significant difference in BMI or presentation of 
clinical HA with age (χ²=0.93, p<0.83). Formal testing for insulin resistance was not 
performed within this study.  
 
2.5  Conclusion 
In conclusion, AMH is a useful tool in the diagnostic armamentarium for PCOS. The 
serum concentration of AMH is closely related to antral follicle count, 
hyperandrogenism and anovulation. Anti-Müllerian Hormone can be on the whole 
interchanged with - and used as a surrogate for - any of the Rotterdam criteria, but 
perhaps most effectively for PCOM. It does reflect severity of disease with those 
exhibiting the full constellation of symptoms having the highest level. Further attempts 
to provide cut-off levels are provided; suggesting 29pmol/L for PCOS and a higher level 
of 45pmol/L to separate PCOM from PCOS. With advancing age the levels are 
maintained and increase in diagnostic ability, whilst care is needed when using it in 
young adults. The test can be used at any point in a regular menstrual cycle without a 
clinically significant effect. In conclusion, AMH lies within the foundations of PCOS and 
with further scientific work the exact contribution to the underlying pathophysiology 
of the condition will be further elucidated. In the meantime, it is a hormonal assay that 
has surmounted the traditional tests available and provides an easy to use tool in this 










3 Chapter 3 
Metformin And GnRH Antagonist Co-treatment In 
IVF For Women With Polycystic Ovary Syndrome 
 
3.1  Introduction 
Metformin has historically been a firm favourite with clinicians’ treating all aspects of 
PCOS. More recently there has been a decline in metformin’s popularity as an adjunct 
treatment during assisted conception, coinciding with several Cochrane reviews (338, 
348) that suggest metformin’s use is limited in ovulation induction, in vitro fertilisation 
cycles and symptom management e.g. hirsutism. A remaining positive association is 
the reduction in OHSS that metformin affords an IVF cycle (Table 3-1). Tso et al (348) 
included 6 of the main studies evaluating metformin and OHSS reduction. A significant 
reduction in OHSS was seen (OR 0.24 95% CI 0.12, 0.47), despite variables that may be 
assumed to aid this reduction revealing minimal change e.g. number of oocytes 
retrieved (mean difference (MD) -0.13, 95% CI -1.43, 1.17), stimulation days (MD 0.03, 
95% CI -0.32, 0.37) and oestradiol level (MD 3.51, 95% CI -0.18, 7.19). The 2 most 
recent papers have opposing views (347, 350) with regard to OHSS. Palomba et al (350) 
agree with previous work that there is a reduced OHSS risk following metformin 
treatment (RR 0.28, 95% CI, 0.11–0.67). Their reasoning for this includes an overall 
reduced oestradiol level and reduction in number of non-periovulatory follicles, 
despite increased stimulation length and dose. Compared with earlier work (260), this 
group selected a higher risk population, who all had either a previous ART cycle 
cancelled or a cycle complicated by moderate to severe OHSS. Kjotrod et al (347) 
found no difference in OHSS rates following metformin treatment. A unique element 
of this trial was the implementation of ‘coasting’ (withholding gonadotrophin 
stimulation and trigger injection) with a trend towards increased coasting with placebo. 





(although not substantiated) and therefore this approach may mask any potential 
benefit from metformin. 
The exact mechanism by which metformin exposure reduces OHSS has not been fully 
investigated. The ideas proposed (350) focus on 2 of the main features common to 
PCOS - namely insulin resistance and hyperandrogenism. Metformin appears to 
operate both directly on ovarian function and also indirectly via modulation of insulin 
excess. Evidence for the direct effect of metformin implicates both the granulosa and 
thecal cells as target cells (322, 493) for the drug. Within human ovarian thecal-like 
androgen-producing tumour cell culture (which has retained the ability to produce 
androstenedione and express steroid-metabolising enzymes under the control of 
cAMP) the addition of metformin (in doses higher than that achieved by oral 
administration) reduced androstenedione production (324). Furthermore, this 
inhibition was greater than that of 17–hydroxypregnenolone suggesting a preferential 
inhibition of 17-lyase activity compared with 17α-hydroxylase activity. This supports 
earlier work whereby a reduction in CYP450c17 activity was shown in women with 
PCOS treated with metformin (18, 494). In addition, Attia et al (324) speculate that the 
reduction in CYP450c17 activity is due to an increase in tyrosine activity in metformin-
treated cells. This speculation was based on earlier work (495) from these authors 
where a significant increase in tyrosine kinase activity was demonstrated. A post-
receptor defect has been suggested to underpin the peripheral hyperglycaemia seen in 
women with PCOS (37, 496). The defect leads to reduced tyrosine auto-
phosphorylation and an increase in serine phosphorylation of the beta chain of the 
insulin receptor. Serine phosphorylation is thought to augment ovarian and adrenal 





Table 3-1 The use of Metformin as an adjunct in in vitro fertilisation treatment cycles 
Reference Research type Cycle Study size & 
Participants 
Duration / Dose Endpoints measured 
Stadtmauer et 
al (2001) (498) 
Retrospective  Agonist Clomiphene 
resistant n = 




Day 1 preceding 
cycle until 
pregnancy test 
Reduced number small follicles.  
Reduced IGFBP and increased IGF II 
Fedorczak et 









(NIH) n=17  
500mg TDS 3 
weeks prior to 
down regulation 
until hCG 
Total dose FSH reduced  <10% 
Increased number oocytes 
Kjotrod et al 






Agonist n = 73 16 weeks 1000mg 
BD until hCG 
No difference in FSH, oocytes, 
fertilisation. BMI<28 had increased CPR 







Agonist n = 110 850mg BD/TDS 
BMI dependant 8 
weeks prior to 
cycle & until 
pregnancy test 
No difference in stimulation or 
pregnancy outcomes. 
No difference in OHSS 
Costello et al 
( 2006) (349) 
Systematic 
review  
_ Includes 5 IVF 
studies 
 Metformin co-administration does not 
improve CPR (OR = 1.29; 95% CI = 0.84–
1.98) or LBR (OR = 2.02, 95% CI = 0.98–
4.14) rates but reduces  risk of OHSS 
(OR = 0.21; 95% CI = 0.11–0.41, P < 
0.00001) 
Doldi et al 




no treatment  




Reduced FSH. Increased oocyte 
number. Reduced OHSS 
Tang et al 





Agonist  n = 101 850mg BD from 
down regulation 
No difference in FSH, oocytes retrieved 
or fertilisation. Significant increase in 
CPR beyond 12 weeks. Significant 
reduction in severe OHSS (MET = 
3.8%, PLA = 20.4%; P = 0.023) 




- 6 studies 
included 
 No improvement clinical outcomes 
(LBR/CPR/miscarriage rates). No 
significant effect on ovarian stimulation 
(total dose FSH, stimulation days, 
oestradiol level, number oocytes 
collected, cycle cancellation rate) or 
fertilisation rate. Significant reduction 
in OHSS (0R 0.24 95% CI 0.12, 0.47) 
Kjotrod et al 







Agonist n = 149 
(intention to 
treat analysis) 
Increasing dose to 
2000mg/day for 
12 weeks prior to 
stimulation until 
pregnancy test 
Metformin pre-treatment improves the 
pregnancy (natural) rate in non-obese 
women with PCOS, but does not affect 
IVF/ICSI outcomes per se. 
No difference in OHSS  
Palomba et al 










OHSS and cancellation rates 
significantly reduced with metformin 
(RR 0.28, 95% CI, 0.11–0.67). With 
metformin, stimulation length and total 
amount of gonadotropins were 
significantly increased with significantly 
reduced oestradiol levels. No 
difference in CPR or LBR. 




- 9 studies 
included 
 Reduced OHSS (OR 0.29; 95% CI 0.18 to 
0.49, eight RCTs, 798 women) 
No difference LBR (OR 1.39, 95% CI 
0.81 to 2.40, five RCTs, 551 women) 
despite improved CPR (OR 1.52; 95% CI 





Evidence for a direct effect of metformin on granulosa cell function also exists (502). 
Adenosine 50 monophosphate-activated protein kinase (PRKA; formerly known as 
AMPK) is a key regulator of cellular energy homeostasis involved in cholesterol 
synthesis (502). Activation of PRKA has been shown to reduce progesterone secretion 
in immature rat granulosa cells and also reduce 3-beta-hydroxysteroid dehydrogenase 
(3BHSD) through the MAPK1/3 signalling pathway (503). Furthermore, metformin has 
been shown to activate PRKA and subsequently reduce basal and FSH-stimulated 
progesterone and oestradiol secretion via a reduction in 3BHSD, CYP11A1, CYP19A1 
(aromatase) and steroidogenic acute regulatory (StAR) protein levels (502). This is 
consistent with La Marca et al (21) who demonstrated a reduction in CYP19A1 activity 
in response to FSH in human granulosa cells from women with PCOS following 
metformin use (21). Similarly, Mansfield et al (493) demonstrated a dose dependant 
reduction in progesterone and oestradiol production in luteinised human granulosa 
cells when co-cultured with metformin. Furthermore, a chronic activation of the PRKA 
pathway is involved in a potential anti-oxidant process at the ovarian level involving 
increased glutathione, nitric oxide synthase and prostaglandin production following 
metformin administration with DHEA (504). To enable steroid hormone production, 
there must be a translocation of cholesterol from the outer to the inner mitochondrial 
membrane. This process has been shown to be mediated by the StAR protein (324). 
Attia et al (324) demonstrated a drop in the StAR protein with metformin (but not an 
equivalent inhibition of StAR mRNA expression).   
Excess androgens have long been considered detrimental to female reproductive 
health. This concept is challenged by work on androgen-receptor knockout mice, 
whereby a global reduction in fertility is seen if androgen deficiency exists (330). This 
effect has been subsequently pinpointed to the granulosa cells (505). Androgen 
receptors (AR) are expressed by the oocyte, thecal cells and cumulus cells but 
predominate in granulosa cells. The highest expression is in preantral / antral follicles 
with a gradual reduction with follicular maturation (506). Work with granulosa cell-





expansion and diminished oocyte viability (although not a global acceleration in follicle 
depletion) (505). Androgen priming is an increasingly ‘hot’ topic, particularly in low 
responders to IVF treatment (507). Paradoxically, PCOS is associated with an increased 
androgenic environment. An increase in the number of AR, AMHR2 and AMH 
expression in granulosa cells from women with PCOS  may suggest an intrinsic 
granulosa cell dysregulation (216). Enhanced FSH-receptor expression (330, 508), 
increased number of FSH-responsive follicles and reduced follicle atresia (330)  have all 
been implicated in the androgenic mechanisms used to regulate folliculogenesis. 
Androgens have been shown to promote miR-125b expression which suppresses pro-
apoptotic proteins and subsequent follicle atresia (330). The expression of miR-125b is 
firstly regulated by extranuclear androgen signalling, before AR nuclear localisation 
and genomic androgen signalling. Sen et al implicate Paxillin as a critical regulator of 
this process (330). Furthermore, via the same Paxillin signalling process androgens can 
upregulate FSH receptor expression, enhancing the sensitivity to FSH stimulated 
follicular growth (330). In addition, in women with PCOS, there appears to be 
enhanced thecal cell androgen production in response to FSH, revealing a potential 
paracrine interaction between granulosa and thecal cells (509). Although the FSH 
receptor has not been located on the thecal cell, early work (510) supports Wachs et al 
(509) who suggested that FSH may augment androgen production via an unknown 
mechanism. An improvement in the intra-ovarian androgen environment with 
metformin may therefore attenuate the follicle response to gonadotrophins (350).  
In a similar fashion, improving insulin resistance and hyperinsulinemia could marshall 
the aberrant response to gonadotrophins often seen in PCOS and the subsequent 
arrested follicle growth (511) (as discussed in Chapter 1). Insulin has been shown to 
directly stimulate several ovarian steroidogenic enzymes including CYP17, 3BHSD, 
P450 side-chain cleavage (P450scc) and StAR protein (37). Insulin also stimulates 
glucose uptake, by translocation of the GLUT4 transporter to the cell surface, via 
activation of the mediator PI3-K. In PCOS, reduced GLUT4 expression has been 





(513). Insulin-like growth factor 1 has been shown to have a synergistic effect with FSH 
via activation of aromatase and increased oestradiol production from granulosa and 
granulosa lutein cells (514). A key binding protein, IGFBP-1, is lower in women with 
PCOS and is inversely proportional to insulin concentration (515). Furthermore, this 
protein is implicated in the response  to gonadotrophins, with an inverse correlation 
between the total amount of human menopausal gonadotrophin required during 
ovulation induction and serum IGFBP-1 (516). The putative mechanism for this may be 
the hyperinsulinimic hyperandrogenic environment leading to a direct reduction in 
hepatic IGFBP-1 production, with loss of the inhibitory control of IGF-1 in granulosa 
lutein cells.  Metformin has been shown to increase plasma IGFBP-1, so reducing the 
IGF-1: IGFBP-1 ratio (43) and thereby modulating plasma androgen levels in PCOS. In 
addition, increased serum IGFBP-3 has been linked to an increased likelihood of 
pregnancy in women with PCOS (which is opposite to those women without PCOS) 
(517). The observed improvement in pregnancy rate occurs despite a reduction in 
circulating concentration of IGF-1 generating more immature oocytes. Insulin also 
augments the synthesis of a key growth factor, VEGF, that is known to be involved in 
the pathogenesis of OHSS and which is overexpressed by granulosa lutein cells from 
the polycystic ovary (259). Given this information, it is surprising that metformin has 
been shown to have little impact on reducing VEGF levels (261). The final target for 
metformin is ovarian morphology. A reduction in the number of antral follicles has 
been shown to be an acute response to metformin therapy, with some ovaries 
reverting to normal appearance (518, 519). The validity of the latter 2 trials is limited 
due to the extremely small sample size in both.        
As shown in Table 3-1, the use of metformin alongside an agonist IVF cycle has been 
addressed. Some trials are powered to establish if a significant OHSS reducing effect 
exists (350) whilst others declare the effect within their secondary end points (260). 
Despite numerous trials, there is an absence of uniformity in the method of metformin 
treatment protocols. For example, the dosage and duration of metformin pre-





(342). With the known side effect profile of metformin, achieving compliance with high 
doses and long courses of treatment can be problematic. Despite some basic 
differences in the methodologies of the trials, the overall outcomes are similar.  
Research has not been conducted to the same depth for the use of metformin as an 
adjunct to antagonist assisted conception cycles. A single trial (12) has compared the 
stimulation outcome in a small sample population. There was no sample size 
calculation for this trial and it should therefore be considered a pilot study. It is 
unknown whether the use of the antagonist cycle alone provides as much OHSS 
protection as the addition of metformin. It is well recognised that an antagonist cycle 
reduces the risk of OHSS and that this strategy has a more pronounced effect in 
women with PCOS (RD -0.10 95% CI -0.14 to -0.07 p < 0.00001) (31). To address this 
knowledge deficit, there is need to conduct a sufficiently powered trial to evaluate the 
efficacy of metformin use in the antagonist treatment cycles, using OHSS as a primary 
end point to test the merit of metformin treatment as an OHSS reduction strategy  for 
women with PCOS.     
The aims of the current chapter were 2-fold: 
(i) To conduct an appropriately powered RCT to evaluate the use of metformin 
as an adjunct in an antagonist IVF treatment cycle with the aim of reducing 
the risk of OHSS in women with PCOS. 
(ii) To establish if metformin use had any impact on ovarian stimulation and  






3.2 Materials And Methods 
 
3.2.1 Eligibility criteria 
Formal ethical approval (ethics reference 09/H1307/52) was granted for this project 
from Leeds West Ethics Committee. As a medicinal product was used, approval was 
sought and granted (EudraCT Number 2009-010952-81) from the Medicines and 
Healthcare products Regulatory Agency (MHRA). To be eligible for the study women 
had to have a known diagnosis of PCOS as defined by the Rotterdam criteria (449). All 
women therefore had at least 2 of the following characteristics: evidence of 
hyperandrogenism (clinical or biochemical), oligo/anovulation (cycles longer than 35 
days) and PCOM on ultrasound with 1 or more ovaries with ≥12 follicles and/or volume 
≥10cc³.  
Further inclusion and exclusion criteria for recruitment into the trial are documented 
within Table 3-2. 
 
Table 3-2 Trial inclusion and exclusion criteria 
Inclusion criteria Normal Follicle Stimulating Hormone (FSH)  <8.0iu/L (Day 1-5 menstrual 
cycle/following progesterone withdrawal) 
Age 20-39 years of age 
BMI<35 (maximum weight treated at clinic) 
Serum Testosterone <5.0nmol/L 
Prolactin <600mU/L 
Thyroid Stimulating Hormone 0.2-6.0mIU/L 
Normal renal, liver and haematological indices  
Exclusion criteria If taking any of following medication: 
- Oral-antidiabetic or blood glucose lowering preparations 
- Phenprocoumon, cimetidine, ketofen 
- Antivirals (Didanosine, Stavudine, Tenofir) 
Radiological examinations using contrast media within preceding 48 hours 
Recent myocardial infarction 
Known vitamin B12 deficiency 






3.2.2 Recruitment process and subjects 
Potential study participants were identified prospectively from the outpatient clinics 
and IVF starter list. Information surrounding the trial was supplied with further face to 
face discussion with the research doctor. After a reasonable time for reflection (at 
least 24 hours), if the patient wished to participate, written consent was completed.  
Following written consent and confirmation of eligibility, patients were randomised to 
receive either placebo or active drug (metformin 850mg twice a day). Randomisation 
was done by the hospital pharmacy, using a random permuted blocks method with a 
50:50 allocation ratio. This process was blinded to both patient and investigator by 
using identical over-encapsulation of the tablets (supplied and over-encapsulated by 
Bilcare Global Clinical supplies, Waller House, Crickhowell, UK). The allocation code 
was not broken until all women had been recruited and commenced treatment. Any 
patients who withdrew consent, continued with their routine IVF treatment. Their 
details were retained for analysis on an intention to treat basis unless the patient 
stipulated otherwise. Demographic and baseline data was recorded at the start of the 
treatment cycle (Table 3-3). Detailed information regarding the nature of the hormonal 
assays has been documented in Chapter 2.2.1.  
 
Table 3-3 Demographic and baseline data 
Demographics Blood tests Ultrasound  
 Age 
 Number menses in 
preceding 6 months 
 BMI 
 Ethnicity 
 Duration of subfertility 
 Parity 
 Previous IVF cycles 
 Previous OHSS 
 
 Anti-Müllerian Hormone 
(AMH) 
 FSH/LH/Oestradiol 
 Thyroid function tests 
 Prolactin 
 Testosterone/SHBG 
 Full blood count (FBC) 
 Liver function tests (LFT) 
 Urea, electrolytes and 
creatinine (U&E) 
 Ovarian parameters 
- Volume 
- Antral follicle count 









3.2.3 Treatment pathway 
Following randomisation and consent, patients were supplied with the study 
medication and the routine ART drugs (Table 3-4). Due to drug availability there were 
different preparations used within the study time period. Within a ‘nurse consultation’ 
patients were instructed on how and when to commence their treatment.  
 
Table 3-4 Standard ART drugs used 
Generic Drug  Drugs used 
Progestogen Medroxyprogesterone Acetate (Provera®, Pfizer, Tadworth, 
Surrey, UK.)  
Progesterone 
 Vaginal - Cyclogest®,Actavis UK Ltd, Barnstaple, UK 
 Intra-muscular - Gestone®, Nordic Pharma Limited, 
Reading, UK; Prontogest®, IBSA International, 
Pambio-Noranco, Switzerland.  
Recombinant Follicle Stimulating 
Hormone (rFSH) 
Follitropin alfa (Gonal-F®, Merck Serono Ltd, Feltham, 
Middlesex, UK) 
Follitropin beta (Puregon®, Organon, Hoddesdon, 
Hertfordshire, UK) 
Gonadotrophin Releasing Hormone 
(GnRH) Antagonist  
Ganirelix (Orgalutron®, Organon) 
Cetrorelix (Cetrotide®, Merck Serono) 
Human Chorionic Gonadotrophin (hCG) Chorionic gonadotrophin (Pregnyl®, Organon) 
Choriogonadotrophin alfa (Ovitrelle®, Merck Serono) 
 
Metformin/placebo  was started either 7 days prior to the patient’s regular menstrual 
cycle (mid luteal) or day 1 of the period for women with an irregular cycle or using a 
progestogen (Provera®, Pharmacia) designed to induce a withdrawal bleed. Drug 
delivery was continued until the day before egg collection. At each subsequent visit 
patient compliance and side effects were documented. The IVF/ ICSI cycle followed the 
routine unit clinical practice for an antagonist cycle (286). For uniformity, recombinant 
FSH (rFSH) (no patients were treated with human menopausal gonadotrophin) was 
commenced on day 2 of the menstrual cycle, on a daily basis, at a dose adjusted for 





(250 micrograms) was added on day 6 of the cycle to prevent premature ovulation. A 
trans-vaginal ultrasound scan (TVUSS) was completed on day 8 of the cycle (6th day of 
stimulation). Dependant on ovarian response, the dose of rFSH was adjusted. 
Participants were then reviewed as clinically indicated until 3 or more follicles were 
>17mm diameter. Follicular growth extrapolation was limited where possible. When 
this target was reached hCG of 5000-10000iu (dependant on follicle number) was 
administered 35-37 hours prior to the planned oocyte collection. If excessive follicular 
response was seen on scan (>30 follicles), consideration was given to stop the cycle 
prior to hCG administration.  
On the day of oocyte collection, blood tests were repeated and a sample of serum 
stored where possible (including oestradiol, testosterone, FBC, U&Es, LFTs, and AMH). 
Oocyte retrieval was performed under conscious sedation using a combination of 
Fentanyl (up to 100μg) and Midazolam (up to 5mg). Trans-vaginal oocyte retrieval was 
performed using the standard approach. Oocytes were than inseminated (IVF) or 
injected (ICSI) within 4 hours of retrieval with either the partner’s or donor sperm 
(520). The decision for insemination or ICSI was based on the WHO criteria for a 
normal human semen characteristics (520). Although individualised to patient and 
treatment cycle, if following sperm preparation the count was >4million/mL, grade a 
and b motility was >70% and yield was >10%, the intention was to use IVF. Samples for 
insemination were prepared using PureCeption sperm preparation media 40%/80% 
(Sage, Origio, Cooper Surgical company, Denmark) (521). For insemination, samples 
were adjusted to give a final motile concentration of 4x10⁶/mL sperm. Luteal phase 
progestogen support was commenced on the day of the collection. Type of 
progesterone (vaginal 400-800mg/day or intramuscular 50-100mg/day as detailed 
above) varied on patient/clinician preference.  
Women who had more than 20 oocytes or 25 follicles aspirated were asked to return 
on day 3 and day 5 following collection to check for signs and symptoms of OHSS as 
shown in Table 3-7 (522). These included routine FBC and observations (weight change 





report if they had any symptoms suggestive of OHSS (shortness of breath, diarrhoea, 
nausea, vomiting, and inability to pass urine). Any women who were symptomatic of 
moderate OHSS had their embryos frozen without embryo transfer. The slow freeze 
technique was used rather than vitrification, using Quinn’s Advantage (Origio, 
Denmark) embryo freeze kit, liquid nitrogen and the Planer freezer (Planer PLC, 
Middlesex, UK) set to Sage freezing programme (523). The time of presentation of 
symptoms dictated at what stage the embryos were frozen (between pro-nuclear and 
blastocyst stage).   
Fertilised oocytes were transferred into single drops of culture media (Medicult/Origio, 
Denmark) and overlaid with Origio oil. Embryos were cultured between 2 to 5 days in a 
Benchtop Incubator BT37 (Planer PLC, Middlesex, UK) in mixed gas 6% CO2 and 5% O2 
at 37°C. Embryos that were cultured to day 5 underwent a media change on day 3.  In 
fresh transfer cycles, ultrasound guided embryo transfer took place between day 2-5 
following oocyte collection. A maximum of 2 embryos were replaced, the number 
being dependant on embryo quality and number. The grading system used for day 3 
and day 5 embryos is shown in Table 3-5 and Table 3-6 respectively. An embryo was 
referred to as good quality if graded ≥ 6.3.3 on day 3 or ≥2Bb (524, 525). 
 






Blastomere number  
Blastomere size (526) 4 = regular, even division 
3 = <20% difference 
2 = 20-50%  difference 
1 = >50% difference 
Fragmentation (527) 4 = <10% fragmentation by volume 
3 = 10-20% 
2 = 20-50% 





Table 3-6 Blastocyst grading - Expansion / Inner cell mass / trophectoderm 
Expansion  1 Early blastocyst (blastocoel less than half volume of embryo, 
little or no expansion in overall size, thick zona pellucida 
(ZP) 
 2 Blastocyst (blastocoel > half volume of embryo, some 
expansion in overall size, ZP thinning) 
 3 Full blastocyst (blastocoel completely fill embryo) 
 4 Expanded blastocyst (blastocoel volume larger than early 
embryo, ZP very thin) 
 5 Hatched blastocyst (blastocyst has evacuated ZP) 
Inner Cell Mass (ICM) A ICM prominent, easily visible, consisting of many cells 
tightly adhered together 
 B Cells less compacted, loosely adhered together, some 
individual cells visible 
 C Very few cells visible, may be difficult to completely 
distinguish from trophectoderm 
 D Cells appear degenerate or necrotic 
 E No ICM cells discernible in any focal pane 
Trophectoderm a Many small identical cells forming continuous layer 
 b Fewer, larger cells, may not be completely continuous 
 c Sparse cells, may be very large, flat or degenerate 
 
A serum pregnancy test was taken on day 14 (Siemens Advia Centaur & Siemens 
reagents, Siemens Healthcare, Camberley, UK) or a urine test on day 18 (Suresteptm, 
Alere, UK). A serum hCG >2 IU/L was deemed positive but if a low reading was 
obtained a repeat hCG was completed 48 hours later to ensure an adequate rise 
occurred. If positive, a TVUSS was completed after ~7 weeks of gestation (5 weeks 
following oocyte retrieval). If a fetal heart was seen on this scan, it was deemed a 
clinical pregnancy. All outcomes were followed up in accordance with the Human 






3.2.4  Primary and secondary trial end points  
The primary end point for this trial was the incidence of moderate to severe OHSS 
within 6 weeks of completing the IVF cycle. OHSS was classified using the definition 
recommended by the Royal College of Obstetrician and Gynaecologists (RCOG) 
outlined in Table 3-7. The trial was appropriately powered for this end point. The 
secondary end points included the ovarian stimulation characteristics (number of 
oocytes collected and total stimulation doses), embryological measures (fertilisation 
rate, % of good quality day 3 embryos and % with day 5 embryo transfer) and cycle 
outcome including CPR and LBR. 
 
Table 3-7 Classification of ovarian hyperstimulation syndrome as recommended by the 
Royal College of Obstetricians and Gynaecologists (522) 
Grade Symptoms 
Mild Abdominal bloating 
Mild abdominal pain 
Ovarian size usually <8cm* 
Moderate Moderate abdominal pain 
Nausea ± Vomiting 
Ultrasound evidence of ascites 
Ovarian size 8-12cm* 
Severe Clinical ascites (occasionally hydrothorax) 
Oliguria 
Haemoconcentration haematocrit >45% 
Hypoproteinaemia  
Ovarian size >12cm* 
Critical Tense ascites or large hydrothorax 
Haematocrit >55% 
White cell count >25000/ml 
Oligo/anuria 
Thromboembolism 
Acute Respiratory Distress Syndrome 
*Correlation with ovarian size may not be useful if follicle aspiration has occurred 
 
3.2.5 Statistical analysis and power calculation 
This study was powered to assess metformin’s ability to reduce OHSS as an adjunct in 





metformin. Although the sample size was not predetermined, a trend to reduced OHSS 
was seen (351). Costello et al (349) performed a meta-analysis of metformin co-
administration during IVF in women with PCOS. A significant reduction in OHSS was 
seen. Pooled analysis showed OHSS occurred at a rate of 12/216 in those patients on 
metformin and 44/210 in those on the Placebo. The odds ratio was 0.21 (95% CI 0.11-
0.41). The chosen power for this study was 80% with a type 1 error of 0.05. From the 
meta-analysis data, the standardised difference (d) for reduction of OHSS following use 
of metformin was 0.454. Using the Altman nomogram (528), when d=0.454 and 
power=0.80, the projected sample size was 146 with 73 in each arm. The same 
outcome was found using a statistical package (Stata, Version 12, StataCorp LP, Texas, 
USA). This sample size calculation was confirmed by Dr Graham Law, senior lecturer in 
statistical epidemiology and Head of Biostatistics, University of Leeds. Intention to 
treat analysis was used. To allow for cycle dropout of recruited subjects, recruitment 
continued until the appropriate number of recruits had started the treatment cycle.  
Statistical analysis was conducted using the IBM SPSS 21 statistics package (IBM 
Corporation, New York, USA). Descriptive statistics include mean and standard 
deviation for parametric data; median and IQR for non-parametric data. Unless stated 
otherwise the placebo group result was listed first in each comparison. Odds ratios 
were constructed where appropriate with 95% confidence intervals. Continuous data 
was tested for normality using the Kolmogorov-Smirnov test. Normally distributed data 
was analysed using Student’s t-test (with Levene’s test for equality of variance). This 
included the baseline demographics of age, BMI and fertilisation rate. This data was 
presented as mean ± standard deviation. Data that was non-parametrically distributed 
were analysed using the Mann-Whitney test. This included the ovarian stimulation 
characteristics, oocytes collected and baseline AMH values. They were presented as 
median (IQR). Contingency tables were employed were necessary with Chi-squared 
statistic (plus continuity correction) and Fisher’s Exact tests. This was used for 
categorical data including OHSS rate, CPR and side effect profile. A p value of <0.05 





independent factors on the dependant factors OHSS and clinical pregnancy rate. A ROC 
curve analysis was used to assess the ability of AMH to predict which women would 
experience moderate to severe OHSS. To establish correlation between ordinal 
variables (e.g. AMH and AFC) Spearman’s Rank correlation coefficient was used. The 




Between October 2009 and June 2014, 169 patients were recruited to the trial. A 
hiatus in recruitment occurred between August 2011 to August 2012, due to a change 
in principal investigator (initial ethical / MHRA approval and recruitment (n=98) 
completed by Dr Christopher Brewer). Of these, 153 patients commenced the study 
drug and were included in the analysis. The remaining 16 patients did not commence 
an IVF cycle or study medication for a variety of reasons (natural conception / lost to 
follow up / unable to take study medication for religious reasons/did not fulfil 
eligibility criteria). Figure 3-1 outlines the patient recruitment pathway and 
randomisation to metformin or placebo. A total of 122 patients had an embryo 
transfer, with an overall clinical pregnancy rate of 45.1%.  For all cycles receiving 
gonadotrophins, the incidence of moderate-severe OHSS was 14.1% (21 women out of 
149). Of these 21 cases, 9 had all embryos frozen with no fresh embryo transfer and 3 
had cycles abandoned prior to the hCG trigger. Randomisation delivered the desired 
50:50 split, regardless of non-starters. The study drug was taken for a median duration 
of 16 days (range 4-38) prior to oocyte collection. Due to work flow patterns and 
duration of recruitment, operator numbers were not restricted and the procedures 













3.3.1 Demographic data 
There were no significant differences in baseline characteristics between the 2 groups 
of women (Table 3 8). Women included in the trial were on average under 30 years of 
age (29.7yrs ± 4.2) with a BMI on the upper limit of normal (25.1/m² ± 3.3). The 
patients’ had on average entered their 3rd year of subfertility (3.6yrs ± 2.3) with an 
average 94% undergoing their first IVF cycle. Hormonal parameters revealed equally 
matched groups with respect to FSH and AMH; although non-significant the placebo 
group had an increased serum testosterone (p=0.05) and androstenedione level. 
Ultrasound features of PCOM were also equally matched with the average antral 
follicle count >30. There was a trend towards increased number of South Asian women 
in the metformin group but this was not significant (19.7% vs. 27.3%; p=0.364). The 
equal baseline characteristics demonstrate equality in risk of OHSS.     
 
3.3.2 Study medication duration and dropouts 
The 2 groups of patients had comparable durations of study drug prior to oocyte 
collection with a median duration of 16 days but the data included a large range of 4 - 
38 days. Only 1 patient stopped the study drug after 4 days (metformin) due to 
physically not liking swallowing the tablet and for a further patient the drug dose was 
reduced to 850mg/day due to side effects. For women who had their cycle stopped 
due to poor response there was a non-significant (p>0.05) increased proportion on 
metformin (3 vs. 6) but in these groups the average duration of study drug 
consumption was similar to the entire population (20 vs. 18.5 days). The proportions 
were similar for cycles stopped for over response (1 vs. 2) and freeze all cycles due to 
risk of OHSS (5 vs. 4). Figure 3 1 highlights the patients who stopped their treatment 







Table 3-8 Patient demographic data*  
 Placebo 
(n=76) 
Metformin (n=77) P value Significance 
Age (Years) 29.6 ± 3.9 29.9 ± 4.4 0.70² ns 
BMI 25.0 ± 3.3 25.3 ± 3.4 0.54² ns 
FSH (iu/mL) 5.1 ± 1.6 5.3 ± 1.4 0.41² ns  
Testosterone 
(nmol/L) 
1.3 (0.9-1.7) 1.1 (0.8-1.5) 0.05⁴ ns  
Androstendione 
(nmol/L) 
5.1 (3.8-6.5) 4.2 (3.4-6.4) 0.19⁴ ns 
AMH (pmol/L)  61.8 (40.8-
98.6) 




57.2 ± 29.6 54.8 ± 29.2 0.71² ns 
At least one ovary 
volume >10cm³ (%) 
55.4 50 0.70¹ ns  
Antral Follicle Count 31.3 ± 9.7 30.0 ± 10.1 0.44² ns   
Women with 
cycles >3months (%) 
18.4 23.4 0.58¹ ns  
Duration subfertility 
(Years) 
3.7 ± 2.3 3.5 ± 2.3 0.57² ns 
1st treatment cycle 
(%) 
92.9 95.5 0.70³ ns  
% South Asian 
women (number) 
19.7 ± 15 27.3 ± 21 0.36¹ ns 
¹Chi squared with continuity correction ²Independent t-test   ³Fisher’s exact ⁴Mann Whitney U 
*Normally distributed data presented as mean ± SD and non-parametric data as median (IQR)  







3.3.3 Treatment outcome data 
Stimulation characteristics of the 2 populations were similar (outlined in Table 3-9) 
with the same duration of stimulation and total dose of gonadotrophins. An equivalent 
number of follicles were punctured and oocytes retrieved. For those patients on 
metformin, there was a significantly reduced clinical pregnancy rate per cycle started 
(48.7% vs. 28.6%; p=0.02) and per embryo transfer (54.7% vs. 34.5%; p=0.04). This 
difference is perhaps more pronounced when expressed as an odds ratio (OR 0.436, 95% 
CI 0.210-0.906), which clearly shows an inferiority with metformin (Table 3-10). A 
similar disparity in live birth rate was seen in favour of placebo (51.6% vs. 27.6%; 
p=0.01). There was no significant difference in quality of embryo or day of transfer to 
support the difference in CPR/LBR.  Using multiple logistic regression analysis (Table 
3-11), metformin use and ethnicity of the patient were the main factors to exert an 
effect on CPR, when controlling for age and BMI. There was a significant difference 
between CPR per cycle started in the AMH concentration (No clinical pregnancy 71.3 
(48.7-92.2) pmol/L vs. clinical pregnancy 53.5 (35.5-83.1) pmol/L; p=0.046). Those with 
an increased AMH had a worse CPR.  
 
3.3.4 Side effects during trial 
A highly significant proportion of women experienced at least 1 side effect whilst on 
metformin during the trial compared with controls (11.8% vs. 42.9%; p<0.001), of 
whom only 2 reduced or stopped the drug. The majority of these problems related to 
transient nausea, vomiting or diarrhoea (81.8%). The chance of experiencing a side 






Table 3-9 Treatment outcome data* 
 Placebo Metformin P value Significance 
% of ICSI cycles 55.3 44.2 0.23¹ ns  
Total days study drug 17(12-20) 16(12-20) 0.93² ns  
Stimulation days (including 
hCG day) 
10 (9-11.8) 10(9-11) 0.89² ns  






0.75² ns  
Total follicles entered 23 (12.8-
30.3) 
20 (14-26.5) 0.74² ns  
Total eggs collected  15(9.8-21) 14 (9-20) 0.66² ns 
Fertilisation rate (%) 60.7 ±22.2 53.3 ±25.4 0.07³ ns 
Good D3 embryos (%)  52.3 ±31.9 47.1 ±32.9 0.37³ ns 
D5 transfer (%) 59.4 48.3 0.30¹ ns 
ESET (%) 76.6 81.0 0.70¹ ns 






0.14⁴ ns  

















Side effect rate (%) 11.8 42.9 <0.001¹ p<0.01 
Moderate/severe OHSS (%) 12.2 16 0.66¹ ns  
¹Chi squared with continuity correction ²Mann-Whitney U ³Independent t-test with Levene’s test for 
equality of variances ⁴Fisher’s Exact. ESET: elective single embryo transfer. 
* Normally distributed data presented as mean ± SD and non-parametric data as median (IQR) 
 
Table 3-10 Odds ratio placebo vs. metformin 
Metformin vs. Placebo Odds Ratio 95% CI 
Mod-severe OHSS  1.376 0.542-3.491 
Clinical Pregnancy per ET 0.436 0.210-0.906 
Live Birth per ET 0.358 0.168-0.762 









Table 3-11 Multiple Logistic Regression Analysis: Clinical Pregnancy Rate per cycle 
(Dependant Variable) 
Independent variables Coefficient  P value 
Metformin/Placebo -0.981 0.006 
Age 0.035 0.427 
BMI -0.0223 0.663 
Ethnicity  -1.066 0.025 
 
3.3.5 Ovarian hyperstimulation outcome 
There was no difference in the incidence of OHSS between the study medication 
groups (OR 1.376, 95%CI 0.542-3.491). This included the grouped moderate-severe 
OHSS and individual levels of OHSS (see Figure 3-2). There were no cases of critical 
OHSS. There were a total of 7 severe OHSS cases in each group. Of these only 1 patient 
with severe OHSS in each group had an embryo transfer. Of the remaining 12, 3 had an 
abandoned cycle pre oocyte collection and 9 had a freeze all cycle following collection. 
Of those who underwent an embryo transfer, there was an overall 6.6% incidence of 
moderate-severe OHSS and for severe alone 1.64%, with no significant difference 
between the groups (p=0.70). Furthermore, of the cycles started that achieved a 
clinical pregnancy following embryo transfer (n=55), there was no difference in OHSS 
between groups (p=0.82). When adjusting for age, BMI, total dose of gonadotrophin 
and study medication, there was no significant effect on the overall incidence of 
moderate-severe OHSS (Table 3-12). Of those patients who had OHSS, 54.2% achieved 
a clinical pregnancy per embryo transfer. There was a trend for increased AMH and 
incidence of moderate-severe OHSS but this did not reach significance (No OHSS 
60.6(40.9-88.0) pmol/L vs. OHSS 73.7(55.7-114.0) pmol/L; p=0.16). This was not shown 
in the individual grades of OHSS as AMH levels in severe OHSS were lower than in mild 









Table 3-12 Multiple logistic regression analysis: moderate-severe OHSS (dependent 
variable) 
Independent variables Coefficient  P value 
Metformin/Placebo 0.352 0.465 
Age -0.056 0.327 
BMI -0.0973 0.160 
Total dose of gonadotropins 0.00 0.935 
 
 
A ROC curve was constructed to assess if baseline serum AMH levels predicted 
moderate-severe OHSS in a PCOS population (see Figure 3-3). This analysis showed 
poor predictive power of AMH in predicting OHSS (AUC 0.60). The AUC value was 
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Figure 3-3 A receiver operator characteristic curve testing AMH as a predictor for 




Due to the population characteristics of the women attending LCRM, the only 2 
ethnicities that fit the recruitment criteria were broadly categorised as White 
Caucasian or South Asian women. Between each study medication treatment group, 
there was no significant difference in pregnancy outcome within in each ethnic group 
(p=0.10) i.e. the CPR was similar for the South Asian group irrespective of study 
medication taken. When combining the study medication groups (see Figure 3-4), 
there was a significant reduction in pregnancy rate in the South Asian population 
(White Caucasian 51.6% vs. South Asian 24.1%; p=0.02). This difference was 
highlighted by multiple logistic regression where ethnicity and study medication 





was seen in incidence of OHSS by ethnicity (White Caucasian 13.3% vs. South Asian 
16.7%; p=0.82) or by ethnicity and study medication (p=0.42). 
 
Figure 3-4 Clinical pregnancy rate and OHSS by ethnicity 
 
 
To further compare the disparity in clinical outcome between the 2 ethnic groups, the 
data was re-evaluated combining the study medication groups by ethnic background 
(Table 3-13). Figure 3-5 further highlights some of these important differences. This 
was possible as within each ethnic group there was no difference between study arms. 
Thereafter there remained no significant difference in age, starting FSH level, ovarian 
morphology and degree of anovulation. There was a significantly increased (p<0.05) 
androgenic profile in the South Asian group. The South Asian group also had a longer 
duration of subfertility (4.6yrs ± 3.2 vs. 3.3yrs ± 1.9; p=0.03) and a reduced number 
were completing their first cycle (83.3% vs. 97.4%; p<0.01). There was also an 
increased proportion of the most ‘severe’ (OA/HA/PCOM) form of PCOS within the 
South Asian cohort (26.5% vs. 38.9%; p=0.127). There was an equal distribution of 
those with this phenotype on metformin or placebo. The South Asian population had a 



















p <0.05 χ² 





Table 3-13  Comparison between White and South Asian baseline demographics, 
stimulation characteristics and outcome* 
 White (n=117) Asian (n=36) P value Significance 
Age (Years) 30.0 ± 4.1 28.9 ± 4.2 0.15³ ns 
BMI 24.9 ± 3.4 26.0 ± 2.8 0.05³ p<0.05 
FSH (iu/mL) 5.3 ± 1.5 4.9 ± 1.7 0.28³ ns  
Testosterone (nmol/L) 1.1 (0.8-1.5)  1.4 (1-1.9) 0.02² p<0.05 
Androstenedione 
(nmol/L) 
4.5 (3.4-6.3) 6.1 (4-7.8) 0.02² p<0.05 
AMH (pmol/L) 61.0 (39.8-92.3) 68.1 (48.4-87.2) 0.56² ns 
At least one ovary 
volume >10cm³ (%) 
57.1% 52.94% 0.81¹ ns 
Antral Follicle Count 30.8 ± 10.2 30.3 ± 8.8 0.80³ ns 
Women with 
cycles >3months (%) 
21.4% 19.4% 0.99¹ ns  
Duration subfertility 
(Years) 
3.3 ± 1.9 4.6 ± 3.2 0.03³ p<0.05 
1st Cycle (%) 97.4% (114/117) 83.3% (30/36) 0.01⁴ p<0.01 
% of ICSI cycles 48.7% 52.8% 0.81¹ ns  
Total days study drug 16.5 (12-19) 20 (13-22) 0.06² ns 
Stimulation days 
(including hCG day) 
10 (9-11) 11 (9-13) 0.05² ns 
Total dose 
gonadotrophins 
1200 (900-1350) 1300 (1100-1631.3) 0.06² ns 
Total follicles entered 21 (14-30) 19.50 (13-28) 0.65² ns  
Total eggs collected  15 (10-20) 13 (7.3-20.8) 0.68² ns  
Fertilisation rate (%) 58.8 ± 24.8 53.9 ± 21.5 0.38³ ns  
Good D3 embryos (%)  48.4 ± 31.0 54.6 ± 36.6 0.37³ ns  
D5 transfer (%) 53.8% 55.2% 1.00¹ ns  
ESET (%) 81.6% 72.4% 0.49¹ ns  
Implantation rate (%; 
gestation sacs/Number 
transferred) 
50.5% (56/111) 24.3% (9/37) 0.01⁴ p<0.05 
Clinical pregnancy rate 
(%; FH/ET) 
51.6% (48/93) 24.1% (7/29) 0.02¹ p<0.05 
CPR (%; FH/cycle 
started) 
44.4% (52/117) 19.4% (7/36) 0.01¹ p<0.05 
Live birth rate (%; LB/ET) 46.2 (43/93) 20.7% (6/29) 0.03¹ p<0.05 
Side effect rate (%) 27.4% (32/117) 27.8% (10/36) 1.00¹ ns  
Moderate/severe OHSS 
(%) 
13.3% (15/113) 16.7% (6/36) 0.82¹ ns 
¹Chi squared with continuity correction ²Mann-Whitney U ³Independent t-test with Levene’s test for 
equality of variances ⁴Fisher’s Exact 






Although there was a trend in the South Asian population for increased stimulation 
and total gonadotrophin dose with fewer oocytes collected, this remained non-
significant. There was no difference in fertilisation rate, quality of embryos or number 
of cycles having a single embryo transfer. As already stated, there was no difference in 
OHSS rate, nor any difference in reported side effects. There was a significant 
inferiority of the South Asian population with respect to implantation rate (24.3% vs. 
50.5%; p=0.01), clinical pregnancy rate (per cycle started 19.4% vs. 44.4%; p=0.01) and 
live birth rate (20.7% vs. 46.2 %; p=0.03).  
 




If the South Asian cohort is removed from the dataset, and the data reanalysed by 
study medication, the significant differences in clinical pregnancy and live birth rate 
are lost. There remains a trend in favour of the placebo arm of the study across 
multiple parameters assessed (placebo data vs. metformin data): fertilisation rate 
























embryo transfer (58.8% vs. 42.9%; p=0.19) and live birth rate (54.9% vs. 35.7%; 
p=0.10). There remains no difference in incidence of OHSS (22.0% vs. 24.1%; p=0.97). 
This was similar if the South Asian population alone were also analysed according to 
study medication.      
 
3.3.7 PCOS phenotype 
There was no significant difference in incidence of OHSS by PCOS phenotype (Table 
3-14, p=0.50) or clinical pregnancy rate (p=0.89). When study medication was taken 
into account there remained no significant difference between phenotypes for OHSS 
(p=0.93) or clinical pregnancy rate (p=0.17). There was no significant difference in AMH 
by phenotype (p= 0.08, Kruskal Wallis).   
 





Total no yes 
PCOS 
Phenotype 
OA/HA 112.7 1 0 1 
OA/PCOM 69 (49.0-87.5) 54 7 61 
HA/PCOM 55.0 (33.8-75.8) 35 4 39 
OA/HA/PCOM 65.5 (46.1-107.8) 38 9 47 
Total  128 20 148 
OA: Oligo-anovulation HA: Hyperandrogenism PCOM: Polycystic ovary morphology 
 
It should be noted that all recruited patients except 1 had PCOM. Table 3-15 shows the 
significant increase in AMH with AFC in the whole cohort. These results should be 
viewed with caution as for some recruited patients, the documentation was 12+ 
follicles/per ovary. Therefore the results are likely to be skewed favouring the lower 






Table 3-15 Anti- Müllerian Hormone and antral follicle count 







P & M 
<24 (n=25) 53.5 (33.3 – 75.2) 38.8 (26.2 – 56.4) 66.0 (45.6 – 87.5) p < 0.05² (0.03) 
24 < 36 (n=88) 59.8 (41.6- 87.9) 63.0 (46.0 -95.6) 55.2 (38.0 -79.1) p = 0.18² 
36 < 48 (n=16) 79.7 (43.0 – 107.6) 89.7 (29.7 – 121.9) 76.8 (53.3 – 81.6) p = 0.72² 
48 < 65 (n=12) 105.3 (72.6 – 161.8) 107.7 (58.5 – 164.2) 103.5 (73.8 – 171.6) p = 1.00² 
p-value across age 
range 
p < 0.01¹ (0.002) p < 0.05¹ (0.01) p = 0.06¹  
¹Kruskal Wallis ²Mann-Whitney U. Values expressed as median (IQR) 
 
Further evaluation of the relationship between AMH and AFC is shown in Figure 3-6 
including between the placebo and metformin group. A significant correlation was 
found (p<0.01) between AMH and AFC when the entire group and White Caucasian 
population were reviewed. There was no significant correlation in the South Asian 
population although this is likely due to small numbers (n=15). There was no significant 






Figure 3-6 Correlation between AMH and AFC in placebo and metformin group. A: all 






3.3.8 Biochemical parameters 
On the day of oocyte collection, only 20 patient serum samples were stored due to an 
early methodological oversight. This limited the evaluation of the medication 
(placebo/metformin) on baseline values of AMH, oestradiol and testosterone (see 
Table 3-16). There was a trend for reduced serum AMH, testosterone and oestradiol 
with metformin although this did not reach significance. There was a significant 
reduction from baseline in median AMH in each medication group but not between 
medication groups.  
 
Table 3-16 Biochemical parameters comparing baseline tests to those on day of oocyte 
retrieval 





AMH Baseline (B) 80.6 (46.4-128.8) 75.26 (48.9-81.2) 0.50¹ ns 
pmol/L Oocyte retrieval (OR) 37.9 (21.4-54.3) 24.8 (17.9-37.3) 0.30¹ ns  
(n=20) Difference between 
B & OR 
35.9 (19.4-93.5) 44.3 (23.0-57.3) 0.66¹ ns  
Oestradiol  Baseline  146 (83-247) 141 (124-225) 0.69¹ ns  
pmol/L Oocyte retrieval  5217 (3039-10638) 3922 (2068-5914) 0.18¹ ns 
(n=23) Difference between 
B & OR 
5012 (2861-10499) 3660 (1947-5689) 0.18¹ ns 
Testosterone Baseline 1.2 (1-1.6) 1 (0.8-1.3) 0.30 ns¹  
nmol/L Oocyte retrieval 3.7 (1.6-4.8) 1.5 (1.4-2.7) 0.18¹  
ns¹ 
(n=20) Difference between 
B & OR 
2.5 (0.35-3.5) 0.7 (0.6-1.7) 0.26¹ ns¹ 









3.4.1 Ovarian hyperstimulation syndrome and metformin 
Ovarian hyperstimulation remains a serious risk of ART despite numerous advances in 
the treatment of infertility, especially for those at high risk of hyper-response. The 
overall reported incidence of clinically relevant OHSS in the literature varies between 
1-60% (248, 264, 269, 529).The current study is the largest randomised placebo 
controlled trial to-date to assess the adjuvant effect of metformin on the risk of OHSS 
in an antagonist IVF cycle in patients with PCOS. Disappointingly, unlike the promising 
trend of reduced OHSS suggested by Doldi et al (351), metformin had no impact on the 
incidence of OHSS when used in this appropriately powered study. The overall 
occurrence of moderate-severe OHSS (14.1%) was in keeping with published data (529, 
530). Similar to many of the published agonist trials, there was no change in the 
stimulation characteristics including total FSH dose, duration of stimulation and 
number of oocytes retrieved (260, 348, 500). It has been suggested that metformin 
may attenuate the risk of OHSS by reducing the number of small follicles (350). 
Although not formally assessed, a trend of reduced follicle entry and smaller follicle 
size range was seen in the metformin group, but this did not affect the overall oocyte 
yield. Alongside this in the small number of patients who had a hormonal profile taken 
on the day of oocyte collection, there was a trend towards reduced oestradiol increase 
following metformin treatment (5012 (2861-10499) vs.  3660 (1947-5689)pmol/l n= 23; 
p=0.18) and suppression of serum testosterone relative to controls with stimulation 
(median change in paired samples with metformin 0.7 (0.6-1.7) nmol/L vs. placebo 2.5 
(0.4-3.5) nmol/l n=20, p=0.26). A reduction in oestradiol and improvement in intra-
ovarian androgenic environment have been proposed as methods by which metformin 
may achieve its effect (350). Had metformin been used for a longer time prior to 
commencement of gonadotrophin stimulation, this effect may have been more 





suggest that with protracted use of metformin (>4 months) a cohort of follicles may 
develop without the stimulatory effects of insulin. It has been observed to take 
approximately 3 months from primary follicle to the antral stages of follicle 
development (531). Thus, with protracted metformin use the follicle cohort can be 
replaced with a smaller cohort formed under a ‘normalised’ insulin drive. These 
authors (242) accept flaws in this theory as there is only an apparent difference 
following a minimum 4 months treatment, with little change in insulin resistance or 
testosterone parameters. This contrasts with Kjotrod et al (346)  who found after 16 
weeks of metformin, there was no improvement in ovarian response or total number 
of oocytes retrieved. A mechanism for this finding  involves endogenous LH (499). 
During down-regulation in an agonist cycle, LH is suppressed. Insulin potentiates the 
effect of LH on steroid synthesis via a synergistic relationship by binding to its own 
receptor on thecal cells and increasing androgen synthesis, although the effect of 
insulin alone is small (532). If the basal LH is low then metformin may not exert enough 
action to modulate the androgenic response. If this theory is right, then the 
antagonist’s shorter duration of action and limited basal LH downregulation, should 
aid metformin in reducing the excessive response to stimulation. A further suggestion 
from Onalan et al (500) is that longstanding hyperinsulinaemia may down regulate the 
insulin receptors in the ovary, reducing the effect of insulin on the granulosa cells. This 
raises the possibility that short term use of insulin sensitisers may have the potential to 
augment insulin’s effect in the ovary by altering the number of insulin receptors and in 
so doing be detrimental in the immediate short term (such as the short use of 
metformin in the current trial).  
A limitation of the current trial is the lack of formal insulin resistance testing. Sex 
hormone binding globulin has been suggested as a surrogate marker for insulin 
resistance in PCOS (533). Although levels were not obtained for all in the trial, there 
was no significant difference in mean value between the placebo or metformin group 
(57.2 ± 29.6 vs. 54.8 ± 29.2, p=0.71, n=91). Furthermore, there wasn’t any difference in 





the mean values for SHBG were in the entirely normal range and would not be 
suggestive of insulin resistance in this cohort. Recommended use of metformin in 
women with PCOS aside from during an ART cycle, is confined to those with glucose 
intolerance (311) related to the biochemical parameters of the patients. Unfortunately, 
hormonal parameters including oestradiol, testosterone and AMH were not 
investigated on the day of oocyte retrieval in the early cases in this trial. These 
measures were included in the later cases, providing limited data on the potential 
impact, if any, of short term use of metformin on the outcome parameters measured.   
A recent web-based survey of IVF clinic treatments suggested that only 46% of clinics 
opted to use the antagonist protocol for PCOS patients (534). At first glance, this is 
perhaps a worrying finding given the superiority that an antagonist has in reducing the 
risk of OHSS (298). The survey was completed in September 2010. Since that date, the 
updated Cochrane review and other papers published are in favour of antagonist use 
in women with PCOS (181, 297). The initial reduction in live birth rate seen with the 
earlier antagonist work has subsequently been refuted (181). The assumption is that 
the antagonist would be favoured if the study was repeated now. The authors (534) 
recognise the limitations of their survey, in particular not acknowledging the use of an 
agonist trigger in an antagonist cycle when questioning how to manage a 
hyperstimulated patient. There has been a resurgence of interest in using  the GnRH 
agonist trigger following the implementation of successful antagonist cycles (535). The 
GnRH agonist has the ability to competitively displace the bound antagonist from 
receptors in the pituitary, generating a flare response. Improved luteal support with 
either a modified hCG dose (536) or addition of extra steroid hormones 
(oestradiol/progesterone) (537) reduce the risk of miscarriage following a deficient 
corpus luteal response seen with the agonist and standard luteal support 
(progesterone alone). Further work supporting the use of the antagonist in the luteal 
phase of severe OHSS cases, shows enhanced luteolysis and reduction in VEGF (538), 





 Achieving a pregnancy following assisted conception can perpetuate the problem of 
OHSS and increase the incidence of the condition. The hormonal drive from the 
sustained corpus luteum and developing pregnancy can lead to a protracted course of 
ovarian hyperstimulation (250). Within this study there was a reduction in CPR and LBR 
for those who had metformin. This may have impacted on the reported rate of OHSS, 
falsely suggesting that there was no difference between the 2 groups. Indeed, if the 
pregnancy rates had been equal we may have seen an increase in OHSS for those on 
metformin.             
 
3.4.2 Pregnancy outcome and metformin 
Earlier studies on agonist cycles failed to reach consensus on the effect metformin has 
on clinical and live birth rates. Some publications suggest improvement (260, 346) but 
the majority (348-350, 500) suggest no difference including a Cochrane review. The 
current study suggests that metformin may actually have a negative impact on 
pregnancy rate in an antagonist cycle. This outcome is difficult to explain and it seems 
that ethnicity may play a larger role in the outcome of this trial than was previously 
expected (see next section). Even when controlling for ethnicity, there was a trend of 
reduced fertilisation, CPR and LBR with metformin (see ‎3.3.6). Although the evidence is 
limited, there are publications that positively evaluate implantation, endometrial 
receptivity and the use of metformin (540, 541). It is suggested that to achieve and 
maintain a successful pregnancy, it is beneficial to have a type 2 T helper  (Th2) 
dominant cytokine profile; whereas a type 1 T helper (Th1) profile, is more likely to 
result in miscarriage (542). Progesterone is a key promoter of Th2 dominance, with its 
action mediated by a number of proteins including progesterone-induced blocking 
factor (PIBF). This factor inhibits the release of arachidonic acid, usually converted to 
prostaglandins via the enzyme cyclooxygenase 2 (COX2) and controls natural killer cell 
activity (543). Mice treated with DHEA, created to mimic PCOS in women, show an 





that metformin could counteract fetal resorption in an androgenic environment (541). 
The mechanisms to account for this observation include restored progesterone 
production, reduced ovarian oxidative stress and improved insulin resistance (545). It 
has also been shown that metformin restores PIBF expression in DHEA treated mice, 
whilst avoiding the reduction of interleukin-6 (IL-6; a Th2 type cytokine). Unfortunately, 
there was no reduction in interleukin-2 (IL-2; a Th1 type cytokine). In contrast, Luchetti 
et al (541) found that metformin treatment alone regardless of DHEA treatment could 
increase IL-6, which aids the generation of protective asymmetric antibodies in 
pregnancy (546). Metformin also prevented the increased COX-2 expression seen with 
DHEA treatment. These factors may explain why some authors (547), have found a 
reduced risk of miscarriage with metformin treatment (OR 0.50, 95%CI 0.30-0.83). It 
should be noted that the doses of metformin given to these mice far exceeded any 
human dose. Luchetti et al (541) gave 2 oral doses of 240mg/kg, proceeding 
implantation. Although a variety of human doses have been used clinically (see Table 
3-1), these do not exceed 2000mg/day. Equivalent doses to the murine studies (an 8 
fold increase of the usual maximum human dose for a 70kg human) would be unlikely 
to be tolerated in humans given the high side effect rate of these drugs (42.9% in the 
current study). In contrast, Maruthini et al (548) showed a reduction in in vitro 
granulosa cell progesterone production with metformin pre-treatment which was 
lower than either the PCOS counterparts or control subjects. In vivo there was no 
apparent alteration in progesterone production in granulosa cells from women with 
PCOS following metformin pre-treatment. Reduced progesterone bio-synthesis may 
have implications on pregnancy outcome for women with PCOS (549). The negative 
impact from metformin exposure on progesterone production may counterbalance 
positive effects such as improved pyruvate production essential for oocyte nuclear 
maturation and developmental capacity (550).     
Endometrial receptivity as assessed by the endometrial (551) and sub-endometrial 
(540) blood flow has shown to be impaired in women with PCOS. Lam and colleagues 





The addition of metformin for 6 months was found to improve the blood flow in 
overweight PCOS women (540). This study (540) did not promote weight loss or 
exercise during the study duration and metformin use alone did not lead to weight 
reduction. This is in agreement with Tang and colleagues (339). Although the limited 
number of studies surrounding implantation and metformin are on the whole positive, 
an interesting finding by Germeyer et al (552) may support the current study’s findings 
of reduced clinical pregnancy with metformin. Following short term use (in this case 48 
hours) a substantial increase in chemotactic interleukin 8 (IL-8) occurred which may 
have deleterious immune effects by fending off embryo implantation. With long-term 
treatment this surge is neutralised. It has been suggested that parameters such as 
insulin resistance may be improved by 4 weeks of treatment (553). This still remains in 
excess of the current study duration of use and therefore will have had negligible 
effect on the trial outcome.                    
A recognised occurrence in ART is the ability to conceive whilst the patients are waiting 
to start their treatment cycle. One large cohort study found on average 9.1% of 
women conceived within a year of awaiting IVF treatment (554). It is also recognised 
that although time to conception may be increased, the final family size is seldom 
affected in women with normo-gonadotrophic anovulation (12). This raises the 
question of when ART interventions should be used, given the high cumulative natural 
conception rate (555) and associated risks of OHSS, imprinting disorders (556) and 
potential obstetric complications (557, 558). The occurrence of conception in the lead 
up to the start of treatment within this trial was 2.61% (4/153) once the study 
medication had started. Although lower than other published work, for example 
Kjotrod et al (347) who had an overall 15.4% (23/149) incidence, the current 
observation is not surprising given the relative short duration of metformin/placebo 







One of the most significant findings from the present study is the wide gap in clinical 
outcome between the White Caucasian and South Asian populations. This divide has 
been well documented in reproductive medicine (559) as well as in wider medical 
fields (560, 561). Whilst a simplistic view of this difference may be case selection, it 
raises an uncomfortable question regarding the application of generic treatments for 
all women regardless of their ethnic origin. It may be that what is seen in a primarily 
White Caucasian British clinic does not reflect the ethnic minority as a whole, but 
rather reflects a bias due to the cohort enlisted into the current trial. Examples of bias 
that could exist include language interpretation and religious practice. Although 
interpreters were used where necessary, it may be inherently more difficult to enrol 
patients if there is any difficulty in interpretation of the benefit of a clinical trial. An 
example specific to the South Asian Muslim population within this trial, was the 
withdrawal of 2 patients before commencing the study medication due to the porcine 
encasing of the drug. Due to their religious views, they did not wish to take part in the 
trial even if there might have been a potential benefit to them. An interesting finding 
from an American survey shows racial difference in those accessing services, despite 
states mandating insurance to cover fertility treatment (562). The reasons behind this 
are multifactorial including educational level, economics and clinician referrals to 
tertiary fertility care. A highlighted deficiency in much of the published data, is the lack 
of reporting of ethnicity or the loose term of ‘ethnicity unknown’ which may affect the 
validity of the conclusions (563).   
The difference in clinical outcome between the South Asian and White Caucasian 
population in an assisted conception setting has been previously documented (559, 
564, 565). Although the reason behind the inferior outcome in the South Asian 
population is not clear, it has been suggested that reduced embryo quality may be 
causative (564). Shahine and colleagues further considered this hypothesis by 
comparing cycles transferring comparable blastocysts in an Indian and Caucasian 





41%, p<0.01) was observed in the Indian population. This result persisted when age, 
stimulation protocol and evidence of PCOS was considered in multivariate analysis 
(lower LBR OR 0.56 95%CI 0.40-0.79). In the current study, there was no difference in 
good quality day 3 embryos or cycles that reached blastocyst transfer between ethnic 
groups. Furthermore, in contrast to Palep-Singh et al (559), there was no increased 
sensitivity to gonadotrophin stimulation or increased oocyte number retrieved. 
Similarly to the latter author and Shahine et al (564) an equivalent ratio of reduced 
CPR and LBR was seen. A large study including >1500 South Asian women confirmed 
the reduced outcome with respect to both clinical pregnancy and live birth rate (566). 
The current South Asian population have a longer duration of infertility, raised BMI 
and worse phenotypic presentation of PCOS. Each of these points can be viewed as 
poor prognostic indicators for clinical outcome. Obesity per se has also been shown to 
impair fecundity, endometrial development and implantation (567). Obesity can also 
worsen the phenotypic presentation of PCOS. Importantly, classification of obesity by 
BMI varies according to ethnicity. The WHO suggest that a BMI >25kg/m² in South 
Asian Indians is equivalent to a BMI>30kg/m² in White Caucasians (55). As the current 
study’s South Asian population exceeds this value (26.0±2.8kg/m²) this may explain in 
part the negative clinical outcome. There is also a greater propensity for insulin 
resistance in the South Asian population which as previously discussed can harm 
clinical outcome (51). Speculation on dietary/environmental factors that could affect 
IVF outcome in the South Asian population include methyl mercury, a reproductive 
toxin found in Seafood (568) and levels of vitamin D. Evidence suggests that those who 
are vitamin D deficient, have a worse assisted conception outcome with the South 
Asian population over represented in this group (569). It has also been suggested that 
those who have PCOS and vitamin D depletion have increased obesity and endocrine 







There are a number of limitations within this study. Firstly, metformin was used for too 
short duration, which although may have had effect on some aspects of metabolism, is 
unlikely to have optimised metformin’s potential. Secondly, formal insulin resistance 
testing was not carried out. The surrogate measure of SHBG suggested that this 
population was not overtly insulin resistant and therefore may not be the best cohort 
to test. If this trial was to be repeated, it may be more appropriate to select women 
with evidence of disordered glucose metabolism and insulin resistance. In summary, 
the current trial does not support the use of metformin in an antagonist cycle to treat 
women with PCOS. There is neither reduction in OHSS with short term use of 
metformin nor any improvement in clinical pregnancy rate. The rather puzzling 
outcome of reduced CPR and LBR is likely to be explained by chance rather than true 
effect. The pertinent point of the trial is the inequality in clinical outcome between the 






4 Chapter 4 
Clinical Application Of In Vitro Maturation for the 
treatment of PCOS 
 
4.1 Introduction 
In vitro maturation is the process of immature oocyte collection and laboratory 
maturation prior to fertilisation. It has been considered a possible low risk alternative 
to standard IVF assisted conception regimens for more than 15 years. For those 
patients with PCOS, who are at high risk of over response and OHSS, the concept of 
minimal gonadotrophin exposure is appealing. Despite the theoretical advantages of 
IVM, low success rates have precluded IVM from routine use. Alongside the low 
success rate, IVM requires more intensive laboratory time and planning of cycles. For 
the patient on the other hand, IVM has been marketed as a ‘patient-friendly’, low cost 
approach (571).      
It is clear from the literature that a consensus on the optimum protocol for IVM 
treatment has yet to be reached. Whilst not exhaustive, Table 4-1 and Table 4-2 
provide an overview of the published protocols and outcomes for the majority of IVM 
treatments published worldwide for women with PCOS. From this summary, it is 
apparent that the majority of centres use hCG priming prior (usually 36 hours) to 
oocyte pick-up with fewer adopting a truncated ovarian gonadotrophin stimulation 
before oocyte collection. Priming with one or both of these agents (hCG or 
gonadotrophin), has been shown to improve the maturation rate of oocytes in some 
studies (359, 395, 397) and may improve implantation (396). The LBR within Table 4-2 
ranges from 7-45.2%, highlighting the inconsistency of the treatment outcome. It also 
highlights the limited number of cycles completed in comparison to conventional ART 
cycles. Although some may view IVM sceptically, the more recent trials have published 









Table 4-1 Clinical trials of in vitro maturation in patients with Polycystic Ovary Syndrome – clinical protocols 
Name Number cycles FSH prime hCG prime Day to OR Endo priming ET / time Oocytes 
Cha et al.(573) (2000) n=94 x x 10-13 




Chian et al.(397) (2000) n=24 x 10000 36³ / x⁴ 10-14 
OR 6-10mg, from ICSI 400mg 





Mikkelsen& Lindenberg (396) 
(2001) n=36 
150 day 3 rFSH 3 
days¹/x² x ¹8-9/²endo 5mm 
OR 2mg TDS E2, OR+2 100mg 
TDS V P  
UK 
7.5 median 
Child et al. (413) (2002) n=107 x 10000 36hrs <10mm DF (9-14) 
Or 6-10mg E2, from ICSI 
200mg BD V P 
If <7mm on 
transfer - 
cryopreserved 10.3±7.6 
Lin  et al.(400) (2003) n=68  
rFSH 75iu 
6days¹/x² 10000 36hrs 10_14 
OR 6-10mg E2, from ICSI 





Le Du et al.(574) (2005) n=45 x 10000 36hrs  Fo.=7mm 
OR 6-10mg E2, V P 8-13mm on 
transfer day 11.4±6.9 
Soderstrom-Anttila et al.(412) 
(2005) 
n=18 IVF:10 
ICSI x x endo 5mm DF 10mm 




Son et al.(575) (2007) n=82 x 10000 36hrs ET (not stated) 
OR+1 6mg E2, OR/OR+1 
100mg IM P 
UK 
24.4±9.9 
Benkhalifa et al.(576) (2009) n=350  x 10000 36hrs ET>6mm (9-11) 
OR E2 if ET >7mm 6mg if 
<7mm 8-10mg. From ICSI V P 
200mg TDS or SC P 100mg 
No transfer if ET 
<7mm 
9±UK 
Zhao  et al.(577) (2009)  n=152 x x DF <10mm (9-14) 
D3-5 if ET<5mm 4mg E2, OR 
if ET<7mm 6-10mg otherwise 
4mg,from ICSI 60-80mg IM P 
8.72mm at 
transfer 
18.2 ± 8.6 
Bos-Mikich  et al.(398) (2011) n=34  x yes - dose UK 36hrs endo≥7mm OR 6mg E2, OR+1 800mg V P UK 16.3±UK 
Gremeau  et al.(358) (2012) n=97 x 10000 35/40hrs Fo.<14mm (8-16) 




Junk & Yeap (359) (2012) n=66 
day 3, 3 days 100-
150 x Fo.10-12mm 
2 days pre-OR 2mg E2 / 3mg 
TDS E2 +patches 50μg/day 
based ET 6mm. From OR 
90mg P V BD 
All ≥8mm at OR 
8.8 ±4.4 (PCO)  
14.4 ±6.4 
(PCOS) 
Roesner et al.(578) (2012) n=215 3 days 125 
10000/250 33-
38hrs trigger last day FSH/+1 
From OR 6mg/day E2 + from 
OR+1 600mg V P 
UK 
8.9 
Shalom-Paz et al.(360) (2012) n=310 
150hMG if endo 
<6mm 10000 8hrs  
endo 6mm/Fo.10-
12mm 
 hMG 150iu/day if ET<6mm 
for 3-5days from day 7-10 
UK 
17.1 ± 13.6  
Zheng et al.(572) (2012) n=82 x 10000 36hrs³ / x⁴ 
endo 6mm. No 
Fo.>10mm 
From OR 6mg E2 /60mg IM P UK 
13.8-14.35 









Table 4-2 Clinical trials of in vitro maturation in women with Polycystic Ovary Syndrome - laboratory protocols 






% Transferred CPR (%) LBR (%) 
Cha et al.(573) (2000) n=94 48 
TCM-199 plus 20% bovine serum, 
10iu/ml FSH/LH, 10iu/ml hCG, 
pyruvate, penicillin G & streptomycin 62.2 
ICSI 
75.1 4.9±2.5 27.1 (23/85) 17/23 
Chian  et al.(397) (2000) n=24 up to 48 
TCM-199 plus 20% bovine serum, 
25mol/l pyruvic acid, 75miu/ml FSH/LH 84.3³/69.1⁴ 
ICSI 
90.7³/83.9⁴ 2.8±0.9³/2.5±1.1⁴ 38.5³/27.3⁴ 25.0 
Mikkelsen & Lindenberg 
(396) (2001) n=36 28-36 
TCM-199 plus pyruvate, penicillin G, 
streptomycin, 0.075iu recFSH, 0.5iu 
hCG, 10% serum  ¹59 / ²44 
ICSI 
¹70 / ²69 UK ¹33 ²0 ¹14.3 / ²0 
Child et al. (413) (2002) n=107 24-48 
TCM-199 plus 20% serum, 0.25mmol/L 
pyruvate, penicillin/streptomycin, 
75mIU/ml FSH/LH 76 
ICSI 
78 3.2±0.9 21.5 15.9 
Lin et al.(400) (2003) n=68  48 
TCM-199 plus 20% serum, 75mIU/mL 




¹75.8 / ²69.5  3.8±1.0 ¹31.4/²36.4 29.4 
Le Du et al.(574) (2005) n=45 24-48 20% serum, 0.75iu FSH/LH 54.2 by 24 ICSI 69.5 by 24 2.5±UK 22.5 by et UK 




10% patient serum, 0.075iu/ml rec 
FSH, 0.1iu/ml hCG 54.3/53.2 
IVF/ICSI 
43.8/78.4 1.7±0.5 / 1.8±0.4 52.9/22.2 UK 
Son  et al.(575) (2007) n=106 UK 
30% human follicular fluid, 1 iu/ml FSH, 
10 iu/ml hCG, 10ng/ml rec human EGF 78.2 
ICSI 
80.5 Blast 2.95 ±0.2 51.9 40.6 
Filali  et al.(579) (2008)  n=49 24-48 20% patient serum, 0.75iu/mL FSH/LH 60.6 ICSI 56.8 2.2 ± 0.1 28.6 UK 
Zhao  et al.(577) (2009)  n=152 48 
20% FBS. 0.25 Pyruvic acid, 75mIU/mL 
FSH, 0.5iu/mL hCG 68.6 
ICSI 
70.28 3.2 ± 0.7 40.0 UK 
Bos-Mikich  et al.(398) 
(2011) n=34  28-30 
75mIU/ml FSH , 0.1iu/mL hCG 
63 
ICSI 
62 3.29±UK d3 32.0 UK 
Gremeau  et al.(358) 
(2012) n=97 48 
75iu/L FSH/LH high humidity 
65.01 
ICSI 
62.9 1.9±0.4 19.6 16.5 
Junk  & Yeap (359) (2012) n=66 24-26 
0.1iu/mL FSH, 0.5iu/mL hCG, 10% 
patient serum 69.7 
ICSI 
71.4 single blast 46.7 (per et) 45.2 
Roesner et al.(578) (2012) n=215 24+ Nil 64 IVF/ICSI 45.1 2.1±UK 15.3 7.3 
Shalom-Paz  et al.(360) 




70.2 3.4±0.8 48.0 29.0 
Zheng  et al.(572) (2012) n=82 32 
0.075iu/mL FSH/LH 55.43³ 
42.29⁴ 
ICSI 
63.4³ 65.49⁴ 2±UK 44.12³ 52.50⁴ 
26.5³ 
32.5⁴ 
¹FSH prime ²No FSH ³hCG prime ⁴No hCG. UK-unknown, OR-oocyte retrieval, DF- Dominant follicle, ET-endometrial thickness, Fo.-follicle, endo- endometrium, E2-oestradiol P- progesterone, Vag- vaginal, 





Both studies are on young (30-31 years) PCOS women and both use ICSI. However, the 
protocols that have been employed pre-oocyte collection use significantly different 
approaches. Junk & Yeap (359) used a 3 day course of FSH (100 or 150iu Puregon, 
Merck Sharp & Dohme Limited, Hertfordshire, UK) stimulation from day 3 of the cycle 
without hCG, whilst Zheng et al (572) only used hCG (10000iu Profasi, Merck Serono, 
Darmstadt, Germany) priming in part of their study group.  The latter study concluded 
that the hCG made no difference to the clinical outcome or live birth rate. The 2 
studies also used different IVM and embryo culture conditions. The 1st group (359) use 
G2-Plus media (Vitrolife, Sweden AB) with the addition of 10% of the patient’s heat 
inactivated serum, 0.1iu/mL FSH (Puregon) and 0.5iu/mL hCG (Pregnyl). While the 2nd 
group (572) use SAGE (CT, USA) IVM maturation media with the addition of 0.075 
iu/mL FSH/LH (Menopur, Ferring, Germany) before switching to a different cleavage 
medium (G-M, LifeGlobal, CT, USA). Both groups used oestradiol and progesterone 
supplementation for endometrial priming, but Junk and Yeap (359) commenced 
oestradiol 2 days prior to oocyte retrieval based on endometrial thickness, with the 
addition of vaginal progesterone following retrieval while Zheng et al (572) started 
both oestradiol and intramuscular progesterone from the day of oocyte retrieval. Due 
to the similar outcomes of CPR and LBR, this suggests either minimal impact from 
these aspects of the treatment protocols on oocyte maturation and quality or that 
neither centre had a fully optimised protocol. The question of which stimulation 
regimen and culture media should be used, has been raised previously with regard to 
IVM (580, 581) and there has been considerable discussion on whether the media 
should be supplemented with gonadotrophins and/or serum (582, 583). The differing 
approaches but similar outcomes of these trials, emphasises that the perfect culture 
and treatment protocol for IVM is yet to be reached.  
The wide variation in clinical pregnancy and live birth rate observed after IVM could in 
part be related to the variability in the average number of embryos transferred 
between centres and countries. The legal boundaries within the UK, for example, limit 





emphasis towards single embryo transfer, whilst many studies outside the UK transfer 
more embryos. From Table 4-2, only 4 of the studies had an average embryo transfer 
of ≤2 (358, 359, 412, 572). One study transferred up to 5 embryos per IVM cycle (573). 
A good quality RCT is clearly needed, to address whether IVM can add anything further 
to the treatment of women with PCOS. The majority of published literature cites 
retrospective observational data. With the advances in assisted conception techniques, 
that limit the risk of OHSS for these patients (e.g. such as the antagonist cycle and the 
use of then GnRH agonist trigger) the validity of continuing to offer IVM is questioned. 
A direct comparison of IVM with a conventional assisted conception cycle (centred on 
controlled ovarian stimulation and IVF/ICSI) is needed in an appropriately powered 
study to answer this question. A secondary outcome of such a trial should be 
assessment of patient welfare and assessment of the relative cost of treatment.  
The aims of this chapter were therefore 2-fold: 
(i) To conduct a pilot study to optimise conditions for the use of IVM as a 
treatment strategy in women with PCOS, as a prelude to conducting a full 
RCT to evaluate the efficacy of IVM as a strategy to treat women with PCOS 
or PCOM. 
(ii) To conduct a cost analysis of IVM as a treatment for PCOS compared with a 
conventional antagonist protocol. 
 
4.2 Materials And Methods 
Women identified with either PCOM alone or PCOM with PCOS using the Rotterdam 
criteria (7) were offered the opportunity to have a research funded cycle of IVM. 
Candidates were identified from the pool of women about to commence an assisted 
conception treatment cycle at LCRM. Once eligibility was confirmed by review of 
clinical notes, an appointment with the research doctor was made to discuss the 





was given and if the couple wished to proceed on to treatment written consent was 
completed.  
Inclusion criteria apart from PCOM, included: age 23-39yrs, BMI ≤30, easily accessible 
ovaries on trans-vaginal scanning and a normal FSH (≤8iu/L). A negative infection 
screen for HIV/Hepatitis B/Hepatitis C/ Syphilis/ Chlamydia was a pre-requisite. Only 
women due to commence an IVF treatment cycle were approached after less invasive 
treatments had failed or were not suitable for them. Couples with severe male factor 
infertility (<1x10^6 sperm/mL) or those who required the use of frozen sperm were 
not eligible.  
Informed consent outlined the nature of the treatment. Information included: first 
time the clinical treatment would be completed at LCRM, clinical pregnancy rates (16% 
(394)) from the literature, that the same laboratory method practiced by Oxford 
Fertility Unit (only UK centre to regularly offer IVM) (358) would be used and that ICSI 
would be used in all cases. Patients were made aware that IVM treatment was 
uncommon and that <2000 children have been born worldwide from the treatment. It 
was highlighted that the safety profile for the children was less robust compared with 
standard IVF/ICSI due to reduced numbers and age of children born following IVM to 
date. From the literature there was no significant increased risk to the unborn children 
either physically or mentally.    
Ethics approval was granted from Leeds West Ethics Committee (09/H1307/51) to 
complete an RCT comparing a standard antagonist assisted conception cycle with an 
IVM cycle. A preliminary 30 patients were recruited and treated using the same clinical 
protocol and laboratory method to ensure the smooth operation and integration of 
the known clinical treatment into the LCRM work setting. Patients were consented in 
the same written manner to ensure that all aspects of the trial were outlined and that 






4.2.1 Treatment pathway 
Prior to the onset of treatment all baseline investigations were completed for each 
patient which included a day 1-3 hormone profile (FSH/LH/oestradiol/testosterone 
/SHBG/TFTs/prolactin; see Chapter 2.2.1 for the assay details) and a TVUSS to assess 
accessibility, as well as ovarian volume and AFC for each ovary. Due to the extra 
laboratory time required per treatment cycle a limited number of cycles were 
completed each week with a maximum 3 a week / 1 per day. Women were 
programmed with the oral contraceptive pill (OCP; microgynon 30®, Bayer Healthcare, 
Germany) to allow optimum cycle planning. The maximum number of days on the OCP 
was 21. If used for longer than 1 week, a 5 day break was given following OCP 
withdrawal prior to commencing the IVM cycle. For women with amenorrhoea or 
oligomenorrhoea (cycles >35 days apart), a progesterone induced withdrawal bleed 
was incurred using medroxyprogesterone (Provera®, Pharmacia, Ltd, Kent, UK) 5mg 
3x/day, 5 days prior to starting treatment.  
All women had a TVUSS on day 2 of their treatment cycle (day 0 = 1st day menstrual 
cycle/progesterone withdrawal bleed ± OCP programming) to ensure no ovarian cysts 
were present. If the ovaries were ‘quiet’ (no follicles >10mm), the first dose of FSH 
150units was given subcutaneously (Fostimon®, Pharmasure, Hertfordshire, UK). A 
further self-administered Fostimon 75units was given on days 4 and 6. A TVUSS was 
completed on day 7 or 8 of the cycle prior to the administration of low or high dose 
hCG (Pregnyl®, Organon, Hertfordshire, UK) either 24 hours or 36 hours prior to the 
oocyte retrieval according to the details in Table 4-3. Minor optimisation modifications 
were made to the clinical treatment pathway through the pilot study with the 
intention of improving the pregnancy outcome. The changes were sequentially made 
following the outcomes of the preceding recruited patients. These were based on the 
varying common practices published in the most recent trials (outlined in Table 4-1), 
with each strategy having a published clinical pregnancy rate. These changes are 
outlined by group in Table 4-3. The laboratory protocol remained constant throughout 





Pharmacia Ltd, Kent, UK) prior to oocyte collection to reduce the risk of infection at 
oocyte retrieval. The majority of ultrasounds (>90%) were carried out by a single 
operator (Dr Susan Nicholas).   
 
Table 4-3 Clinical treatment protocols (methodology groups)  
 Details of Treatment 
Group 1 5000 hCG¹ given day 8, 24 hours prior to day 9 oocyte collection. 6-8mg 
Oestrogen²/400mg Progesterone³ 
Group 2 10000 hCG¹ given day 8, 24 hours prior to day 9 oocyte collection. 6-8mg 
Oestrogen² / 800mg Progesterone³  
Group 3 10000 hCG¹ given day 9 prior to day 10 oocyte collection. Luteal phase as 
group 2  
Group 4 As group 3 but embryos frozen if possible with frozen embryo transfer cycle 
Group 5 10000 hCG¹ given 36 hours prior to collection, determined by lead 
follicle/endometrial thickness (aim follicle>10 &/or endometrium >6mm). 
Luteal phase as group 2 
Sequential allocation of recruited patients into outlined methodology groups based on recognised 
clinical treatment strategies (Table 4-1).  ¹Pregnyl (Organon) ²Progynova (Bayer Healthcare) ³Cyclogest 
(Actavis) 
 
On the day of oocyte retrieval (OR), patients were fasted from midnight prior to the 
collection. An anaesthetist was present to administer conscious sedation under LCRM’s 
normal conditions using a combination of Midazolam (up to 5mg) and Fentanyl (up to 
100μg) ± Propofol (up to 20mg). Patient’s had an empty bladder prior to oocyte 
collection. Using a double lumen flushing Clarendon needle (Casmed International Ltd, 





punctured trans-vaginally. Multiple follicles were drained per collection tube. Each 
follicle was flushed at least 3 times using Vitrolife heparinised flushing media (Vitrolife 
AB, Göteborg, Sweden) before moving onto the next follicle. An example of a pooled 
follicular sample is shown in Figure 4-1. If more than 1 puncture per ovary was 
required a dose of intravenous antibiotics were given according to the clinic’s standard 
guidelines (1.2g Augmentin®, GlaxoSmithKline, Middlesex, UK). Haemostasis was 
confirmed at the end of the procedure. Patients were discharged home later the same 
day.  
 
Figure 4-1 Example of a pooled sample at an in vitro maturation collection showing 









On the day of the oocyte collection, a fresh sperm sample was obtained from the male 
partner and prepared ready for the ICSI procedure according to the standard clinical 
protocol. Following production, the sperm was allowed to liquefy at room temperature, 
before adding 1.0mL of semen onto a PureCeption gradient (40 & 80%, Sage, Origio Ltd, 
Reigate, UK) and centrifuged at 300g for 20 minutes. The sperm pellet was then 
washed twice in 2mL of Quinn’s Sperm Washing Medium (Origio Ltd). Sperm samples 
were then stored at room temperature until it was required for insemination. From the 
day of oocyte collection, patients received an increasing dose of oestradiol valerate 
(Progynova®, Bayer Healthcare, Germany) of 6mg to 10mg and also commenced 
vaginal pessary progesterone support of either 400mg or 800mg dependant on 
treatment group  (cyclogest®, Actavis, Dublin, Republic of Ireland) to prepare the 
endometrium for the embryo transfer. Patients were given information regarding 
which OHSS symptoms to be vigilant for and were asked to report to the Unit if they 
experienced any of them e.g. shortness of breath, extreme bloating, diarrhoea and 
nausea.  
For women undergoing an IVM cycle, fertilised embryos were cultured to Day 3. 
Optimally, 2 embryos were selected for double embryo transfer if available. Embryos 
were used where possible from the Day 0 or Day 1 matured oocytes. If not possible or 
obviously inferior quality graded embryos were produced following insemination then 
Day 2 embryos were used for transfer. An embryo was referred to as good quality if 
graded ≥ 6.3.3 on day 3 or ≥2Bb (524, 525). Classification of embryos for day 3 and day 
5 are shown in Table 3-5 and Table 3-6. For simplification of displaying results any 
ungradable embryo was classified as abnormal and those below <6.3.3 or <2Bb were 
referred to as poor quality. 
Embryo transfer took place using a Cook catheter (Cook Medical Inc., Bloomington, 
USA) and directed with abdominal ultrasound. Remaining embryos were cultured to 
blastocyst stage and graded prior to discarding the embryos. There was no freezing of 
embryos for an additional frozen embryo transfer cycle, apart from group 4. This group 





embryo transfer cycle. The slow freeze technique was used rather than vitrification, 
using Quinn’s Advantage embryo freeze kit (Origio), liquid nitrogen and the Planer 
freezer (set to Sage freezing programme). The hormone replacement cycle included 
down-regulation with a GnRH analogue (Prostap 3.75mg SC, Takeda UK, High 
Wycombe, UK) before preparation with 12 days of oestradiol valerate 4-6mg. 
Following an USS on day 12 of oestradiol, if the endometrium was >6mm, vaginal 
progesterone 800mg was added for 4 nights prior to the day 3 transfer. All embryos 
were thawed at once and cultured to day 3 and the best embryos selected for transfer.  
Confirmation of pregnancy test took place on day 14 using maternal serum hCG as an 
index of implantation (Siemens Advia Centaur & Siemens reagents, WHO 5th IS 07/364). 
A positive test was confirmed if hCG was >2 iu/L. If the test was positive a further test 
was conducted 48 hours later. If this was positive a TVUSS was booked for 7 weeks 
gestation to confirm a viable intrauterine pregnancy. The oestradiol and progesterone 
commenced at oocyte collection was planned to continue until 10 weeks gestation. 















4.2.2 Laboratory protocol for IVM 
The full laboratory protocol is outlined in Figure 4-2 – 4-4, which includes the 
preparation required for an IVM cycle and the steps involved during the retrieval, 
maturation and culture. 
 




















Oocytes were scored according to Wynn et al (395) to reflect/predict the oocytes’ 
maturation potential. This occurred at collection, 24 hours following collection (Day 1) 
and immediately prior to stripping at the end of cumulus oocyte complex (COC) culture 
(termed strip). Due to the technical difficulty of assessing nuclear maturation with 
surrounding cumulus intact, all oocytes were stripped on day 1. A score was generated 
for both cumulus-oocyte coverage (mass) and cumulus expansion (see Table 4-4 and 
appendix 1). Examples of oocytes and their corresponding mass and expansion scores 
are given in Figure 4-5. 
 
Table 4-4 Cumulus mass and expansion score 
 Cumulus Mass Cumulus Expansion 
Grade C0:  ≤3 layers cumulus 
cells 
E0: tight, dense corona 
cells 
 C1: >3<10 layers E1: moderate expansion 
 C2: ≥10 layers E2: fully expanded cells 
 
Intra-cytoplasmic sperm injection was used for all cases in this pilot study using the 
Unit’s standard protocol. In preparation, 13mL of liquid paraffin oil (Origio Ltd) per 10 
eggs was placed into 15mL tubes in incubator to warm overnight. Approximately 2 
hours before stripping, cumulase (Origio Ltd) and Quinn’s Advantage medium with 
HEPES (QA-H, Origio Ltd) was removed from the fridge and placed in the warming oven, 
alongside pre-gassed sterile Nunc (Thermo Fisher Scientific, Hemel Hempstead, UK) 
culture dishes (150270) and sterile Nunc ICSI dishes (150265). Polyvinylpyrrolidone 
(PVP; Sage, Origio Ltd) was placed in hot block set at 37°C 20 minutes before use. 
Oocytes were denuded of cumulus layers to assess maturity using a range of sterile 
Pasteur pipettes or EZ tips (Research Instruments Ltd, Cornwall, UK). Metaphase II 







Figure 4-5 Oocyte grading based on cumulus mass (M) and expansion (E) from different 
patients a) top to bottom: E0 M0, E0 M0, E0 M0, E0 M1 b) clockwise from top left: E0 M2, 
E0 M1, E0 M0, E0 M1 c) left to right: E2 M2, E0 M2, E0 M2 d) clockwise from top left: E1 
M1, E1 M2, E0 M2 
 
 
Cumulase and wash drops of QA-H were dispensed into a sterile NUNC culture dish 
then overlaid with pre-warmed oil with a maximum of 4 COCs eggs per dish. The COCs 
were transferred into the cumulase and aspirated vigorously before moving through 
successively smaller pipettes in the QA-H drops. All denuded oocytes were transferred 





PVP were overlaid with oil and kept in the un-gassed desktop incubator until needed. 
To the PVP drop 1-5μl sperm was added to the upper section with the fastest sperm 
collected from the bottom. Metaphase II oocytes were added to the QA-H drops and 
the dish transferred to a pre-warmed microscope stage at 37°C. A motile, normal 
sperm was picked up and brought to the side of the oocyte. Using a holding pipette the 
oocyte was grasped at 9 o’clock with the polar body at 6 o’clock. Using an ICSI pipette, 
the zona and oolemma were gently pierced half way in to the cytoplasm at 3 o’clock 
and the sperm deposited. The injected oocytes were returned to the post-ICSI dishes 
containing EMM and returned to the incubator for culture. 
 
4.2.3 Cost analysis 
Cost analysis of IVM treatment was based on cycle costings produced for the time 
period of the trial by Leeds Teaching Hospitals NHS Trust. These were based on the 
2010 pay scales for employees of the trust. A comparison was made between an IVM 
cycle and a standard antagonist cycle using 10 days of gonadotrophin stimulation (150 
units/day) appropriate for women with PCOS. The comparison with the antagonist 
protocol was made due to the recommendation to use such a protocol in women with 
PCOS. The analysis included the average time for carrying out a procedure and the cost 
of the member of staff completing the procedure. The analysis also included 
consumable costs such as the medication required for an average treatment cycle. The 






4.2.4 Primary and secondary end points 
The primary end point of this pilot study was to achieve a clinical pregnancy. This was 
defined as ultrasound evidence of a fetal heart beat. The secondary end points were: 
1) oocyte maturation rate 
2) fertilisation rate 
3) embryo quality 
4) OHSS (or rather the elimination of OHSS).  
The pilot study had a set number of participants based on the recommendation by the 
Ethics committee that a clinical pregnancy should be achieved within this number of 
patients.  
 
4.2.5 Statistical analysis  
Statistical analysis was conducted using the IBM SPSS 21 statistics package (IBM 
Corporation, New York, USA). Continuous data was tested for normality using the 
Kolmogorov-Smirnov test. If the test was significant (p<0.05) normality was not 
assumed. Normally distributed data was analysed using the parametric tests including 
Student’s t-test (with Levene’s test for equality of variance) and ANOVA. Normally 
distributed data included the baseline demographics of age, BMI, FSH and number of 
oocytes retrieved. This data were presented as mean ± standard deviation.  Non-
parametric data was analysed using Mann-Whitney and Kruskal-Wallis tests. This type 
of data included the number of oocytes that matured and fertilised. These data were 
presented as median and IQR. Contingency tables were employed where necessary 
with Chi-squared statistic (plus continuity correction) and Fisher’s Exact tests (if any 
cell had an expected count less than 5). This was used for categorical data including 
percentage of oocytes matured, fertilised and CPR/LBR. A p value of <0.05 was 





grading score and oocyte maturation) Spearman’s Rank correlation coefficient was 
used.  
4.3 Results    
 
4.3.1  Patient recruitment and outcome 
Between September 2012 and October 2013, 31 patients consented to undergo IVM 
treatment within the pilot group at LCRM (see Figure 4-6).  Of the 31 women, 27 
women underwent 30 IVM oocyte collections (3 of whom had 2 cycles each). Of the 
remaining 4, 2 became pregnant before commencing treatment and 2 women 
withdrew consent after further reflection. At oocyte collection the average oocyte 
number retrieved was 17 ± 8 (total number 503). The transition of oocytes from GV to 
MII is highlighted in Figure 4-8. No oocytes were found to be mature on day 0 (day of 
retrieval). Of the 30 oocyte retrievals, 28 cases had an embryo transfer and 2 women 
had no embryo to transfer. Twenty-six women had a double embryo transfer. All 
embryos transferred except 1 were created from day 1 matured oocytes. The first 2 
patients in the pilot study had a single cleavage stage embryo transferred on day 2. Of 
the embryos transferred, 87.0% were deemed good quality (47 embryos). The overall 
embryo quality is shown in Figure 4-8. Embryos created from oocytes maturing on day 
1 had an increased cleavage and blastocyst formation rate. The majority of day 3 
embryos were classified as poor quality. Twenty-one blastocysts were created of which 
23.8% were deemed good quality (5 blastocysts from 4 patients). The endometrial 






Figure 4-6 Patient recruitment and treatment pathway 
 
Of the 28 embryo transfers, 9 (32.1%) had a positive serum hCG on day 14. Eight of 
these resulted in a biochemical pregnancy (with low hCG readings) and 1 an ectopic 
pregnancy (see Figure 4-7). The ectopic was managed medically with Methotrexate 
and required two repeated doses (each dose 50mg/m² based on actual body weight). 
Ten IVM treatment cycles yielded blastocysts from the remaining embryos produced. 
Only 2 of these 10 cycles had a positive day 14 serum hCG. There were no reported 
cases of OHSS. One patient had significant discomfort on day 2 post-oocyte collection 
but only required simple analgesia. All 27 women had PCOS and not PCOM alone. The 





(range 20-30.5).  Following the unsuccessful IVM treatment, 4 women achieved a 
natural conception within 4 months following their treatment cycle. All were 
confirmed as a clinical pregnancy with unfortunately 1 patient miscarrying around 8 
weeks of gestation. Fifteen women subsequently underwent a conventional IVF cycle 
with or without a frozen embryo transfer cycle of whom 9 achieved a clinical 
pregnancy. Twelve had not undergone any further treatment at LCRM to date. 
 
Figure 4-7 Clinical outcome of pilot IVM study at 14 and 39 days post insemination of 
mature oocyte 
 
From 30 started cycles of IVM, 9 positive hCG results were achieved on day 14 but by day 39 only 1 





























Figure 4-8 Outcome of oocytes from oocyte retrieval*.  A: Cumulative data regarding level 
of oocyte maturation with reference to time in culture. B: Pooled data of the outcome of 
all MII oocytes regardless of day of maturation. C: Embryo outcome rates based on when 
oocyte maturation reached and insemination completed. 
 
* Fertilisation rate = Number of 2PN zygotes/Number metaphase II oocytes. Cleavage rate = Number cleaving 
embryos / Number of 2PN zygotes. Blastocyst rate = Number of Blastocysts / Remaining cleavage embryos following 





4.3.2  Oocyte grading system and maturation 
The cumulus-oocyte coverage (mass, M) and expansion (E) scores assigned to the 
different time points were correlated with day 1 maturation (excluding the late day 1 
oocytes) and total maturation. This included the grouping of oocytes classified as 
abnormal (by morphology or degeneration), as this did not affect the correlations. The 
stronger correlations were seen between the scores assigned at the point of cumulus 
stripping and maturity (see Figure 4-9). In particular, the expansion score with day 1 
maturation and the coverage score with total maturation. Although these were the 
strongest links, the coefficient value was well below 1, revealing a less than perfect 
correlation.  
 
Figure 4-9 Correlations between cumulus-oocyte grading scores relating to mass and 
expansion with oocyte maturity 
Oocyte score Maturation Spearman’s Rank 
coefficient 
Significance 
Day 0 M Day 1  0.133 P<0.01 
Day 1 M Day 1 0.216 P<0.01 
Day 1 Strip M Day 1 0.247 P<0.01 
Day 0 E Day 1 0.080 ns 
Day 1 E Day 1 0.315 P<0.01 
Day 1 Strip E Day 1 0.407 P<0.01 
Day 0 M Total Maturation 0.171 P<0.01 
Day 1 M Total Maturation 0.243 P<0.01 
Day 1 Strip M Total Maturation 0.305 P<0.01 
Day 0 E Total Maturation -0.14 ns 
Day 1 E Total Maturation 0.150 P<0.01 






Figure 4-10 represents the scores assigned for oocytes that were either GV or MII by 
day 2. Although there are significant differences between the scores and mass / 
expansion, when you compare the charts, the predictive capacity of oocyte maturity 
appears limited especially on day 0. On day 1, a score of 2 for either mass or expansion 
was more likely to result in a MII oocyte. 
 
Figure 4-10  Cumulus score for mass and expansion following oocyte retrieval and prior 




4.3.3 Comparison by treatment methodology group   
The baseline demographics for these women are shown in Table 4-5. There were no 
significant differences (p>0.05) between treatment groups (as detailed in Table 4-3) in 
age, BMI and FSH. There was also no difference in predicted numbers of oocytes and 





Table 4-5 Baseline patient demographics ordered by treatment methodology group 
 Group 1  
(n=5) 
Group 2  
(n=4) 
Group 3  
(n=6) 
Group 4  
(n=5) 





















27.2 ± 3.7 24.6 ± 3.5 25.1 ± 
3.1 
ns¹ (0.50) 
FSH (iu/L) 1.8-8 5.2 ± 1.1 5.2 ± 2.1 4.9 ± 
2.3 
6.4 ± 1.3 5.2 ± 2.0 5.4 ± 1.8 ns¹ (0.72) 
Number of 















prior to hCG 
6.0 ± 1.4 5.0 ± 1.9 3.8 ± 
1.1 
6.8 ± 3.9 4.9 ± 1.0 5.2 ± 2.1 ns¹ (0.14) 
¹ANOVA ²Kruskal-Wallis Test ³Fisher’s Exact Test ⁴Chi squared statistic *Parametric data presented as 
mean ± SD; non-parametric data as median (IQR) 
 
Table 4-6 outlines the different oocyte, embryo and outcome results per treatment 
group as outlined in the methodology section. There was no significant difference in 
baseline demographics including age, BMI and FSH level. A similar number of oocytes 
were collected from each group of patients. There was no significant difference 
(p>0.05) in maturation by individual patient or cumulative total for each group. There 
was a significant difference in favour of group 3 for total fertilisation of day 1 matured 
oocytes and total fertilisation of all matured oocytes. Despite this finding, there was a 
significant difference (p<0.05) in good day 3 embryos, in favour of group 1 and 2. 
Furthermore, there was a trend for an improved occurrence of positive pregnancy test 
in first two groups, although this was not significant (p=0.72). Overall, there was a poor 
development of embryos to the blastocyst stage. For the full results per patient please 
see Appendix 2. It is evident from Figure 4-11 that irrespective of treatment group, the 
better quality embryos were produced from day 1 matured oocytes, but these resulted 





Figure 4-11 Embryo quality analysed according to patient treatment group: a) Day 3 
embryos from day 1 matured oocytes b) Day 3 embryos from day 2 matured oocytes b) 










Table 4-6 Oocyte, embryo and pregnancy outcome results by treatment methodology group* 
 Group 1  
(n=5) 
Group 2  
(n=4) 
Group 3  
(n=6) 
Group 4  
(n=5) 






Oocytes per patient 10.8 ± 3.7 21.0 ± 9.4 15.3 ± 6.2 18.8 ± 10.9 17.9 ± 7.5 16.8 ± 7.9 ns¹ (0.32) 
Oocytes per group 54 84 92 94 179 503 na 
Mature oocytes day 1 per patient 5 (2-7.5) 8 (5.5-20.3) 9 (5.3-12.8) 9 (3.5-12) 8.5 (5.8-10.8) 7.5 (5-10.3) ns² (0.43) 
Mature oocytes day 2 per patient 1 (0-3) 4 (0.5-0.8) 1 (0-4.3) 4 (1.5-10) 3 (2-4.8) 2 (1-4.5) ns² (0.21) 
Total mature oocytes day 1 (%) 24 (44.4%) 45 (53.5%) 54 (58.7%) 40 (42.6%) 82 (45.8%) 245 (48.7%) ns⁴ (0.14) 
Total mature oocytes day 2 (%) 7 (13.0%) 16 (19.1%) 13 (14.1%) 27 (28.7%) 39 (21.8%) 102 (20.3%) ns⁴ (0.08) 
Fertilised oocytes day 1 matured per patient 2 (1-5) 5 (2.5-12) 6 (4.3-11.8) 5 (1.5-8.5) 4.5 (3-7.3) 5 (2.8-7) ns² (0.39) 
Fertilised oocytes day 2 matured per patient 0 (0-2) 1.5 (0-3.8) 1 (0-2.5) 2 (1.5-6) 0.5 (0-2.8) 1 (0-3) ns² (0.28) 
Total oocytes fertilised D1 (% of D1 mature) 14 (58.3%) 26 (57.8%) 44 (81.2%) 25 (62.5%) 47 (57.3%) 156 (63.7%) P<0.05⁴ (0.04) 
Total oocytes fertilised D2 (% of D2 mature) 4 (57.1%) 7 (43.8%) 8 (61.5%) 17 (63.0%) 15 (38.5%) 51 (50%) ns³ (0.29) 
Total cumulative mature oocytes by day 2 
(%) 
31 (57.4%) 61 (72.6%) 67 (72.8%) 67 (71.3%) 121 (67.6%) 347 (69.0%) ns⁴ (0.30) 
Total fertilised of mature oocytes (%) 18 (58.1%) 33 (54.1%) 52 (77.6%) 42 (62.7%) 62 (51.3%) 207 (59.7%) p<0.01⁴ 
D3 embryos/patient 3.4 ± 2.3 8 ± 4.6 8 ± 4.9 6.6 ± 4.0 5.6 ± 3.1 6.2 ± 3.8 ns¹ (0.28) 
Good D3 embryos/ patient 2.0 ± 0.7 4.8 ± 3.5 3.3 ± 2.9 1.6 ± 1.1 2.5 ± 2.0 2.7 ± 2.3 ns¹ (0.25) 
Total good quality D3 embryos of graded 
ones  
10 (10/17; 58.8%) 19 (19/32; 
59.4%) 
20 (20/48; 41.7%) 8 (8/33; 24.2%) 25 (25/56; 44.6%) 82 (44.1%) P<0.05⁴ (0.04) 
Patients achieving a blastocyst per group (of 
remaining cleavage stage embryos after D3 
transfer) 
1 (1/5;20%) 1 (1/4; 25%) 4 (4/6;66.6%) 1 (1/5; 20%) 3 (3/10; 30%) 10 (33.3%) ns³ (0.52) 
Positive pregnancy test (per collection) 60% (3/5) 50% (2/4) 33.3% (2/6) 20%  (1/5)  10% (1/10)  30% ns³ (0.72) 
Max. mean serum hCG level (range)  12.1 (3.1-22.3) 1489.5 (9.5-
2976) 
22.6 (11.2-34) 3.9 8 na  na 





4.3.4  Comparison by age 
To compare the effect of age on the results, the patients were regrouped into those 
under 35 years and those 35 years or more (see Table 4-7). This was based on the 
common understanding of declining fertility after the age of 35 years. Age group 2 had 
a combination of treatment groups 1-3 within it but not treatment groups 4 or 5. Due 
to the significant findings related to fertilisation and embryo quality by treatment 
methodology group, these points have not been analysed by age category. There was 
no significant difference (p>0.05) in BMI or FSH by age group. There was a trend for 
reducing oocyte number collected per patient with age but this was not significant. 
Although individually, maturation did not differ by group, a significantly higher 
proportion (p<0.01) of oocytes from the oldest age group (age group 2) matured by 
day 1. In contrast, significantly more oocytes from group 1 matured by day 2. Using 
Spearman’s rank, there was no significant correlation between age and total 
maturation of oocytes.  There was no significant difference (p>0.05) in positive 






Table 4-7 Results by age group* 












Age (Years) 29.3 ± 3.4 36.6 ± 1.3 30.5 ± 4.2 - 
BMI (kg/m²) 25.2 ± 3.2 24.4 ± 2.5 25.1 ± 3.1 ns¹ (0.58) 
FSH (iu/L) 5.2 ± 1.8 6.2 ± 1.1 5.4 ± 1.8 ns¹ (0.31) 
Oocytes per patient 17.7 ± 7.8 12.2 ± 7.4 16.8 ± 7.9 ns¹ (0.16) 
Total oocytes retrieved per age 
group 
442 61 503 - 
Mature oocytes D1 per patient 8.1 ± 3.6 8.6 ± 9.1 8.2 ± 4.8 ns¹ (0.91) 
Mature oocytes D2 per patient 3.9 ± 3.4 1.0 ± 1.3 3.4 ± 3.3 p<0.01² 
(0.004) 
Total mature D1 by age group (% 
of collected oocytes) 
202 
(45.7%) 




Total mature D2 by age group (% 
of collected oocytes) 








48 (78.7%) 347 
(69.0%) 
ns² (0.11) 
Positive pregnancy test (per 
collection) 
9 (36%) 0 (0%) 30% ns³ (0.29) 






4.3.5  Comparison by ovulatory status and phenotype 
The patients were regrouped by ovulatory status (see Table 4-8). The proportion of 
patients who were ovulatory, was similar in each of the original 5 treatment groups, 
hence all the data was re-evaluated including fertilisation and embryo development. 
Those with a menstrual cycle consistently >35 days were termed an-ovulatory (based 
on the definition of oligo/anovulation in the Rotterdam criteria for PCOS). The reason 
for this analysis was to determine any characteristics that may influence IVM outcome 
and therefore future patient selection. Women who are anovulatory may often have a 
more pronounced form of PCOS than their ovulatory counterparts and may therefore 
represent a group of women who may benefit more from IVM as a treatment. 
There was no significant difference in baseline demographics of age, BMI or FSH when 
data were analysed according to ovulatory status.  A similar number of oocytes were 
retrieved from each patient group. Although no difference in individual maturation 
rates were recorded, an increased proportion of the oocytes matured in the ovulatory 
group. There was no difference in fertilisation rate or number of good quality day 3 
embryos (p>0.05). A significantly increased proportion of blastocysts formed from 
oocytes harvested from anovulatory patients (p=0.05). There was no difference in the 
number of positive pregnancy tests between the ovulatory or anovulatory women. If 
the anovulatory group was further split into those with cycles <6months or ≥6 months, 
the group with the longer cycles had a significantly lower maturation (ovulatory & 
cycles <6months (n=23) 75.5% vs. cycles >6months (n=7) 53.4%; p<0.01) but no 
significant difference in fertilisation rate, proportion of good day 3 embryos formed or 






Table 4-8 Comparison of results by ovulatory status 




Age (Years) 30.1 ± 4.5 30.8 ± 4.1 ns¹ (0.67) 
BMI (kg/m²) 24.3 ± 3.1 25.5 ± 3.0 ns¹ (0.28) 
FSH (iu/L) 5.6 ± 2.2 5.3 ± 1.5 ns¹ (0.64) 
Oocytes per patient 14.5 ± 6.8 18.1 ± 8.3 ns¹ (0.23) 
Oocytes per group 159 344 - 
Mature oocytes day 1 per patient 7 (5-12) 9 (5-10) ns² (0.83) 
Mature oocytes day 2 per patient 3 (1-4) 2 (1-7) ns² (0.58) 
Total mature oocytes day 1 (%) 84 (52.8%) 161 (46.8%) ns³ (0.25) 
Total mature oocytes day 2 (%) 36 (22.6%) 66 (19.2%) ns³ (0.44) 
Total mature oocytes (%) 120 (75.5%) 227 (66.0%) P<0.05³ (0.04) 
Fertilised mature oocytes day 1 
/per patient 
4 (2-8) 5 (3-7) ns² (0.58) 
Fertilised mature oocytes day 2 / 
per patient 
1 (3-7) 1 (0-3) ns² (0.40) 
Total fertilised oocytes day 1 (% of 
mature) 
51 (42.5%) 105 (46.3%) ns³ (0.58) 
Total fertilised oocytes day 2 (% of 
mature) 
13 (10.8%) 38 (16.7%) ns³ (0.19) 
Total fertilised of mature oocytes 
(%) 
64 (53.3%) 143 (63%)  ns³ (0.10) 
D3 embryos/patient 5 (3-7) 7 (4-9) ns² (0.22) 
Good D3 embryos/ patient 2 (1-3) 2 (1-3) ns² (0.78) 
Total good quality D3 embryos (%) 26 (26/58; 44.8%) 56 (56/128; 
43.8%)  
ns³ (1.00) 
Patients achieving blastocyst per 
group (of remaining cleavage stage 
embryos after D3 transfer) (% of 
cycles) 
1 (1/11; 9.1%) 9 (9/19; 47.4%) P=0.05⁴ 
Positive test (per collection) 3 (3/11; 27.3%) 6 (6/19; 31.6%) ns⁴ (1.00) 






The classification of ovarian morphology as PCOM was an essential criterion for this 
pilot study; therefore 3 of the 4 main phenotypes of PCOS were sampled (according to 
the Rotterdam criteria combinations). There was no significant difference in spread of 
phenotypes across the original 5 methodology treatment groups (p>0.05). There was 
also no significant difference in positive pregnancy test by phenotype (p>0.05) (see 
Figure 4-12). There were too few patients in the HA/PCOM group to warrant making 
further comparisons. 
 

























Phenotype of PCOS 
Not Pregnant
Pregnant






4.3.6  Cost analysis 
Table 4-9 provides a cost breakdown of a standard antagonist IVF with ICSI treatment 
cycle compared with an IVM treatment cycle. A cycle of IVM is marginally cheaper, 
with a £204.76 reduction in apparent costs. The difference may have been more 
marked if an agonist cycle had been used due to additional scans and potential 
increased gonadotrophin costs. This cost breakdown is per cycle started and does not 
take into account hospital admissions for OHSS or clinical pregnancy rate. The cost of 
medication (NHS cost prices kindly supplied by C. England, Pharmasure) for a standard 
antagonist IVF/ICSI cycle, based on 10 days stimulation using 150units/daily of FSH was 
£624.94 compared with an IVM cycle of £165.90. Although this favours IVM, the 
additional costs for IVM sequential media, laboratory time and clinician time reduces 
the medication cost advantage. The prices given in Table 4-9 are based on an 
optimised IVM cycle which involves a single ICSI procedure on day 1 matured oocytes. 
This decision was made on the data provided in this study, which suggests that embryo 
quality is poor if the day 2 matured oocytes are used.  






Table 4-9 Cost per IVF/ICSI cycle compared with a modified IVM cycle up to day 3 transfer 
(based on 2010 staff pay scales) 
 Procedure Specific Cost IVF-ICSI Modified 
IVM  
HFEA fee per cycle £75 per treatment 75 75 
Nurse consultation 1.5hr x £20.83 31.25 31.25 
counselling 1hr x 16.70 16.7 16.7 
Documentation Info leaflet/consents/plan/notes 2.8 2.8 
Pre-stim/Day 2 scan  Doctor 0.33hr x £28.52 9.41 9.41 
 Equipment (Condom, gel, gloves, linen, Scanner)  5.38 5.38 
Teach Injection Nurse time 0.25hr x £20.83 5.21 5.21 
 Needles, syringes &  sharps bin 0.9 0.9 
Day 7 scan either Doctor 0.33hr x £28.52 9.41 9.41 
 Equipment as Day 2 scan 5.38 5.38 
Day 8-9 scan IVF Doctor 0.33hr x £28.52 9.41  
 Equipment as Day 2 scan 5.38  
Egg collection Admission & recovery nurse 1.5hrs x 20.83 plus equipment 31.95 31.95 
 Laboratory set up embryologist 0.2 x 17.91 3.58 7.16 
 Theatre set up Nurse 0.75 x 10.26 7.7 7.7 
 Registrar 0.66 x 28.52 18.8 28.52 
 Embryologist 0.66 x 20.83 13.8 27.8 
 Nurse 0.66 x 10.26 6.8 10.26 
 Anaesthetist & anaesthetic drugs 100.48 100.48 
 Egg collection pack inc. cannula, pudendal, equipment, sterilisation 18.95 18.95 
 Egg collection needle 35.02 28 
 Hospitality 3 3 
 Theatre garments (staff/patient), gloves, linen 39.26 39.26 
Laboratory  Laboratory miscellaneous inc 60mm dishes, plate pipettes 28.96 28.96 
 Additional for IVM 35mm dishes, filters, tubes 19.98 
Sperm prep Witness 0.1x 13.18 1.32 1.32 
 Embryologist 0.5 hr x 20.83 10.42 10.42 
 Equipment (5ml culture tube, 15ml conical sperm tube, pipettes, tips, 
microscope, stage, flow hood) 
9.32 9.32 
 Suprasperm  3.47 3.47 
Medium IVM medium pack na 234 
 IVF/ICSI medium 10.6  
 SAGE oil 7.2 7.2 
 Vitrolife flush 10.2 20.4 
IVM/ICSI procedure Embryologist (inc. OCC wash, strip and inject) hr 20.83 40.62 40.62 
 ICSI equipment & hyaluronidase etc 57.7 57.7 
 Electronic witnessing 16.2 16.2 
Fertilisation check Embryologist 0.5 x 20.83 10.42 10.42 
 Witness 0.1x 20.83 2.08 2.08 
Embryo grading D2 Embryologist 0.2 x20.83 4.17 4.17 
 Culture equipment  18.75 18.75 
Embryo  transfer Registrar 0.5 x28.52 14.26 14.26 
 Nurse 0.67x 20.83 13.96 13.96 
 Embryologist 0.5 x 20.83 10.42 10.42 
 Accessories theatre (Tissues/Glove/clothing/scanner/sterilisation ) 44.42 44.42 
 Laboratory equipment inc. Catheter, medium 31.36 31.36 
Pregnancy test Serum hCG 5 5 
 Nurse 0.33 x 20.83 6.87 6.87 
Pregnancy scan Registrar 0.50 x 28.52 14.26 14.26 
 Equipment  5.38 5.38 
Cycle documentation Registrar/nurse/embryologist  76.76 76.76 
OHSS monitoring Nurse 0.33 x 20.83 8.25  
Trust overheads Lighting/heating/buildings/maintenance 590.35 590.35 
Medication Standard antagonist IVF cycle (based on 10 days stimulation) 624.94  
 Standard IVM cycle  165.9 







The ability to collect, mature and fertilise immature oocytes has been confirmed within 
our laboratory. The maturation and fertilisation rates replicate earlier work by 
different groups (358, 359, 398). No incidence of OHSS following an IVM treatment 
cycle was an ideal outcome, but is perhaps arbitrary when no clinical pregnancies were 
achieved in this study. Embryos, including blastocysts were generated but overall 
embryo quality was poor. This was reflected by the substantial number of low level 
biochemical pregnancies that did not yield clinical pregnancies. Never the less, it is 
important to evaluate and reflect on the positive outcomes alongside the short 
comings of this pilot study. To do this each stage of the treatment pathway should be 
addressed including patient selection, oocyte quality, stimulation and the in vitro 
environment. The poor outcome could finally also be attributed to chance, whereby if 
the trial had continued pregnancies could have been achieved. Discussing the outcome 
with an expert at the Oxford Fertility Unit reached the same conclusion, where they 
have had similar periods of poor outcome despite no change in a functioning protocol 
(unpublished data).    
 
4.4.1 Patient factors and oocyte quality 
The majority of published data on the clinical application of IVM relates to patient’s 
with PCOS (see Table 4-1). The belief is those with PCOS have poorer quality oocytes 
with a lower developmental potential. This raises the question as to whether those 
with PCOS are the most suitable for the more challenging IVM laboratory process. 
Despite this, it had been shown that those with PCOS can achieve the same LBR as 
normal ovulatory controls but with a higher oocyte yield and lower fertilisation rate 
(294). Studies have examined factors integral to the oocyte, surrounding cumulus cells 
and extra-ovarian factors, in an attempt to establish markers and cause of differences 





The oocyte has an uncoupled transcription and translation process, with a meiotic cell 
cycle that stops and starts twice during the lifespan of the gamete (585). Due to the 
uncoupling and long half-life of individual mRNAs, there are a wealth of maternal 
mRNAs in the oocyte cytoplasm, that are needed for completion of the meiotic cell 
cycle, the 1st embryonic mitotic cycle and activation of the embryonic genome (584, 
586). Any disruption in the transcription process or mRNA instability may impact on 
the oocyte’s growth, maturation and its developmental competence post fertilisation 
(584). Microarray analysis demonstrates an increased content of mRNA in oocytes 
from women with PCOS compared with normal oocytes (584); these include maternal-
effect genes (producing mRNA and/or protein required around the time of zygotic 
genome activation) and genes involved in the meiotic/mitotic cell cycle. Specifically, 
microarray analysis revealed a 3-fold increase in transcripts of Mater/NALP5, which is 
required for developmental progression past the 2-cell stage.  Also, a 4-fold increase in 
Basonuclin 1 and Formin 2 was shown, genes which are involved in transcription 
regulation and spindle dynamics during oogenesis. Murine work has revealed the 
necessity for timely degradation of the RNA, likely signalling the transition from the 
maternal to zygotic genome, to ensure appropriate embryonic development (587).  
Furthermore, work in Zebrafish has shown that impaired RNA degradation leads to 
disordered embryogenesis and can result in compromised development including 
neural tube defects (588). These facts lead Wood et al (584) to speculate that 
increased mRNAs disrupt the timely maternal-to-zygotic transition and contributes to 
the embryo developmental failure in oocytes from women with PCOS. Furthermore, 
these authors have identified putative binding sites for androgens and Peroxisome 
Proliferating Receptor (PPAR) gamma receptors. These receptors have been implicated 
in normal follicular development and ovulation (589). Also, insulin has been shown to 
phosphorylate PPAR-γ resulting in its activation (590). Wood et al concluded (584) that 
the genes involved in spindle dynamics and centrosome function contain these 
putative nuclear receptor binding sites. With an increased intra-follicular testosterone 
level and circulating insulin concentration seen in their patients with PCOS undergoing 





may negatively affect the meiotic cell cycle of the oocyte and/or early embryo. Indeed, 
the list of follicular fluid factors involved in folliculogenesis is long; including members 
of the numerous growth factor families, cytokines and inhibins (329, 511). Any 
imbalance in these factors can alter the oocyte competence.  
Further support for the concept of an altered follicular microenvironment in PCOS 
patients is provided by Desforges-Bullet et al (591). These authors describe a 
disproportionately high level of AMH in the follicular fluid (FF) of women with PCOS 
which was accompanied by a lowered FSH concentration. No relationship was shown 
between LH or androgen levels that had been previously considered integral to the 
increased FF AMH (215, 217, 592). A lower availability of FSH may lead to a reduced 
inhibitory impact of FSH on AMH secretion in those with PCOS. This supports Baarends 
et al (127) who suggested that FSH may play a role in AMH down-regulation in vivo. 
Furthermore, Pellatt et al (215) has shown that FSH inhibits AMH production in the 
polycystic ovary but not in the normal ovary.  A negative relationship between 
pregnancy rate and FF AMH was also shown, supported by Cupisti et al (593), 
suggesting high FF AMH may be harmful to oocyte maturation and development 
potential. Conversely, others (594, 595) suggest the opposite with improved 
fertilisation and implantation. In early folliculogenesis, a relative deficiency of AMH 
protein has been reported in the primordial and transitional follicles in women with 
PCOS, implicating AMH in the accelerated progression of follicles from the primordial 
pool (222).  
The layers of cumulus cells surrounding the oocyte are known to play a crucial role in 
supporting the growth and development of the oocyte and of inhibiting or supporting 
meiotic progression in a timely manner. Up until the LH hormone surge, the corona 
radiata cells provide a transport link between cumulus and oocyte allowing exchange 
of substances such as GDF–9 and kit ligand, thought necessary for oocyte maturation 
(596). In good quality MII oocytes that were either transferred or vitrified (if a high 
grade blastocyst), no significant differences were seen in gene expression between the 





cumulus was evaluated i.e. no knowledge of the oocyte developmental capacity, 
where an altered gene expression profile were shown in those with PCOS including 
members of the epidermal growth factor-like and IGF-like families (598), both groups 
of genes are involved in the acquisition of oocyte developmental competence. In 
addition, there was a deregulation of mRNA transcripts involved in steroid metabolism 
in PCOS cumulus cells (598). Further transcriptomic analysis of cumulus, showed up-
regulation of pathways involved in DNA replication and cell cycle, in the cumulus cells 
from women with PCOS (597). Usually, a distinct down-regulation of these pathways 
occurs at the LH/hCG surge (599).  Wissing et al (597) speculate that the up-regulation 
in PCOS reflects a delayed response to the maturation LH trigger. The theory of 
increased proliferation within the cumulus of PCOS oocytes is supported by a small 
study by Polzikov et al (600), who show increased ribosomal RNA expression and 
number of ribosomes. Proliferation and protein synthesis correlates with ribosomal 
synthesis (601).  Furthermore, within lean and overweight patients with PCOS, there is 
a differential expression of genes within the cumulus (602), supporting potential 
differing pathophysiological pathways of PCOS related to weight. Indeed, it has been 
well documented that lean and overweight PCOS women often differ in respect to the 
underlying pathogenesis of PCOS. Lean women have higher basal LH levels with 
increased LH responsiveness to GnRH (603). In contrast, overweight women with PCOS 
exhibit increased insulin resistance, reduced IGFBP-1 and increased testosterone to 
SHBG ratio (604).  Overweight women with PCOS share similar cumulus gene 
expression profiles with overweight normal ovary controls. One exception is the up-
regulation of genes involved in the insulin signalling system including INSR, IRSI and the 
fat mass and obesity associated gene FTO previously associated with PCOS (66). Lean 
PCOS women had the most pronounced number of differentially expressed genes in 
the cumulus cells. One set of down-regulated genes included the Wnt/β-catenin and 
MAPK signalling pathways which have been shown to work together in regulating and 
aiding folliculogenesis and ovulation (602). An upregulated set of genes in lean PCOS 
augment the extracellular matrix assembly, a key factor in folliculogenesis. An example 





cumulus expansion in response to gonadotrophins. Within the current study, there 
was a clear correlation between the crude categorisation of expansion and coverage of 
cumulus around the oocyte with oocyte maturity. This is in agreement with Wynn et al 
(395). Although the gross appearance of the expanded cumulus may look similar 
between oocytes, underlying transcriptomic analysis may reveal a further perturbed 
system within the oocyte or cumulus cells from women with PCOS during IVM cycles.  
The extra-ovarian endocrine environment common in those with PCOS can interrupt 
and disrupt the complex developmental process of oocyte maturation and embryo 
development. Similar to previous discussion of follicular fluid hormone levels, this can 
be extended to incorporate serum levels found in the complete individual. The key 
factors are FSH, LH, oestrogen, androgens and insulin. Follicular recruitment and 
growth is dependant on FSH, where there is a fine balance between recruitment and 
atresia. Prior to the acquisition of aromatase activity and increasing oestrogen levels, 
small human antral follicles (2-5mm) become responsive to FSH and are recruited 
(605). As oestrogen rises, FSH falls towards the end of the follicular phase with only the 
most advanced follicle proceeding to ovulation. Women with PCOS have been shown 
to have lower serum FSH levels (606) and an accumulation of small antral follicles, of 
which many may undergo premature growth arrest (511). Furthermore, it has been 
suggested that high oestrogen levels demonstrated during assisted conception cycles 
in patients with PCOS, may be detrimental to oocyte maturation and embryonic 
development (607). Alongside an FSH deficiency, a tonic hyper-secretion of LH in the 
follicular phase is recognised in women with PCOS (608). High LH levels have been 
implicated as a cause of the reduced oocyte maturation, fertilisation, embryo quality 
and the higher incidence of miscarriage associated with PCOS (329, 609). Premature 
luteinisation and follicular atresia may occur, due to suppressed FSH function, 
culminating in premature oocyte maturation and terminal differentiation of the 
granulosa cell layer (511, 610). Impaired endocrine control of meiosis and extrusion of 
the polar body may contribute to chromosomal and embryonic aneuploidy and 





primarily ovarian in origin with substantial contributions from adrenal and adipose 
tissues (611). Like LH, high levels of thecal androgen have been shown to have a 
negative impact on oocyte development (612). In vitro work has shown a strong 
inhibition by testosterone on cumulus-free oocyte meiotic maturation (327). This 
evidence suggests that cumulus cells may protect the oocyte during the final stages of 
meiotic maturation. Elevated testosterone levels surrounding the oocyte, may reduce 
calcium oscillations, so inhibiting oocyte cytoplasmic maturation (329). The mechanism 
for this has not been fully elucidated but appears to be non-genomic and related to the 
ratio of oestradiol to androgen, rather than the individual levels of steroids per se. 
Calcium oscillations initiated by oestradiol are limited by treatment with androgens 
(613). Insulin resistance and compensatory hyperinsulinemia, has been widely 
implicated in reduced oocyte competence summarised by Qiao and Feng (329). These 
mechanisms include upregulation of LH receptor mRNA expression (37), inhibition of 
FSH-induced aromatase activity, local induction of androgen production (614) and 
altered molecular spindle dynamics and centrosome function (584). 
Extra-ovarian and intra-ovarian mechanisms inherent to PCOS can generate poor 
quality oocytes that may enter but falter in an in vitro system, leading to poor 
outcomes in an IVM treatment. There is limited clinical data on the patients in the 
current study. The group of women were young (30.5 ± 4.2yrs) with a normal BMI 
(25.1 ± 3.1kg/m²). Limitations of the study include unknown systemic androgen, AMH 
levels and also their insulin resistance status of the recruits. The latter is particularly 
relevant when considering potential causes of IVM failure inherent to those with PCOS. 
It can be assumed that all of these factors are elevated compared with normo-
ovulatory women without PCOS, especially as more than half of the population have 
ovulatory dysfunction with prolonged menstrual cycles. A judgement on enhanced 
patient selection for IVM cannot be made. The only difference by ovulatory status 
(Table 4-8) was a reduction in oocyte maturation rates in women who were either 
ammenorhoeic or who had cycles of >6months. This is in agreement with Barnes et al 





difficult to explain, unless removal from the detrimental PCOS follicular environment 
into a more favourable in vitro culture environment even for for such a short period of 
time could be considered beneficial. Despite many reasons for women with PCOS 
being poor candidates for IVM including compromised oocyte quality, the overriding 
fact is that IVM offers a way to eliminate OHSS in those individuals at high risk, thus 
making the compromise in clinical outcome acceptable in this population. With respect 
to the poor outcome of this pilot study, patient selection was seemingly not the reason 
given the CPRs achieved in other identical PCOS populations, outlined in Table 4-1.  
 
4.4.2 Stimulation protocol and endometrial preparation 
It is clear from the literature, that many different stimulation protocols have been used 
for IVM. The use of gonadotrophin stimulation has been shown to improve maturation 
rates (395) but there is still a debate as to whether both FSH and hCG are needed for 
stimulation (359, 400, 401). In the current pilot study, minor changes were made to 
the initial stimulation protocol to establish the optimum working protocol for use in 
the planned RCT. The main change was the duration of time from hCG trigger to the 
time of oocyte retrieval. Initially time to retrieval was 24 hours (which appears unique 
to our study). Group 5 followed a more classical IVF pathway with 36 hours to retrieval. 
Group 3 (see Table 4-3), where hCG was administered 24 hours before oocyte retrieval 
on day 10 of the cycle, had a significantly improved fertilisation by 48 hours. In 
contrast, there were significantly more good quality day 3 embryos in Groups 1-2. 
Furthermore, there was a trend for positive pregnancy tests in favour of Groups 1-2. 
Overall there was a better IVM outcome for those patients who had a shorter 
exposure to hCG. This questions the benefit of including an hCG trigger pre collection 
of oocytes during an IVM cycle. In support of this notion, 2 of the most recent studies 
have omitted use of hCG prior to oocyte retrieval (359, 572) with good results. Zheng 
et al (572) showed that although maturation was improved with hCG priming this was 





although nuclear maturation may be triggered in vivo by hCG, the impact on oocyte 
cytoplasmic maturation in vitro remains unclear. The impact of hCG priming in IVM 
cycles on oocyte maturation may also be confined to oocytes from women with PCOS, 
whereby LH receptor expression in cumulus and granulosa cells from PCOS follicles 
may occur in smaller follicles compared with normal women allowing hCG action (615, 
616). The mechanism for this may be related to the stimulating effects of LH on AMH 
expression and loss of the down-regulation of the AMH-II receptor in anovulatory 
PCOS women but not ovulatory normal or PCOS women (129). Similar maturation 
benefit from hCG priming has not been shown in non-PCOS women (617).  Better 
outcomes in the earlier recruited patients in the pilot study, suggests that if the study 
was to be run again hCG should either be omitted or used closer to the planned time 
of oocyte retrieval.  
It is reassuring that the maturation parameters were equal with another UK centre 
(see Table 4-10) highlighting that gross errors within the oocyte retrieval and 
maturation process were not occurring, particularly as it was the first time that IVM 
had been offered as a clinical treatment at LCRM. To compare our data with Oxford 
Fertility Unit (from whom the laboratory protocol is modelled), data was extracted 
from their most recent publication (358).  This included 97 IVM cases conducted 
between January 2007 and March 2010. Table 4-10 summarises the comparative 
results. Despite a younger cohort of patients enrolled at LCRM, there was no 
difference in baseline FSH, BMI or ovulatory status. There was no significant difference 
between oocyte number retrieved, maturation by 48 hours or fertilisation of mature 
oocytes. A direct comparison of embryo development was not possible from the 
results. The closest comparison was number of cleaving embryos (6.4 ± 4.8; Oxford) 
and day 3 embryos (6.4 ± 3.8; LCRM), for which there was near identical findings. No 
significant difference was seen in biochemical pregnancy rate (although day 16 urine 
hCG was reported by Oxford compared with day 14 serum hCG at LCRM). There was a 
significant difference in clinical pregnancy rate, with unfortunately no ongoing 






Table 4-10 Comparison between Oxford Fertility Unit and Leeds Centre for Reproductive 
Medicine* 
 Oxford Fertility Unit (n=97) LCRM (n=30) Significance 
Age (Years) 32.4 ± 3.8 30.5 ± 4.2 P<0.05¹  
BMI (kg/m²) 24.2 ± 4.6 25.1 ± 3.1 ns¹ 
FSH (iu/L) 5.5 ± 1.4 5.4 ± 1.8 ns¹ 
Ovulatory PCO/PCOS % (n) 46.4 (45) 43.3 (13) ns² 
Anovulatory PCOS % (n)  53.6 (52) 56.7 (17) ns² 
Oocytes collected 15.8 ± 7.2 16.8 ± 7.9 ns¹ 
Total maturation 48 hours % (n) 65.0 (1087) 69.0 (348) ns² 
Average mature oocytes 11.2 ± 7 11.6 ± 5.8 ns¹ 
Fertilisation mature oocytes % 62.9 59.7 ns² 
Biochemical Pregnancy % (n) 28.9 (28) 30 (9) ns² 
Clinical Pregnancy % (n) 19.6 (19) 0 (0) P <0.01² 
OHSS cases 0 (0) 0 (0) ns² 
ns = non-significant; significance level <0.05 unless specified ¹Student’s t test ²Chi squared statistic with 
continuity correction *results are presented as mean ± SD or % (number) 
 
The high biochemical pregnancy rate and its lack of translation into ongoing 
pregnancies in the present pilot study were disappointing. It has been suggested that 
women undergoing IVM have a higher miscarriage rate (618). Although this may be 
related to the underlying PCOS aetiology rather than IVM per se (619), it has also been 
shown that a higher rate of aneuploidy is present in embryos derived from IVM (425). 
Furthermore, confocal microscopy had shown a higher frequency of abnormal meiotic 
spindles and chromosomal alignments in IVM human oocytes (427). More recent data 
refutes these suggestions (620-622) and has demonstrated comparable morphological 
parameters between in vivo and in vitro matured human oocytes. It is important to 
note that the serum hCG levels were extremely low in the current study (see Table 4-6). 
The half life of hCG 10000 units subcutaneous injection has been shown to be 32hours 





unlikely that the hCG detected at day 14 in the patients was due to residual hCG from 
the trigger injection.  
Endometrial preparation is a key factor for successful IVM.  Asynchrony between 
endometrium and embryo would lead to implantation failure regardless of embryo 
quality. A major criticism of this pilot study was the failure to record endometrial 
thickness on the day of embryo transfer. Endometrial thickness was only recorded 
sporadically either within clinic before hCG or at oocyte retrieval. This omission would 
have provided valuable basic information on how the endometrium performed 
through the IVM process. The endometrial thickness prior to hCG was 5.2 ± 2.1mm 
with no significant differences between treatment groups. The endometrium would be 
expected to increase in thickness following hCG and during the priming phase before 
embryo transfer. Many of the published studies used a policy based on endometrium 
thickness with no embryo transfer with an endometrium <7mm (Table 4-1). A thin 
endometrium has been suggested as a poor prognostic factor for IVF outcomes, 
although a recent meta-analysis suggested that both the prognostic and predictive 
capacity of endometrial thickness is limited (624). Child et al (625) have shown no 
difference in endometrial thickness on the day of oocyte retrieval between successful 
and unsuccessful pregnancy cycles, but by embryo transfer successful cycles have a 
considerably thicker endometrium. Attempts to improve the endometrium, has seen 
the trial of low dose oestrogen prior to oocyte retrieval (393), which was detrimental 
to oocyte maturation although not overall fertilisation rates. Minimal stimulation 
followed by the administration of oestrogen and progesterone for endometrial priming 
has been the general approach used by all groups who practice IVM. Oral oestradiol 
and vaginal progesterone from retrieval was used in this study, with doses in keeping 
with the majority of trials (see Table 4-1). Interest in an endometrial ‘implantation 
window’ has gained momentum (626), whereby the endometrium shifts from a pre-
receptive to receptive state. It has been suggested that ovarian stimulation in ART can 
hasten the onset of this implantation window compared with natural cycles (627). 
Indeed, both transcriptomic and proteomic technologies have shown a change in gene 





(626). IVM techniques perhaps sit somewhere in between the natural cycle and 
stimulated cycle. It would be useful therefore to classify the optimum transfer window 
for IVM using these technologies.              
       
4.4.3 In vitro environment and media 
As alluded to in the introduction to this chapter, various types of media have been 
used in IVM treatments. This comparison was drawn between the most recent trials 
with successful outcomes in which 2 different commercial medias were used (359, 
572). Certainly within this country, an IVM medium with a known composition is 
needed to gain ethical approval for clinical research treatments, preventing the 
addition of some serum additives known to improve reproductive outcome (628). This 
enables the marketing and use of standardised commercial media which has 
undergone rigorous quality control, rather than in-house specialist media as has been 
used previously in our IVM research program. In the current study, commercially 
available and Conformité Européene (CE) marked Sage IVM media was used, which 
provides a sequential series of media that the oocyte moves through during the 
maturation process in vitro. The cost of this medium per cycle (£234/cycle) is higher 
than standard IVF culture medium (£10.60/cycle) and it has a far shorter shelf life. This 
is an important consideration when IVM cycles are infrequently completed. Recent 
murine and human work has suggested that there is little difference between using 
conventional blastocyst culture medium instead of IVM-specific medium on embryo 
development (580, 629). Kim et al (629) show that the only difference in a blastocyst 
culture medium (BMI, Suwon, South Korea) compared with a conventional IVM 
medium (Sage) is the presence of taurine and calcium lactate (although not specified in 
the paper one assumes that it is the maturation medium in the sequential IVM media 
pack these authors use in comparison). These authors speculate that these additives 
may improve outcome through the provision of energy substrates and enhanced anti-
oxidant capacity. Taurine is a by product of hypo-taurine following free radical 





thus by supplementing culture medium with taurine it is hypothesised that, oocyte 
meiotic maturation and embryo development can be improved (630). During oocyte 
maturation, mitochondria redistribute to the areas of the cell that require high energy 
(629, 631), namely the perinuclear and subcortical regions of the gamete. It has been 
suggested that increased free calcium is needed to ensure that appropriate 
mitochondrial redistribution occurs to prevent blastomere formation with low energy 
and reduced mitochondrial number (632). Interestingly, Kim et al (629) found that 
Tissue culture medium – 199 (TCM-199) was inferior to blastocyst media for 
maturation and blastocyst development. They even suggest that blastocyst media 
outshines the standard IVM media (Sage) in blastocyst development. Kim et al (629) 
compare the content of these media but do not make reference to the quantity of 
each constituent. A set 1ml drop is used to culture cumulus-oocyte-complexes which 
may not contain the same comparative volume of each constituent altering the 
oocytes maturation ability. TCM-199 was the media preferentially used in earlier work 
by Cha et al (368) and Child et al (413). Due to its undefined IVF specification, this 
media is no longer regularly used in human clinical treatment (579). In contrast to Kim 
et al (629), Filali et al (579) reported no significant difference in overall maturation or 
implantation between TCM-199 and a commercial IVM media supplied by Medicult Ltd.  
Despite much research, the success rates for IVM on the whole remain inferior to 
conventional IVF (see Table 4-1) which perhaps reflects its minimal uptake into clinical 
practice over the last 20 years. A potential method to improve the synchronous 
nuclear and cytoplasmic maturation of oocytes (633) has recently been presented by 
Albuz et al (634). The recognition of cyclic-AMP (cAMP) as an important signalling 
molecule within the oocyte has provided a base to improve laboratory treatments. 
Limited amount of this second messenger is made within the oocyte, with the greater 
majority being supplied via gap junction connections from the cumulus cells (635, 636). 
Elevated levels of oocyte cAMP maintain meiotic arrest. Phosphodiesterase is 
responsible for degrading cAMP. The activity of PDE is inhibited by cyclic GMP supplied 





surge a cascade of events occur allowing oocyte maturation to proceed. A drop in 
cGMP is seen within the oocyte and follicle (383, 638). There is also a release of 
epidermal growth factor (EGF)-like proteins within the follicle required for maturation 
(639, 640). The further discovery that PDE subtypes are compartmentalised within the 
ovarian follicle, allows targeted treatment of cumulus cells or oocyte PDEs (641, 642). 
Oocytes will resume meiosis spontaneously, once removed from the controlling 
follicular environment, in the absence of the aforementioned endocrine and paracrine 
control, following a drop in endogenous cAMP (634). This has been termed ‘precocious’ 
oocyte maturation, as meiotic progression is reinitiated but in the absence of the 
gamete gaining its full in vivo developmental competence. There is also a breakdown 
of the gap junction connections between oocyte and cumulus cells, preventing 
exchange of beneficial nucleotides and nutrients (642). The concept of biphasic IVM 
has been previously documented (634, 643, 644). This prevents meiotic resumption, 
using high concentrations of cAMP analogues or PDE inhibitors following oocyte 
retrieval for a period of time (24 - 48 hours), before these factors are removed by 
media change allowing maturation to occur. Unfortunately, this strategy has had a 
largely disappointing impact on improving IVM outcome. Albuz et al (634) present a 
system they term as simulated physiological oocyte maturation (SPOM) in mice. It 
includes a pre-IVM phase that rapidly generates an increased cAMP within the 
cumulus oocyte complex followed by an extended IVM phase with enough FSH to drive 
meiosis in the presence of a PDE inhibitor. The mice were primed with hCG prior to 
oocyte retrieval but subsequently only FSH was used in culture of the oocytes, which 
seems contrary to the usual physiological trigger of hCG/LH. The authors qualify this 
with evidence suggesting that oocytes will mature spontaneously regardless of in vitro 
gonadotrophin stimulation (634). In contrast, it has been suggested that in vitro 
maturation without gonadotrophin presence hampers the developmental potential of 
the oocyte (645, 646).  Furthermore, FSH uses the EGF receptor in these authors SPOM 
system. Firstly, over 1-2 hours the COC’s are exposed to cAMP modulating agents 
(Forskolin, a potent adenylate cyclase activator and Isobutylmethylxanthin (IBMX), a 





time via the gap junctions. Within the extended IVM phase, continuous exposure to a 
PDE3 (Cilostamide) oocyte specific inhibitor occurs (unlike the biphasic systems). They 
speculate that this enhances the G2 to M-phase cell cycle resumption which has also 
been benefited by the extended gap cell cumulus communication. Furthermore, Albuz 
et al (634) confirm that the EGF receptor is implicated in oocyte maturation following 
gonadotophin stimulation/surge, requiring an ERK 1/2-mechanism previously 
documented (639, 640, 647, 648). It is important to note that clear species differences 
exist. In mammalian systems EGF was found to aid oocyte maturation in vitro (649), 
however microarray analysis did not identify EGF as significant in human granulosa 
cells. More recently, other members of the Regulin family that includes EGF have been 
implicated in both sheep (645) and human work including amphiregulin and epiregulin 
(650). The SPOM system for IVM was been shown to improve the blastocyst rate 
following the IVM over 24 hours of murine and bovine oocytes. Cattle breeding 
programmes usually generate blastocyst rates of <40% (651), where as using the SPOM 
system achieved 69%. The SPOM system certainly seems compelling, particularly when 
minimal change has occurred in conventional IVM systems; nor improvement in 
success rates over the last 2 decades. Whether this can be transferred effectively into 
the human clinical setting is yet to be seen but perhaps it will provide a basis to 
improve the clinical IVM systems in the future. It may transpire that SPOM is only 
relevant to animals that have a shorter oocyte maturation time in vitro i.e. mouse and 
cow oocytes mature in IVM over 24 hours vs. humans 36 hours post hCG. 
Encouragingly, there seems to be no ill effect from having IBMX in the culture medium 
on chromosomal and aneuploidy rate (620) but this compound has yet to be approved 
for clinical use in human cells. 
 
4.4.4 Embryo quality and embryo selection 
The inherent characteristics of poor oocyte quality in those with PCOS continues to 





patients can compensate for these deficiencies culminating in normal cumulative 
pregnancy rates (294, 652). Although it has been suggested that increased embryonic 
fragmentation and decreased blastocyst formation occurs in patients with PCOS (653); 
there is contrasting work that suggests similar fertilization and achievement of good 
quality embryos (654, 655). In the current study, although 87% of transferred embryos 
were regarded as good quality; only 43% of all day 3 embryos reached the same good 
category. The conversion to blastocyst was also poor. As the ‘best’ embryos were 
transferred on day 3, a lower blastocyst rate could be expected. If this is compared to 
unpublished work from the LCRM at the same time in women with PCOS, the 
percentage of good quality day 3 embryos was ~50%. Although lower, this is unlikely to 
be significant. It raises the question of impaired implantation following IVM rather 
than poor embryo grade.  
The optimum timing for ICSI in an IVM cycle would seem critical to ongoing embryo 
development as it is essential to  allow for oocyte nuclear and cytoplasmic maturation 
to be completed in vitro. The nature of IVM cycles mean that oocytes may not all reach 
MII at the same time and therefore performing ICSI at a set time point may be 
detrimental for some oocytes. For example, it has been shown that delaying 
insemination of oocytes after MII has been reached, rather than immediate 
insemination leads to more embryos developing to advanced preimplantation stages 
(656). To perform insemination / ICSI at exact time points from MII arrest in IVM cycles 
would be near impossible in the clinical setting due to work force demands. In contrast, 
it is also recognised that there is impaired fertilisation if oocytes take longer to mature 
(657). De Vos et al (658) showed that embryo development was similar in ‘rescue- IVM’ 
oocytes compared with MII oocytes from a stimulated IVF cycle (47% vs. 52%). It 
should be noted that these oocytes may have had enhanced development due to in 
vivo culture prior to retrieval and the limited 4 hour in vitro culture, making 
comparison difficult. Furthermore, given the short IVM incubation in this study(only 4 
hours) the oocytes would almost certainly have not been at GV at the start of culture 





embryos by day 3. They classified 69.8% embryos as ‘good’ or ‘fair’ (which included all 
embryos with <30% fragmentation). Direct comparison with the current data set is not 
possible as good embryos were <20% fragmentation, but the overall impression 
suggests the current study did not reach the IVM embryo quality levels achieved by 
other centres using this technology. Unfortunately, the more recent trials did not 
publish the % of good quality embryos generated, making further conclusions 
impossible surrounding the current study’s embryo quality. 
Optimum embryo selection is critical for a successful IVM cycle. This has led to many 
selection strategies being developed, of which some are more successful than others 
(659). The current study used only a conventional classical grading system (526, 527). 
After fertilisation had taken place, there were only 2 further embryo checks on day 2 
and 3 prior to transfer. This allowed only a snapshot of the embryo development to be 
assessed. So although 87% of transferred embryos were between the 6-8 cell stage 
with <20% fragmentation, any other aberrant behaviour the embryo may have 
displayed was unknown. It should also be noted that the better quality blastocysts 
produced from the remaining embryos, came from embryos that would have been 
classified as poor using this system on day 3. During the preliminary trial, the LCRM 
had acquired and were regularly using the Embryoscope® (Vitrolife, Unisense 
Fertilitech, Denmark) time-lapse system. This tool provides an uninterrupted culture 
environment whilst capturing multiple images of the embryos fine morphological 
development. It would have been beneficial for this trial to use this technology to 
understand if the embryos created from IVM performed in a grossly different way to 
embryos from conventional IVF. It has been suggested that time-lapse imaging should 
improve the clinical outcome (660). An RCT comparing Embryoscope® with a morpho-
kinetic selection model with a standard incubator and morphological selection 
revealed a significantly improved on going pregnancy rate and reduced miscarriage 
rate (661). A Cochrane review (662) on the subject, which includes the last RCT (661), 
concludes that there is insufficient evidence particularly on live birth rates to instigate 





further information pertinent to IVM (663). Increased fragmentation was noted in 
embryos from oocytes that had a detectable meiotic spindle later (>36.2hrs) following 
hCG injection. In the IVM stimulation protocols, there is a range of durations of hCG 
prior to collection and the in vitro process. This may inadvertently predispose the 
oocytes to increased fragmentation related to stimulation. Furthermore, it has been 
shown that FSH stimulation can alter the chromosomal alignment in metaphase 1, 
increasing aneuploidy in in vitro matured mouse oocytes (664). A focus on PCOS 
embryos has also shown that in embryos from hyperandrogenic women, delayed 
cleavage is seen compared with regularly cycling women, using the Embryoscope® 
(665). This last point highlights the differences that can occur in women with PCOS and 
the developmental competence of their embryos.  
Apart from time-lapse imaging, proteomic and metabolomic measurements have been 
considered potential biomarkers for embryo selection (659). Once again these 
technologies were not implemented in this study, but may have provided more 
information on failings of the trial and ways to improve IVM in general. Harris et al 
(666) have shown that oocytes from women with PCOS have a higher consumption of 
glucose and pyruvate (the key energy substrate used by human oocytes), which can be 
attenuated by prior use of Metformin. Although the chromosomal constitution of in 
vitro matured oocytes was no different to controls, a higher pyruvate turnover was 
associated with abnormal oocyte karyotypes. Amino acid profiling has been shown to 
have a predictive capacity for determining embryos that have a developmental 
capacity to reach blastocyst stage, in particular increased take up of Leucine (667). 
Furthermore, amino acid turnover has been related to aneuploidy and embryo sex 
(354). This phenomenon has been further investigated in the oocyte; with oocytes that 
arrest at the GV stage after 24 hours of in vitro culture displaying differences in amino 
acid profiling compared with oocytes that progress through to MII (668). The latter 
data was achieved from oocytes that had failed to mature during routine IVF 
stimulation, which could have impacted on the results due to the limited capacity of 





system with a known clinical outcome (i.e. where the embryo’s viability was assessed 
during culture and transfer).   
 
4.4.5 Outcome following an unsuccessful IVM cycle 
Although the outcome from this pilot study was disappointing, an interesting point to 
note was the natural conception of 4 couples within 4 months of completing an IVM 
cycle. A similar finding was published by Frantz et al (669), whereby 3 natural 
conceptions occurred shortly after an IVM treatment cycle. Whilst a causal link cannot 
be proved or indeed ruled out, it is possible that ovarian puncture during an 
unstimulated IVM treatment cycle may have similar properties to that seen with 
“ovarian drilling”.  Three of the conceptions occurred in couples where repeated cycles 
of conventional IVF had been unsuccessful, resulted in an exuberant abandoned 
attempt or in 1 couple failed fertilisation. Two of the 4 women were amenorrhoeic. 
These factors depict a group of women that were hard to treat and perhaps had a 
more pronounced form of PCOS. Troude et al (670) reviewed rates of natural 
conception following unsuccessful IVF treatment cycles in a retrospective survey of 
patients. They found that the LBR following a natural conception was a cumulative 24% 
over a 7 year period (slightly higher than the 17% in previously successfully treated 
couples). The majority of births happened by the end of the 2nd year following 
treatment, with only 6% of the 24% happening within the 1st year. This suggests that 
our cohort have had a better than average conception rate within the 1st 4 months 
following IVM treatment. It should be noted that the reason for initial IVF treatment is 
often not recorded consistently, making direct comparison difficult. The long term 
benefit of IVM has been suggested by Agdi et al (671). Their study was designed to 
assess the effect IVM had on subsequent IVF cycles. An increased proportion of 
retrieved MII oocytes and fertilised oocytes were seen following IVM. An earlier pilot 
study by Ferraretti et al (672) had drawn the same conclusion. Women who had 2 





month period prior to a repeat IVF cycle. The outcome was an increased requirement 
of FSH stimulation but significantly improved fertilisation and cleavage of embryos. 
The overall pregnancy rate was similar to a normo-ovulatory patient with tubal 
pathology. Ferraretti et al (672)  proposed that this technique provided a safer and 
lower cost alternative to laparoscopic ovarian drilling with electro-cautery. 
Furthermore, (673) it has been shown that IVM can transiently alter hormonal markers 
including AMH and Testosterone levels.  This alteration is short lived, especially in 
relation to AMH. A shortcoming of this study (673) was the limited follow up of 
patients, relying on testing patients who chose to return at 3 months to complete the 
study. From the small number who completed the study, the group hypothesise that 
the benefit seen did not exceed 3 months. The long term benefits of laparoscopic 
ovarian drilling with electro-cautery are recognised and exceed what has been seen 
with IVM (674).  The exact mechanism that ovarian drilling uses to improve ovulation 
remains unknown. One theory suggests that local ovarian trauma interrupts the intra-
ovarian androgen synthesis pathway, reducing androgen levels and the inhibitory 
control on follicular maturation (675). Furthermore, the decreased androgen levels 
may reduce peripheral conversion to Oestrogen, therefore impacting on the feedback 
system of LH secretion. Destruction of the ovarian tissue through drilling, may remove 
these inhibitory factors, allowing a new cohort of follicles to be recruited and develop 
(672). Moreover, the reduction in AMH levels seen particularly with electro-cautery 
may restore ovulatory function by inducing a new wave of activation of primordial 
follicle growth and by improving follicular sensitivity to the circulating FSH (676). 
Although not as effective as laparoscopic ovarian drilling (LOD), IVM/ trans-vaginal 
ovarian drilling are likely to operate on a similar level. As it is less invasive, the patients’ 
underlying steroid synthesis and folliculogenesis will resume quickly, restoring the pre-
treatment ovulatory pattern for the individual (673). The validity of trans-vaginal 
ovarian drilling as a treatment in its’ own right is limited, although 1 RCT suggests that 
it is equally as effective as LOD and has potential as an ‘office’ procedure (677). The 
most recent Cochrane review for LOD (678) concludes that there is no difference in 





medical treatment. As the effects of IVM are short lived on ovarian function, there 
seems little point in championing its use for natural conception. Despite this 
conclusion, it seems churlish not to accept that there may have been some benefit for 
the 3 patients who now have a child following this study.       
An interesting point is raised by Shalom-Paz et al (360) regarding the learning curve in 
clinical and laboratory practice when introducing a new technique within a clinic. 
These authors show a progressive improvement in cleavage, implantation and live 
birth rate over a 5 year time period, with no change in their conventional IVF results in 
the same time period. They acknowledge that the learning curve is hard to quantify 
with multiple factors contributing to the improvement (679). Although LCRM have 
previously run research trials centred on IVM, this was the first time IVM was practiced 
as a clinical treatment at the LCRM. Personally, as I completed all oocyte retrievals, the 
practical procedure did become easier as my dexterity with the procedure improved. If 
the same occurred for all steps of IVM, it should be hoped that our clinical pregnancy 
rates would have improved likewise if we had continued the trial. As the fertilisation 
and embryo quality reduced through the trial, perhaps the minor changes to 
stimulation protocol had more impact than perhaps accounted for.    
A further factor to take into account is the performance of the LCRM as a whole. 
During the time period of the preliminary trial, a slight downturn in results occurred 
across the board at LCRM. Results published on the HFEA website include data from 
2012. The CPR and LBR per cycle started were 28.3% and 25.4%; which were both 
below the national average of 36.1% and 32.9% respectively. The results for the 
duration of the trial for IVF-ICSI was a CPR of 32.2% and LBR of 28.09%, which although 
improving remained below the national average. Although the effect of this downturn 
will not have directly attributed to the poor outcome of the IVM pilot study, it would 





4.4.6 Cost analysis of IVM 
In vitro maturation is marketed as a lower cost alternative compared with 
conventional IVF due to the minimal use of expensive gonadotrophins. Despite this 
assertion, there is minimal data on the exact costings of an IVM cycle in comparison 
with a short antagonist IVF cycle (358). An estimate costing between the 2 types of 
treatment up to a day 3 transfer is shown in Table 4-9. The cost of an optimised IVM 
cycle is marginally cheaper when compared with a standard short antagonist IVF cycle 
(£1928.47 vs. £2133.23). The suggested ‘optimisation’ is based on the outcome of the 
pilot study with reference to the poor quality of embryos generated from day 2 
matured oocytes. It is proposed that only oocytes matured by day 1 should be 
inseminated and used for treatment, thereby reducing laboratory costs. Despite 
increased gonadotrophin costs with standard IVF (£624.94 vs. £165.90); the cost 
difference is marginalised by the increased costs of commercial sequential IVM media 
packs and increased clinician / embryologist time. This costing has not taken into 
account unplanned hospital admissions sometimes required for OHSS management. 
Nor has it balanced the treatment cost to pregnancy ratio. Rose et al (571) describe a 
91% price reduction in medication costs for IVM. Overall they calculate that an IVM 
cycle is 45.9% cheaper than an IVF cycle (antagonist cycle) but unfortunately do not 
include with this the outcome data. These authors calculate the results based on, in 
part, the insurance company pay-outs for treatments. This makes comparison with the 
UK system difficult as these prices are based on one company alone (the NHS).  
Although Rose et al (571) agree with the current study that more laboratory and 
technical expertise is needed for IVM, this is not reflected in the price that is attributed 
to what they term ‘procedure and anaesthesia costs’. In fact they suggest that the 
mean cost of this part is less than for IVF ($7532 ± 1275 vs. $8681 ± 1874; p=0.02). The 
authors reason that this is due to IVF procedures generating more oocytes for more 
expensive ICSI, less time is needed in the incubators as embryos are transferred at day 





These theories seem fundamentally flawed and would likely be revealed if the clinical 
pregnancy rate and cumulative pregnancy rate (including frozen cycles) was included.  
Apart from financial costs, other costs such as time and visits for the patient should be 
considered. Within this pilot study there were a reduction in visits before (reduced 
follicular monitoring) and after oocyte retrieval (no OHSS monitoring). Importantly, 
patient’s who experienced both an IVF and IVM cycle, subjectively reported that they 
preferred IVM if it had generated a pregnancy. Reasons given included a reduced 
number of self given injections, fewer visits and overall felt better through treatment. 
The latter may be partially explained by taking part in a clinical trial and continuity of 
care, but reveals the potential advantage for patients not easily quantified.  
       
4.5 Conclusion 
Drawing conclusions on a study that has failed to achieve even one clinical pregnancy 
is a difficult task. The successful oocyte retrieval, maturation and fertilisation to create 
embryos suitable for transfer was an encouraging finding. The necessity to close this 
trial following the pilot study before embarking on the full RCT to compare IVM against 
the standard antagonist protocol was hugely disappointing. In the initial ethical 
approval for the trial, if a clinical pregnancy was not confirmed following the treatment 
of 30 patients, the investigators were obliged to stop the trial. Although only the 
preliminary group, the team felt it was appropriate to stop the trial following the same 
principal.    
Oocytes from those with PCOS may predispose the IVM treatment cycle to achieve a 
less successful outcome. Minimal change in clinical IVM treatment despite low 
CPR/LBR’s also suggests that the momentum for this treatment has faltered. Although 
there is a continued interest in culture conditions, e.g. SPOM (634), it may be that this 
is confined to the animal industry, for example cattle breeding, where successes seem 





antagonist cycle, agonist trigger and minimal stimulation IVF, provide a treatment 
pathway that reduces the risk of OHSS without compromising the pregnancy outcome. 
Due to this the merits of IVM now appear limited and supports why the treatment is 
not offered on a large scale worldwide. With respect to the current trial, there are 
obvious limitations (e.g. minimal baseline data recorded and unknown endometrial 
thickness) and new technologies that may improve future attempts (e.g. Embryoscope). 
For now though, I do believe that IVM for those with PCOS may have had its time 











5 Chapter 5 
General Discussion And Future Directions 
 
5.1 Summary 
Polycystic ovary syndrome remains the most common endocrine disturbance to affect 
women during their reproductive years. The complex pathophysiological process 
remains superficially understood. Insulin resistance, hyperinsulinemia and 
hyperandrogenism are central players in the pathophysiology and reproductive 
dysfunction. Obesity and metabolic disturbance have significant impact on the 
reproductive outcome but also the long term health of many women with PCOS. For 
those with PCOS, although successful fertility may be the patient’s goal, these 
individuals provide a challenge for the clinician. Large cohorts of antral follicles can 
remain refractory to gonadotrophin stimulation, until a threshold is reached and an 
exuberant follicular response may then occur in an unpredictable fashion. This 
response predisposes the individual to both the risk of multiple pregnancy and OHSS, 
with its attached morbidity and occasional mortality. Whilst the risk of OHSS is 
relatively low with ovulation induction for anovulatory infertility, it is in the context of 
superovulation for assisted conception techniques such as IVF or ICSI and related 
treatments that the risks are much greater. It is reassuring that in the most recent 
confidential enquiry into maternal deaths, OHSS was not cited as a cause of death. 
Indeed, only 3.1% of the 321 women who died between 2009-2012 had undergone 
assisted conception technologies (680). Although encouraging, this fact does not leave 
room for complacency. The incidence of severe OHSS ranges from 0.5-2.0% and mild-
moderate OHSS upwards of 30% (681). In 2013, 46 instances of severe OHSS requiring 
hospital admission were reported to the Human Fertilisation and Embryology 





Based on the impact of gonadotrophin stimulation for those at high risk of over 
response, the objective of this thesis was to evaluate 3 ways of reducing the risk for 
women undergoing superovulation. The research looked at women with PCOS and 
integrated appropriate diagnostic testing with methods to attenuate or eliminate the 
incidence of OHSS. Three key hypotheses were outlined from the beginning and 
provided the foundation for the research presented in this thesis. 
Aim 1  
‘AMH has clinical utility as a diagnostic test for PCOS and can be used as a marker of 
severity of the condition’ 
The work presented in this thesis has clearly shown that AMH provides a 4th dimension 
to the diagnostics of PCOS in women. The clear correlation of AMH levels with AFC 
(138) has been replicated in the present study. In agreement with the work of many 
(87, 232, 234), the subjective morphological description of the polycystic ovary can be 
replaced  or enhanced by the measurement of AMH. Whether this is appropriate in 
assisted conception is debatable given the extra anatomical information a high 
resolution ultrasound can generate, but certainly quantification of the AMH level adds 
significant weight to the simple AFC description of PCOM and in doing so AMH can 
distinguish between those women with isolated PCOM and those with the full 
syndrome of PCOS. This corroborates data reported by Homburg et al (228). With 
respect to the other factors named in the Rotterdam criteria, the current study 
supports an independent correlation with both anovulation and hyperandrogenism (83, 
217). Within the current study, these links remained irrespective of BMI, which is often 
reported to have a negative relationship with AMH level (151). Based on the current 
findings, the suggested cut off values for PCOM (29pmol/L) and oligo-anovulation or 
hyperandrogenism (45pmol/L) using the AMH generation II assay support other 
proposed values (224). Using these suggestions on the data from chapter 3, Table ‎5-1 
compares the categorisation of PCOS phenotypes against the cohort of women 





(p<0.01) alteration in phenotype categorisation with up to 11% of the cohort being 
deemed not to have PCOS. Evidently further work is needed to optimise the ideal 
surrogate values, especially when substituting for OA or HA. However, the substitution 
for PCOM may reflect the need to increase the follicle number in the PCOM definition, 
to prevent over diagnosis of PCOS.  
  
Table ‎5-1 Comparison of phenotype categorisation using suggested AMH levels as surrogate 














OA/HA 1 3 1 1 
OA/PCOM 61 57 48 22 
HA/PCOM 34 30 24 21 
OA/HA/PCOM 46 41 56 83 
Not PCOS 0 10 13 15 
Comparison 
against original 
 p = 0.01*  p < 0.001*  P < 0.001*  
* Fisher’s exact test. 
 
Phenotypic presentation of PCOS is perhaps a little more difficult to discern from a 
single AMH value. From the current study, the phenotype that could be classed as the 
most ‘severe’, which possesses all 3 of the Rotterdam criteria, had a significantly 
elevated AMH value compared with the others. This reflected a heavier and more 
androgenic subset of subjects. Importantly, the elevated AMH value (72.7pmol/L (61.0-
86.7 95%CI)) may identify a subset of women who may be the hardest to treat during 
ART and who present the greatest risk of OHSS following ovarian stimulation. It would 
be interesting to continue this research to ascertain if this is indeed true when women 





respect to age, although AMH is recognised as having an inverse relationship with 
increasing age, for those women with PCOS the AMH concentration followed a slower 
decline. This may in part be due to the trend of women to present to an infertility clinic 
at a later age rather than a true reflection on the age related decline of AMH in women 
with PCOS. None of these associations are surprising given the integral role AMH plays 
both in initial follicle recruitment and selection of the dominant follicle (113). The 
current study has therefore provided additional data on the biological importance of 
AMH to PCOS using the current generation II AMH assay and the data suggests a 
diagnostic benefit of AMH assays in the diagnosis of PCOS. 
Aim 2. 
‘Metformin treatment can significantly reduce the risk of OHSS in women with PCOS 
undergoing a GnRH antagonist treatment cycle’. 
Individually, metformin treatment and the GnRH antagonist cycle are known to reduce 
the incidence of OHSS in women with PCOM/PCOS who are undergoing superovulation 
for assisted conception. Evidence supports the use of metformin as an adjunct in the 
GnRH agonist cycle to decrease the risk of OHSS (260, 501). The antagonist cycle is the 
recommended approach for those with PCOS due to the reduction in OHSS risk (181). 
Metformin is believed to act directly on the ovary and indirectly via attenuation of 
insulin resistance and hyperinsulinemia (322). In stark contrast to the pilot study by 
Doldi et al (351), the current RCT has demonstrated no difference in OHSS risk with 
metformin use (placebo 12.2% vs. metformin 16%, p=0.66). Similar to our team’s 
earlier work with metformin in the agonist cycle (260), there was no change in total 
gonadotrophin dose, duration of stimulation or number of oocytes retrieved after drug 
exposure. There was minimal increase in systemic testosterone level from baseline to 
oocyte retrieval in the metformin group, unlike the placebo group. Furthermore, there 
was a trend for a greater increase in oestradiol in the placebo group by the time of 
oocyte retrieval. These changes reflect the rapid effect metformin may have on 





may have had greater effect. This finding highlights the greatest limitation of the 
current study design, which was the short use of metformin prior to oocyte retrieval. 
An intriguing outcome of the current study is the trend for reduced clinical pregnancy 
and live birth rate with metformin use. This may be due to factors such as altered 
progesterone production suggested in earlier work by our group (Maruthini et al (548)). 
A reduction in progesterone production may alter and impede endometrial receptivity, 
thereby reducing the implantation and ongoing pregnancy rate. A clear disparity in 
clinical outcome between the South Asian and White Caucasian population, unrelated 
to metformin consumption, has once again been found (559, 564). Despite obvious 
markers of potential poor outcome (raised BMI, longer duration of subfertility and 
worse phenotypic presentation) it remains disappointing that such an ethnic gap 
persists. Further directed research into narrowing this discrepancy is needed, with the 
possibility of ethnic specific protocols for assisted conception.      
Aim 3.  
‘IVM is an effective alternative to a standard IVF assisted conception cycle for those 
with PCOS who wish to avoid OHSS’. 
The ability to collect, mature and fertilise oocytes in an in vitro environment is not 
questioned. The current study has shown that this is possible and that a high 
maturation and fertilisation rate can be attained, in agreement with the work of other 
groups (358, 359, 572). The poor embryo quality and lack of clinical pregnancy rate in 
the pilot study does however raise the question as to whether IVM is an effective 
alternative to standard IVF cycles. The variable CPRs in the literature (see Table 4-2, 
chapter 4) despite decades of research support the concept that IVM is a more difficult 
procedure in a clinical ART setting and fully optimised clinical and laboratory protocols 
have yet to be established . With advances in other risk reduction strategies such as 
the adaptation of the antagonist cycle for the treatment of PCOS with vastly reduced 
OHSS rates, it does seem that IVM has perhaps had its time as a viable option for 





for IVM, despite its obvious advantage in reducing the risk of OHSS. Reduced oocyte 
quality, an altered hormonal microenvironment and impaired implantation are a small 
selection of the suggested reasons why oocytes from women with PCOS are not ideal 
candidates for IVM (329, 584). Conversely, this patient group have the most to gain 
from a cycle of IVM. Elimination of the risk of OHSS may offset reductions in clinical 
outcome per cycle started. Financially, it has been reported that IVM provides a low 
cost alternative to a long treatment protocol in assisted conception (571). Our study 
has challenged that concept and shown that the cost of IVM is approximately similar to 
a short antagonist cycle of treatment. Even using an optimised cost plan, whereby 
oocytes are only injected at one time point (due to limited benefit of later maturing 
oocytes contributing to the best embryos for transfer) only £200 separates the cost of 
an antagonist treatment cycle from IVM, in favour of the later. More expensive culture 
media with limited shelf life and extra clinician and embryologist time particularly 
around oocyte retrieval, limit IVM’s clear advantage of reduced gonadotrophin costs. 
Although the costing hasn’t taken into account costs of hospital admission for OHSS, 
this is immaterial when no pregnancy has been achieved. If the pilot study had been 
continued, it would seem appropriate to discontinue hCG priming. The addition of this 
trigger in vivo appears to have been detrimental to oocyte developmental competence 
in the current study and as such  supports the findings of other groups (359, 572). The 
use of the Embryoscope would have been interesting as a vehicle to monitor 
fertilisation and early preimplantation development of IVM derived embryos but is 
unlikely to have altered the outcome. To conclude, IVM does not appear to provide 
either a clinically efficient or a cost effective alternative to the antagonist IVF protocols 
despite eliminating OHSS.         
 
5.2 Future Research 
Optimisation of the current successful strategies to reduce OHSS should form the basis 





investigations such as AMH and individualised treatment plans will target those most 
at risk of OHSS. Perhaps it is time to revisit the type of gonadotrophin used within 
superovulation. It is well recognised that FSH exists in a number of different isoforms 
dependant on the number of branching carbohydrate moieties in particular sialic acid 
residues found on the molecule (683). Within the menstrual cycle, the more acidic 
isoform predominates in the early follicular cycle with a switch to the less-acidic form 
around ovulation (684). The follicle controls this switch via oestradiol. A rising 
oestradiol level downregulates glycosyltransferase, the enzyme responsible for 
incorporating sialic acid residues into FSH within the pituitary (685). In vivo acidic 
isoforms are shown to have a longer half-life and increased biological activity. 
Furthermore, the acidic type provokes a less pronounced steroidogenic response with 
a gradual rise in oestradiol and selective follicle growth (686).This contrasts with the 
less-acidic isoform which induces exponential growth of the follicles (mainly related to 
granulosa proliferation), in a less selective manner (687). There is a difference in the 
ratio of acidic to less acidic isoforms of FSH within the various urinary and recombinant 
FSH preparations used in ART today; with the purified human preparation exhibiting a 
more acidic profile (683, 688). It has been suggested that use of acidic isoforms for 
controlled ovarian stimulation may therefore reduce peak oestradiol levels and reduce 
the risk of OHSS. In practice, no difference in oestradiol level has been demonstrated. 
Although Abate et al (689) found a reduction in total gonadotrophin dose and 
stimulation length, this was not replicated by others (690, 691). A recent Cochrane 
review concludes that there is no difference in OHSS rate between human or 
recombinant FSH in controlled ovarian stimulation (692). The lack of difference in 
clinical trials to date may in part be related to the type of GnRH analogue used (all 
studies use the agonist). In the classic GnRH agonist cycle, the pituitary is down 
regulated with suppression of FSH and LH secretion. Theoretically, residual FSH 
secretion may tend towards the acidic isoform due to a low oestrogen environment. In 
the antagonist cycle, no such pituitary suppression occurs. Adding a less acidic FSH 
stimulation to the normal pituitary FSH may therefore alter the natural dynamics of 





environment and predispose to OHSS. No studies as yet address this question in the 
antagonist cycle.  
Intuitively, the next step is to consider how best to trigger oocyte maturation and 
ovulation. The traditionally employed hCG marks the end of controlled ovarian 
stimulation, yet can create a cascade of events that culminate in the sequelae of OHSS. 
Kisspeptins and the connected neuronal network of Kisspeptin-neurokinin-B-dynorphin 
(KNDy) have provided insight into how upstream modulation of the GnRH signal can be 
harnessed to improve reproductive outcome (693). Encoded by the KiSS1 gene, 
Kisspeptin is a 54 amino acid peptide that can undergo further cleavage; and are 
collectively known as the kisspeptins (694). The function of these peptides has been 
identified in regulation of puberty and sex-hormone mediated secretion of 
gonadotrophins (695). Direct signalling to the GnRH neurone via the kisspeptin 
receptor, allows pulsatile release of GnRH into the portal circulation. In turn this 
stimulates pituitary gonadotrophin release, with a preferential secretion of LH and to a 
lesser extent FSH (696). Variation between the male and female is recognised; in the 
former the hypothalamic clock can be effectively reset by exogenous use of kisspeptin, 
unlike the latter in which the menstrual cycle exerts an effect (697). Kisspeptin is under 
both positive and negative feedback control from progesterone and oestradiol (693). 
Due to co-localisation of neurokinin-B and kappa opioid peptide receptor within the 
hypothalamus, auto-synaptic control of kisspeptin secretion occurs (698). Neurokinin-B 
is stimulatory and dynorphin inhibitory. The ability to induce an LH surge capable of 
triggering ovulation provides an interesting alternative to the classic hCG. Jayasena and 
colleagues (699), provide results from an eloquent proof of concept study using 
kisspeptin as the ovulation trigger in an antagonist IVF cycle. Fifty-three patients 
underwent a standard antagonist cycle with a single subcutaneous dose of kisspeptin-
54, 36 hours before oocyte retrieval. Maturation, fertilisation and embryo formation 
were all achieved. The clinical pregnancy rate was 23%. Maximum peak oestradiol 
levels were seen 12 hours following injection reaching 16000pmol/L ± 2000 but fell 





or GnRH receptors on the pituitary has generated ovulation. Kisspeptin adopts a 
physiological approach using the hypothalamic endogenous GnRH reserve, which was 
reflected in the lower peak levels of LH when compared with a GnRH agonist trigger 
(700). Furthermore, it is recognised that hCG has a long half-life and sustained effect 
on ovarian stimulation (701). In contrast, kisspeptin exposure is short lived with a half-
life of only 28 minutes (702). Within this study, women with PCOS were excluded 
(although the median AFC was still 20-30). It would be interesting to see within larger 
scale studies whether kisspeptin is useful for women with PCOS; in particular if it is 
capable of inducing ovulation in a greater cohort of oocytes without the effects of 
OHSS. In addition, the dose that kisspeptin should be used, given the increased pulse 
frequency of LH and basal LH levels (703) plus the finding of an elevated kisspeptin 
level in those with PCOS (704).          
Whilst kisspeptin may be in the fledgling stages of clinical use, the agonist trigger 
should now be considered a viable, if not mainstream, option for high responder 
individuals such as those women with PCOS. Although OHSS is not eliminated using the 
agonist trigger, the rate is far below that seen using hCG as the trigger (705, 706). 
Unlike hCG which maintains the corpus luteum and progesterone production, 
optimised luteal phase support is necessary. Following the LH surge and oocyte 
maturation, direct pituitary down regulation provides insufficient LH to maintain the 
corpus luteum, leading to a potential luteal phase insufficiency and reduced clinical 
pregnancy outcome (707). With optimised luteal phase protocols including 
combinations of exogenous hCG, oestradiol and progesterone, the success rates 
should silence the sceptics of the agonist trigger (708). Two recent retrospective 
reviews (681, 709) reveal clinical pregnancy rates (40-41.8%) that equal if not exceed 
those seen with the conventional approach. It is encouraging that an ongoing survey 
suggests that clinics are tending towards the antagonist cycle and case based selection 
for the GnRH agonist trigger approach (710). This is a marked improvement on a 
previous survey (534) and perhaps reflects a paradigm shift in the clinician’s support of 






5.3  Overall Conclusion 
Irrespective of risk reduction strategy employed for those with PCOS, the underlying 
focus should be to use superovulation strategies only when necessary. Rapid resort to 
IVF with only limited duration of trying to conceive exposes patients to both known (i.e. 
OHSS risk) and unknown risks (e.g. epigenetic changes) that are potentially 
unnecessary and unjustifiable (555). For those with PCOS, emphasis should continue to 
be placed on lifestyle modification (339), weight reduction and ovulation induction 
strategies. When assisted conception is necessary optimum diagnostics before 
proceeding to treatment can help to tailor safe treatment. Anti-Müllerian Hormone 
has an undisputable literature base correlating the systemic circulating level firstly with 
AFC but foremost with elements of PCOS. Work in this thesis has strengthened the 
knowledge surrounding AMH as a diagnostic tool for PCOS using the AMH Gen II assay, 
suggesting reference levels that can be adopted by primary and tertiary care providers. 
The significance of elevated AMH and the impact of PCOS on the outcome of assisted 
conception technologies should focus the clinician’s choice of a safe treatment 
strategy. Attempts to further attenuate risk, with the addition of metformin has 
proven unsuccessful. No benefit was seen in the antagonist cycle in stimulation, 
embryological or clinical outcome parameters. Empirical metformin use for those with 
PCOS should therefore not be advocated, although metformin may have a role for 
those with impaired glucose tolerance and type 2 diabetes mellitus. Finally, it would 
seem that the theoretical advantage of IVM has been superseded by advances in OHSS 
reduction approaches seen with the antagonist cycle, agonist trigger and optimised 
luteal phase support. The latter strategy has been replicated by many with good 
pregnancy outcomes together with limited risk for the individual, unlike in vitro 
maturation as a vehicle to treat PCOS. Perhaps IVM should remain confined to the 
successful commercial ART sheep and cattle market and no longer in the treatment of 
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Patient Id No_______________________________________ Date of Egg Recovery_______________________  Page ___/ ___  
       
Follicle No & diameter at hCG__________________________________ 
 
Grading Scores for cumulus expansion at the start and end of culture (see Wynn et al 1998 for images) 
  Cumulus mass (Mass)    Cumulus expansion (Exp) 
Grade:  C0: 3 layers of cumulus cells  E0: tight, dense cells  
  C1: >3<10 layers of cells   E1: moderate expansion of cells 
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Number Age BMI PCOS 
Phenotype 

































1 32 22 PCOM/OA/HA 6mo 4.4:4.9 9 24 8.26 8 58 13 3 1 0 0 Bio22.3  8.26  4.3.3 (d1) 1 1 no blast only 
single embryo 
2 35 22 PCOM/OA 32-3mo 5.1:6.7 9 24 5.97 8 31 6 1 1 3 3 Negative  5.97  5.3.3 (d1) 2 4 no blasts 
3 33 23 PCOM/OA 28-35 6.8:6.9 9 24   19 8 5 3 0 0 Bio 3.1  5.55  8.4.4/7.3.4 2 3 no blasts 
4 29 28 PCOM/OA 6mo 3.9:2.5 9 24 4.59 7 27 12 7 7 1 1 Negative  4.5  10.3.4 x2 3 7 2 blasts d6 
4bc/5Bb 
5 34 25 PCOM/HA 32 5.7:7.9 9 24 5.8 8.5 39 15 8 2 3 0 bio10.8  5.8  3.3.4/4.3.4 2 2 no other 
embryos 
6 32 26 PCOM/OA amen 05:10.3 9 24   41 33 9 6 8 3 Ectopic 
(2976) 
 4.2  8.4.4/8.3.3 3 9 no blasts 
7 32 27 PCOM/OA 30-37 2.6:1.7 9 24   23 14 7 2 6 4 Negative  2.68  4.3.4 x2 3 5 no blasts 
8 31 23 PCOM/OA 8wks 7.6:11.8 9 24   45 13 5 4 2 0 Bio9.5  6.1  8.4.4/7.3.3 3 4 no blasts 
9 36 23 PCOM/OA 3mo 5.6:4.2 9 24 2.21 7 38 24 24 14 0 0 Negative  7  8.3.4/8.4.3 10 14 3 blasts 2dc-4cb 
10 36 25 PCOM/OA 2mo 08:09.5 10 24   31 15 9 6 1 1 Negative  3.45 4.1 6/3/4:6/3/3 2 7 d6 4bc/3cc 
11 31 24 PCOM/OA/HA amen 1.8:<.3 10 24   30 22 15 14 0 0 bio 34  3.37 6 8/4/4:8/4/3 8 13 3 blasts 4bb 
12 38 25 PCOM/OA 34+ 6.8:7.2 10 24   23 8 6 5 0 0 Negative  5.67 7 6.3.3/6.3.2 1 5 2 blasts 3dc 
13 38 28 PCOM/OA/HA 30-37 7.4:4.6 10 24 4.33 8.5 28 8 3 2 1 1 negative  4.3 7.2 4/2/2:6/4/4 1 3 no blasts  
14 29 22 PCOM/OA 26-36 4.9:3.6 10 24 2.39 9 27 21 12 11 8 4 Negative  2.39 7 8.3.4/9.3.4 6 15 4dc 
15 23 29 PCOM/OA 28-42 3.8:5.8 10 24   26 18 9 6 3 2 bio 11.2  3.6 10 8/4/4:7/3/4 2 5 no blasts 
16 28 28 PCOM/OA 90 5.8:6 10 24 5.02 8 36 18 6 3 9 7 negative 
(fet) 
 7.3  10.2.3/8.3.3 1 8 no blasts 
17 33 30 PCOM/OA 3mo 6.9:11.8 10 24   28 19 13 10 2 2 negative 
(fet) 
 9.8  9.3.3/8.3.3 3 10 no blasts 
18 24 30 PCOM/OA amen 4.6:5 10 24 5.6 7 50 23 9 5 4 2 bio3.9(fet)  9.19  8/4/4 7/3/3 2 6 no blasts 
19 26 21 PCOM/OA/HA 28-29 
(upto 7 
wks) 
08:06.4 10 24   29 2 1 0 1 1 no 
transfer 
 nd  failed 
cleavage 
0 0  










21 30 20 PCOM/OA 28-49 7.9:4.5 13 36  10 27 18 6 5 4 0 Negative 6.1 5.64  8.4.4/8.3.4 3 5 no blasts 
22* 26 27 PCOM/OA/HA 3mo 6.9:6.4 15 36  9.5 28 24 10 7 7 5 Bio 8 5.4 4.5  8.4.4/7.3.4 5 9 2 poor 1cc/5dc 
23 32 28 PCOM/HA 28-31 7.1:4.0 12 36  13 22 10 7 4 2 0 Negative 6.8 4  8.4.4/7.4.4 4 4 no blasts 
24 25 31 PCOM/OA amen 5.4:5.8 15 36  7 40 29 10 3 1 0 Negative 5.9 5.24  8.4.4/7.4.4 3 3 1 4cc 
25 30 22 PCOM/OA/HA 28-35+ 1.8:3.9 15 36  9 33 24 13 8 4 1 Negative 6.1 4.2  9.4.4/9.3.4 3 9 no blasts 
26* 29 28 PCOM/OA 90 5.8:6 18 36  7.5 27 22 5 3 11 6 Negative 7.7 5.51  8.3.4/9.3.4 5 9 1 5aa 
27 27 25 PCOM/OA 30-3mo 2.8:3 15 36  10 30 9 6 3 2 0 Negative 8.5 4.42  6.2.3/10.2.3 0 3 no blasts 
28* 33 23 PCOM/OA/HA 6mo 4.4:4.9 16 36  7 45 16 10 6 2 1 negative 7.8 7.05  7.3.3/7.3.3 2 7 no blasts 
29 34 21 PCOM/OA 4mo 06:04.6 12 36  10.5 20 6 2 0 2 2 no 
transfer 
4.3 3.75  failed 
cleavage 
0 0 na 
30 24 23 PCOM/OA/HA 28-42 51:11.4 14 36  9 38 21 13 8 4 0 negative nd 4.75 nd 5.2.3/5.3.3 0 7 no blasts 
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